Study ID,first author,study design,publication date,primary series vaccine,booster vaccine,historyofCOVID ,reference group,timing_of_dose_days,outcome_detail,outcome_category,country,population_detail,population_category,VE,LCL,UCL,variant_sequenced,variant_context,max duration follow-up,notes,,,,
1,Bar-On,Retrospective cohort,07Oct2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,≥ 18 years,general pop,92.0,90.0,93.0,,delta,3 weeks,,,,,
1,Bar-On,Retrospective cohort,07Oct2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,12+,severe disease,severe,Israel,≥ 18 years,general pop,94.0,91.0,96.0,,delta,3 weeks,,,,,
2,Patalon,Test-negative case-control,30Nov2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,14-20,infection,infection,Israel,≥ 40 years,≥ 40 years,85.0,83.0,86.0,,delta,~7 weeks,,,,,
2,Patalon,Test-negative case-control,30Nov2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,28-65,infection,infection,Israel,≥ 40 years,≥ 40 years,86.0,85.0,87.0,,delta,~7 weeks,,,,,
2,Patalon,Matched case-control,30Nov2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,14-20,infection,infection,Israel,≥ 40 years,≥ 40 years,87.0,85.0,87.0,,delta,~7 weeks,,,,,
2,Patalon,Matched case-control,30Nov2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,28-65,infection,infection,Israel,≥ 40 years,≥ 40 years,83.0,82.0,85.0,,delta,~7 weeks,,,,,
2,Patalon,Matched case-control,30Nov2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,14-20,hospitalization,severe,Israel,≥ 40 years,≥ 40 years,92.0,87.0,95.0,,delta,~7 weeks,,,,,
2,Patalon,Matched case-control,30Nov2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,28-65,hospitalization,severe,Israel,≥ 40 years,≥ 40 years,97.0,95.0,98.0,,delta,~7 weeks,,,,,
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,16-29 years,16-29 years,94.2,93.6,94.9,,delta,~3.5 weeks,,,,,
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,30-39 years,30-39 years,88.6,87.8,89.5,,delta,~4.5 weeks,,,,,
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,40-49 years,40-49 years,89.7,89.1,90.4,,delta,5 weeks,,,,,
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,50-59 years,50-59 years,91.8,91.2,92.4,,delta,6 weeks,,,,,
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,≥ 60 years,≥ 60 years,91.9,91.6,92.2,,delta,8 weeks,,,,,
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,12+,severe disease,severe,Israel,40-59 years,40-59 years,95.4,90.6,97.8,,delta,6 weeks,,,,,
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,12+,severe disease,severe,Israel,≥ 60 years,≥ 60 years,94.5,93.4,95.3,,delta,8 weeks,,,,,
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,12+,death,death,Israel,≥ 60 years,≥ 60 years,93.2,89.4,95.7,,delta,8 weeks,,,,,
4,Hardt,Randomized placebo control trial,31Jan2022,Ad26.COV2.S (Janssen),Janssen,unknown,complete vaccination with 1 dose,7+,infection,infection,"North America, South America, Africa, Asia, Europe",≥ 18 years,general pop,51.1,29.5,66.4,,"non-VOC, alpha, & delta",~8 weeks,,,,,
4,Hardt,Randomized placebo control trial,31Jan2022,Ad26.COV2.S (Janssen),Janssen,unknown,complete vaccination with 1 dose,7+,asymptomatic infection,asymptomatic,"North America, South America, Africa, Asia, Europe",≥ 18 years,general pop,34.2,-6.4,59.8,,"non-VOC, alpha, & delta",~8 weeks,,,,,
4,Hardt,Randomized placebo control trial,31Jan2022,Ad26.COV2.S (Janssen),Janssen,unknown,complete vaccination with 1 dose,7+,moderate symptomatic infection,symptomatic,"North America, South America, Africa, Asia, Europe",≥ 18 years,general pop,70.7,45.4,85.1,,"non-VOC, alpha, & delta",~8 weeks,,,,,
4,Hardt,Randomized placebo control trial,31Jan2022,Ad26.COV2.S (Janssen),Janssen,unknown,complete vaccination with 1 dose,7+,moderate and severe/critical infection,severe,"North America, South America, Africa, Asia, Europe",≥ 18 years,general pop,75.2,54.5,87.3,,"non-VOC, alpha, & delta",~8 weeks,,,,,
4,Hardt,Randomized placebo control trial,31Jan2022,Ad26.COV2.S (Janssen),Janssen,unknown,complete vaccination with 1 dose,7+,infection,infection,"North America, South America, Africa, Asia, Europe",≥ 18 years,general pop,94.2,62.9,99.9,,alpha,~8 weeks,,,,,
4,Hardt,Randomized placebo control trial,31Jan2022,Ad26.COV2.S (Janssen),Janssen,unknown,complete vaccination with 1 dose,7+,infection,infection,"North America, South America, Africa, Asia, Europe",≥ 18 years,general pop,63.1,-27.9,91.6,,mu,~8 weeks,,,,,
5,Saciuk,Retrospective cohort,02Nov2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses,7+,infection,infection,Israel,≥ 18 years,general pop,89.1,87.5,90.5,,delta,10 weeks,,,,,
6,Barda,Retrospective cohort,29Oct2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,7+,infection,infection,Israel,≥ 18 years,general pop,88.0,87.0,90.0,,delta,~7 weeks,,,,,
6,Barda,Retrospective cohort,29Oct2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,7+,symptomatic disease,symptomatic,Israel,≥ 18 years,general pop,91.0,89.0,92.0,,delta,~7 weeks,,,,,
6,Barda,Retrospective cohort,29Oct2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,7+,hospitalization,severe,Israel,≥ 18 years,general pop,93.0,88.0,97.0,,delta,~7 weeks,,,,,
6,Barda,Retrospective cohort,29Oct2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,7+,severe disease,severe,Israel,≥ 18 years,general pop,92.0,82.0,97.0,,delta,~7 weeks,,,,,
6,Barda,Retrospective cohort,29Oct2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,7+,death,death,Israel,≥ 18 years,general pop,81.0,59.0,97.0,,delta,~7 weeks,,,,,
7,Andrews,Test-negative case-control,17Dec2021,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses ≥140 days prior,14+,symptomatic disease,symptomatic,England,≥ 50 years,≥ 50 years,84.5,83.7,85.3,,delta,~7.5 weeks,,,,,
7,Andrews,Test-negative case-control,17Dec2021,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with 2 doses ≥140 days prior,14+,symptomatic disease,symptomatic,England,≥ 50 years,≥ 50 years,89.1,88.3,89.9,,delta,~7.5 weeks,,,,,
7,Andrews,Test-negative case-control,17Dec2021,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,England,≥ 50 years,≥ 50 years,94.3,93.9,94.6,,delta,~7.5 weeks,,,,,
7,Andrews,Test-negative case-control,17Dec2021,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,England,≥ 50 years,≥ 50 years,93.8,93.3,94.3,,delta,~7.5 weeks,,,,,
8,Sharma,Matched retrospective cohort,30Nov2021,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses ≥180 days prior,0+,infection,infection,USA,veterans,veterans,45.7,37.9,52.5,,delta,~7 weeks,,,,,
8,Sharma,Matched retrospective cohort,30Nov2021,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses ≥180 days prior,0+,hospitalization,severe,USA,veterans,veterans,44.8,26.6,58.4,,delta,~7 weeks,,,,,
8,Sharma,Matched retrospective cohort,30Nov2021,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses ≥180 days prior,0+,infection,infection,USA,veterans,veterans,46.6,36.4,55.3,,delta,~7 weeks,,,,,
8,Sharma,Matched retrospective cohort,30Nov2021,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses ≥180 days prior,0+,hospitalization,severe,USA,veterans,veterans,50.0,26.2,66.1,,delta,~7 weeks,,,,,
9,Goldberg,Retrospective cohort,05Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,12+,infection,infection,Israel,16-39 years,16-39 years,91.0,90.1,91.3,,delta,~8 weeks,,,,,
9,Goldberg,Retrospective cohort,05Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,12+,infection,infection,Israel,40-59 years,40-59 years,89.0,88.3,89.3,,delta,~8 weeks,,,,,
9,Goldberg,Retrospective cohort,05Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,12+,infection,infection,Israel,≥ 60 years,≥ 60 years,82.2,81.5,82.8,,delta,~8 weeks,,,,,
10,Arbel,Prospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,14+,death,death,Israel,≥ 18 years,general pop,33.0,26.0,40.0,,delta,~8 weeks,,,,,
10,Arbel,Prospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,54+,death,death,Israel,≥ 18 years,general pop,91.0,87.0,93.0,,delta,~8 weeks,,,,,
10,Arbel,Prospective cohort,08Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,54+,infection,infection,Israel,≥ 18 years,general pop,83.0,82.0,94.0,,delta,~8 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,68.7,67.9,69.5,omicron,omicron,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,10+ weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,50.1,49.0,51.2,omicron,omicron,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,74.7,73.7,75.7,omicron,omicron,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,5-9 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,65.3,63.1,67.4,omicron,omicron,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,62.7,62.0,63.4,omicron,omicron,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,10+ weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,44.1,42.2,45.9,omicron,omicron,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,70.3,69.5,71.0,omicron,omicron,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,5-9 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,61.6,60.0,63.1,omicron,omicron,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,67.0,63.0,70.0,omicron,omicron,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,68.0,64.0,72.0,omicron,omicron,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,95.2,94.9,95.5,delta,delta,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,10+ weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,90.2,89.6,90.8,delta,delta,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,96.8,96.2,97.3,delta,delta,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,5-9 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,94.7,92.7,96.2,delta,delta,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,95.4,95.2,95.7,delta,delta,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,10+ weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,88.5,87.0,89.7,delta,delta,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,97.1,96.8,97.4,delta,delta,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,5-9 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,94.9,93.6,95.9,delta,delta,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,97.3,91.5,99.1,delta,delta,~14 weeks,,,,,
11,Andrews,Test-negative case-control,14Jan2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,≥ 18 years,general pop,95.8,88.8,98.4,delta,delta,~14 weeks,,,,,
12,Berec,Retrospective cohort,12Dec2021,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses ≥6-8 months prior,7+,infection,infection,Czech Republic,≥ 18 years,general pop,92.0,91.0,92.0,,delta,~8 weeks,,,,,
12,Berec,Retrospective cohort,12Dec2021,mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses ≥6-8 months prior,7+,infection,infection,Czech Republic,≥ 18 years,general pop,94.0,91.0,96.0,,delta,~8 weeks,,,,,
12,Berec,Retrospective cohort,12Dec2021,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with 2 doses ≥6-8 months prior,7+,infection,infection,Czech Republic,≥ 18 years,general pop,82.0,68.0,90.0,,delta,~8 weeks,,,,,
12,Berec,Retrospective cohort,12Dec2021,BNT162b2 (Pfizer),Moderna,included,complete vaccination with 2 doses ≥6-8 months prior,7+,infection,infection,Czech Republic,≥ 18 years,general pop,92.0,88.0,95.0,,delta,~8 weeks,,,,,
12,Berec,Retrospective cohort,12Dec2021,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses ≥6-8 months prior,7+,infection,infection,Czech Republic,≥ 18 years,general pop,94.0,91.0,95.0,,delta,~8 weeks,,,,,
12,Berec,Retrospective cohort,12Dec2021,AZD1222 (AstraZeneca),Moderna,included,complete vaccination with 2 doses ≥6-8 months prior,7+,infection,infection,Czech Republic,≥ 18 years,general pop,91.0,63.0,98.0,,delta,~8 weeks,,,,,
13,Tartof,Retrospective matched cohort,14Feb2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,88.0,86.0,89.0,delta,delta,~12 weeks,,,,,
13,Tartof,Retrospective matched cohort,14Feb2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,hospitalization,severe,USA,≥ 18 years,general pop,97.0,95.0,98.0,delta,delta,~12 weeks,,,,,
13,Tartof,Retrospective matched cohort,14Feb2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses ≥6 months prior,14+,infection,infection,USA,≥ 18 years,general pop,75.0,71.0,78.0,delta,delta,~12 weeks,,,,,
13,Tartof,Retrospective matched cohort,14Feb2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses ≥6 months prior,14+,hospitalization,severe,USA,≥ 18 years,general pop,70.0,48.0,83.0,delta,delta,~12 weeks,,,,,
14,Hansen,Retrospective cohort,23Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses in 60+ year olds,1-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,54.6,30.4,70.4,omicron,omicron,~4 weeks,,,,,
14,Hansen,Retrospective cohort,23Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses in 60+ year olds,1-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,81.2,79.2,82.9,delta,delta,~4 weeks,,,,,
14,Hansen,Retrospective cohort,23Dec2021,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses in 60+ year olds,1-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,82.8,58.8,92.9,delta,delta,~4 weeks,,,,,
15,Amir,Quasi-experimental,21Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses <60 days prior, 12-14 years of age",14+,infection,infection,Israel,16-18 years,16-18 years,73.4,67.1,78.9,,delta,~4 weeks,,,,,
15,Amir,Quasi-experimental,21Dec2021,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,Israel,16-18 years,16-18 years,96.2,94.8,97.2,,delta,~4 weeks,,,,,
16,Lustig,Prospective cohort,09May2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,10+,infection,infection,Israel,HCW,HCW,85.6,79.2,90.1,,delta,~7 weeks,,,,,
17,Gray,Test-negative case-control,09Jun2022,Ad26.COV2.S (Janssen),Janssen,excluded,unvaccinated individuals,14-27,hospitalization,severe,South Africa,HCW,HCW,84.0,67.0,92.0,,omicron,~13 weeks,,,,,
17,Gray,Test-negative case-control,09Jun2022,Ad26.COV2.S (Janssen),Janssen,excluded,unvaccinated individuals,1-2 months,hospitalization,severe,South Africa,HCW,HCW,85.0,54.0,95.0,,omicron,~13 weeks,,,,,
17,Gray,Test-negative case-control,09Jun2022,Ad26.COV2.S (Janssen),Janssen,excluded,unvaccinated individuals,14-27,ICU admission,severe,South Africa,HCW,HCW,69.0,26.0,87.0,,omicron,~13 weeks,,,,,
17,Gray,Test-negative case-control,09Jun2022,Ad26.COV2.S (Janssen),Janssen,excluded,unvaccinated individuals,28-87,ICU admission,severe,South Africa,HCW,HCW,82.0,57.0,93.0,,omicron,~13 weeks,,,,,
18,Buchan,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,Canada,≥ 18 years,general pop,60.0,55.0,65.0,omicron,omicron,~9 weeks,,,,,
18,Buchan,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,infection,infection,Canada,≥ 18 years,general pop,65.0,55.0,72.0,omicron,omicron,~9 weeks,,,,,
18,Buchan,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,severe disease,severe,Canada,≥ 18 years,general pop,95.0,87.0,98.0,omicron,omicron,~9 weeks,,,,,
18,Buchan,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,severe disease,severe,Canada,≥ 18 years,general pop,93.0,74.0,98.0,omicron,omicron,~9 weeks,,,,,
18,Buchan,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,Canada,≥ 18 years,general pop,97.0,96.0,98.0,delta,delta,~9 weeks,,,,,
18,Buchan,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,infection,infection,Canada,≥ 18 years,general pop,97.0,95.0,98.0,delta,delta,~9 weeks,,,,,
18,Buchan,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,severe disease,severe,Canada,≥ 18 years,general pop,99.0,98.0,99.0,delta,delta,~9 weeks,,,,,
18,Buchan,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,severe disease,severe,Canada,≥ 18 years,general pop,100.0,98.0,100.0,delta,delta,~9 weeks,,,,,
19,Tan,Retrospective cohort,11Feb2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,infection,infection,Singapore,≥ 60 years,≥ 60 years,73.0,71.0,74.0,,delta,~6 weeks,,,,,
19,Tan,Retrospective cohort,11Feb2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,symptomatic disease,symptomatic,Singapore,≥ 60 years,≥ 60 years,72.0,71.0,74.0,,delta,~6 weeks,,,,,
19,Tan,Retrospective cohort,11Feb2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,severe disease,severe,Singapore,≥ 60 years,≥ 60 years,95.0,92.0,97.0,,delta,~6 weeks,,,,,
19,Tan,Retrospective cohort,11Feb2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,infection,infection,Singapore,≥ 60 years,≥ 60 years,82.0,77.0,86.0,,delta,~6 weeks,,,,,
19,Tan,Retrospective cohort,11Feb2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,symptomatic disease,symptomatic,Singapore,≥ 60 years,≥ 60 years,82.0,76.0,87.0,,delta,~6 weeks,,,,,
19,Tan,Retrospective cohort,11Feb2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,severe disease,severe,Singapore,≥ 60 years,≥ 60 years,92.0,44.0,99.0,,delta,~6 weeks,,,,,
19,Tan,Retrospective cohort,11Feb2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,infection,infection,Singapore,≥ 60 years,≥ 60 years,86.0,81.0,90.0,,delta,~6 weeks,,,,,
19,Tan,Retrospective cohort,11Feb2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,symptomatic disease,symptomatic,Singapore,≥ 60 years,≥ 60 years,85.0,79.0,89.0,,delta,~6 weeks,,,,,
19,Tan,Retrospective cohort,11Feb2022,mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,infection,infection,Singapore,≥ 60 years,≥ 60 years,90.0,73.0,96.0,,delta,~6 weeks,,,,,
19,Tan,Retrospective cohort,11Feb2022,mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,symptomatic disease,symptomatic,Singapore,≥ 60 years,≥ 60 years,90.0,69.0,97.0,,delta,~6 weeks,,,,,
20,Tseng,Test-negative case-control,18Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,70.0,68.0,71.9,omicron,omicron,8 weeks,,,,,
20,Tseng,Test-negative case-control,18Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-60,infection,infection,USA,≥ 18 years,general pop,71.6,69.7,73.4,omicron,omicron,~6.5 weeks,,,,,
20,Tseng,Test-negative case-control,18Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,>60,infection,infection,USA,≥ 18 years,general pop,47.4,40.5,53.5,omicron,omicron,8 weeks,,,,,
20,Tseng,Test-negative case-control,18Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,hospitalization,severe,USA,≥ 18 years,general pop,99.2,76.3,100.0,omicron,omicron,8 weeks,,,,,
20,Tseng,Test-negative case-control,18Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,infection,infection,USA,immunocompromised,immunocompromised,29.4,0.3,50.0,omicron,omicron,8 weeks,,,,,
20,Tseng,Test-negative case-control,18Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,94.5,92.9,95.7,delta,delta,8 weeks,,,,,
20,Tseng,Test-negative case-control,18Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-60,infection,infection,USA,≥ 18 years,general pop,93.7,92.2,94.9,delta,delta,~6.5 weeks,,,,,
20,Tseng,Test-negative case-control,18Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,>60,infection,infection,USA,≥ 18 years,general pop,86.0,78.1,91.1,delta,delta,8 weeks,,,,,
20,Tseng,Test-negative case-control,18Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,infection,infection,USA,immunocompromised,immunocompromised,70.6,31.0,87.5,delta,delta,8 weeks,,,,,
20,Tseng,Test-negative case-control,18Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,hospitalization,severe,USA,≥ 18 years,general pop,99.7,96.5,100.0,delta,delta,8 weeks,,,,,
21,Spitzer,Prospective cohort,10Jan2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥1 month prior,7+,infection,infection,Israel,HCW,HCW,93.0,80.0,98.0,,delta,~4 weeks,,,,,
21,Spitzer,Prospective cohort,10Jan2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥1 month prior,7+,symptomatic disease,symptomatic,Israel,HCW,HCW,93.0,75.0,98.0,,delta,~4 weeks,,,,,
21,Spitzer,Prospective cohort,10Jan2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥1 month prior,7+,asymptomatic infection,asymptomatic,Israel,HCW,HCW,92.0,52.0,99.0,,delta,~4 weeks,,,,,
22,Waxman,Retrospective cohort,22Apr2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥5 months prior,7+,hospitalization,severe,Israel,≥ 16 years,general pop,89.0,87.0,91.0,,delta,~15.5 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),Coronavac (Sinovac),excluded,unvaccinated individuals,14+,infection,infection,Chile,≥ 16 years,general pop,78.8,76.8,80.6,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),Coronavac (Sinovac),excluded,unvaccinated individuals,14+,hospitalization,severe,Chile,≥ 16 years,general pop,86.3,83.7,88.5,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),Coronavac (Sinovac),excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 16 years,general pop,92.2,88.7,94.6,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),Coronavac (Sinovac),excluded,unvaccinated individuals,14+,death,death,Chile,≥ 16 years,general pop,86.7,80.5,91.0,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,Chile,≥ 16 years,general pop,96.3,96.1,96.5,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,Chile,≥ 16 years,general pop,96.1,95.3,96.9,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 16 years,general pop,96.2,94.6,97.3,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,death,death,Chile,≥ 16 years,general pop,96.8,93.9,98.3,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,14+,infection,infection,Chile,≥ 16 years,general pop,93.2,92.9,93.6,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,14+,hospitalization,severe,Chile,≥ 16 years,general pop,97.7,97.3,98.0,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 16 years,general pop,98.9,98.5,99.2,,delta,~11 weeks,,,,,
23,Jara,Prospective cohort,23Apr2022,CoronaVac (Sinovac),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,14+,death,death,Chile,≥ 16 years,general pop,98.1,97.3,98.6,,delta,~11 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,USA,veterans,veterans,64.0,63.0,65.0,omicron,omicron,~20 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,USA,veterans,veterans,89.0,88.0,91.0,omicron,omicron,~20 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,death,death,USA,veterans,veterans,94.0,90.0,96.0,omicron,omicron,~20 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,USA,veterans,veterans,90.0,88.0,92.0,delta,delta,~20 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,USA,veterans,veterans,94.0,90.0,96.0,delta,delta,~20 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,death,death,USA,veterans,veterans,96.0,87.0,99.0,delta,delta,~20 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,ED visit,symptomatic,USA,hospital admissions,general pop,75.0,70.0,79.0,omicron,omicron,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14 to <3 m,ED visit,symptomatic,USA,hospital admissions,general pop,77.0,72.0,81.0,omicron,omicron,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,3+ m,ED visit,symptomatic,USA,hospital admissions,general pop,53.0,36.0,66.0,omicron,omicron,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,hospitalization,severe,USA,hospital admissions,general pop,82.0,77.0,87.0,omicron,omicron,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14 to <3 m,hospitalization,severe,USA,hospital admissions,general pop,85.0,80.0,89.0,omicron,omicron,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,3+ m,hospitalization,severe,USA,hospital admissions,general pop,55.0,28.0,71.0,omicron,omicron,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,ED visit,symptomatic,USA,hospital admissions,general pop,83.0,79.0,86.0,delta,delta,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14 to <3 m,ED visit,symptomatic,USA,hospital admissions,general pop,84.0,80.0,87.0,delta,delta,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,3+ m,ED visit,symptomatic,USA,hospital admissions,general pop,72.0,58.0,82.0,delta,delta,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,hospitalization,severe,USA,hospital admissions,general pop,87.0,81.0,92.0,delta,delta,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14 to <3 m,hospitalization,severe,USA,hospital admissions,general pop,89.0,83.0,93.0,delta,delta,~23 weeks,,,,,
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,3+ m,hospitalization,severe,USA,hospital admissions,general pop,71.0,40.0,86.0,delta,delta,~23 weeks,,,,,
26,Thompson,Test-negative case-control,21Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,94.0,93.0,95.0,omicron,omicron,~18 weeks,,,,,
26,Thompson,Test-negative case-control,21Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,90.0,80.0,94.0,omicron,omicron,~18 weeks,,,,,
26,Thompson,Test-negative case-control,21Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,94.0,93.0,94.0,delta,delta,~18 weeks,,,,,
26,Thompson,Test-negative case-control,21Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,94.0,93.0,95.0,delta,delta,~18 weeks,,,,,
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination ≥6-8 months prior,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,49.4,47.1,51.6,omicron,omicron,~10 weeks,,,,,
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination ≥6-8 months prior,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,49.9,47.6,52.2,omicron,omicron,~10 weeks,,,,,
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination ≥6-8 months prior,7+,"severe, critical, or fatal disease",severe,Qatar,≥ 18 years,general pop,76.5,55.9,87.5,omicron,omicron,~10 weeks,,,,,
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination ≤8 months prior,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,38.0,28.8,46.0,omicron,omicron,~10 weeks,,,,,
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination >8 months prior,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,50.5,48.2,52.8,omicron,omicron,~10 weeks,,,,,
27,Abu-Raddad,Matched retrospective cohort,12May2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination ≥6-8 months prior,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,47.3,40.7,53.3,omicron,omicron,~10 weeks,,,,,
27,Abu-Raddad,Matched retrospective cohort,12May2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination ≥6-8 months prior,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,52.0,45.1,57.9,omicron,omicron,~10 weeks,,,,,
27,Abu-Raddad,Matched retrospective cohort,12May2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination ≤8 months prior,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,41.5,32.3,49.5,omicron,omicron,~10 weeks,,,,,
27,Abu-Raddad,Matched retrospective cohort,12May2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination >8 months prior,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,56.8,47.0,64.8,omicron,omicron,~10 weeks,,,,,
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥6-8 months prior,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,86.1,67.3,94.1,delta,delta,~10 weeks,,,,,
28,Spensley,Prospective cohort,26Jan2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,infection,infection,UK,end stage kidney disease patients,end stage kidney disease patients,66.0,36.0,81.0,omicron,omicron,~15 weeks,,,,,
28,Spensley,Prospective cohort,26Jan2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14+,infection,infection,UK,end stage kidney disease patients,end stage kidney disease patients,47.0,2.0,70.0,omicron,omicron,~15 weeks,,,,,
29,Tenforde,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompromised hospitalized adults,immunocompromised hospitalized adults,88.0,81.0,93.0,,delta,~16 weeks,,,,,
29,Tenforde,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,97.0,95.0,99.0,,delta,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,infection,infection,USA,nursing home residents,LTCF residents,37.7,25.4,44.2,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,hospitalization,severe,USA,nursing home residents,LTCF residents,74.4,44.6,86.2,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,death,death,USA,nursing home residents,LTCF residents,87.9,75.9,93.9,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,hospitalization or death,severe,USA,nursing home residents,LTCF residents,80.3,65.7,88.5,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,infection,infection,USA,residents of Veterans Affairs community living centers,residents of Veterans Affairs community living centers,57.7,43.5,67.8,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,hospitalization,severe,USA,residents of Veterans Affairs community living centers,residents of Veterans Affairs community living centers,64.1,41.3,76.0,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,death,death,USA,residents of Veterans Affairs community living centers,residents of Veterans Affairs community living centers,46.6,-34.6,94.8,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,hospitalization or death,severe,USA,residents of Veterans Affairs community living centers,residents of Veterans Affairs community living centers,63.8,41.4,76.1,,delta & omicron,~10 weeks,,,,,
31,Willet,Test-negative case-control,26Jan2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,infection,infection,Scotland,≥ 18 years,general pop,43.2,38.1,47.8,omicron,omicron,~11 weeks,,,,,
31,Willet,Test-negative case-control,26Jan2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,infection,infection,Scotland,≥ 18 years,general pop,46.3,41.3,51.0,omicron,omicron,~11 weeks,,,,,
31,Willet,Test-negative case-control,26Jan2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,infection,infection,Scotland,≥ 18 years,general pop,85.9,84.2,87.4,delta,delta,~11 weeks,,,,,
31,Willet,Test-negative case-control,26Jan2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,infection,infection,Scotland,≥ 18 years,general pop,86.5,84.8,88.0,delta,delta,~11 weeks,,,,,
32,Lytras,Retrospective cohort,14Jun2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,intubation,severe,Greece,15-79 years,15-79 years,98.2,97.2,98.9,,"non-VOC, alpha, & delta",~12 weeks,,,,,
32,Lytras,Retrospective cohort,14Jun2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,intubation,severe,Greece,≥ 80 years,≥ 80 years,97.5,95.5,98.6,,"non-VOC, alpha, & delta",~12 weeks,,,,,
32,Lytras,Retrospective cohort,14Jun2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,death,death,Greece,15-79 years,15-79 years,98.3,96.9,99.1,,"non-VOC, alpha, & delta",~12 weeks,,,,,
32,Lytras,Retrospective cohort,14Jun2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,death,death,Greece,≥ 80 years,≥ 80 years,98.4,97.4,99.0,,"non-VOC, alpha, & delta",~12 weeks,,,,,
33,Roberts,Test-negative case-control,31Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,14+,infection,infection,USA,≥ 18 years,general pop,87.3,85.0,89.2,,"non-VOC, alpha, & delta",~20 weeks,,,,,
33,Roberts,Test-negative case-control,31Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,14+,severe disease,severe,USA,≥ 18 years,general pop,94.0,89.5,96.6,,"non-VOC, alpha, & delta",~20 weeks,,,,,
34,Bar-On,Prospective cohort,01Feb2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 3 doses ≥4 months prior,12+,infection,infection,Israel,≥ 60 years,≥ 60 years,50.0,50.0,53.0,,omicron,2 weeks,,,,,
34,Bar-On,Prospective cohort,01Feb2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 3 doses ≥4 months prior,12+,severe disease,severe,Israel,≥ 60 years,≥ 60 years,77.0,59.0,87.0,,omicron,2 weeks,,,,,
35,Sritipsukho,Test-negative case-control,03Feb2022,CoronaVac (Sinovac),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,7+,infection,infection,Thailand,≥ 18 years,general pop,86.0,74.0,93.0,,delta,~6 weeks,,,,,
35,Sritipsukho,Test-negative case-control,03Feb2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,Thailand,≥ 18 years,general pop,98.0,87.0,100.0,,delta,~8 weeks,,,,,
36,Lauring,Test-negative case-control,09Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,USA,≥ 18 years,general pop,86.0,77.0,91.0,omicron,omicron,~3 weeks,,,,,
36,Lauring,Test-negative case-control,09Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,USA,≥ 18 years,general pop,94.0,92.0,95.0,delta,delta,~25 weeks,,,,,
36,Lauring,Test-negative case-control,09Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompromised,immunocompromised,87.0,78.0,92.0,delta,delta,~25 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,<1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,59.9,51.2,67.0,omicron BA.1,omicron BA.1,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,40.5,30.8,48.8,omicron BA.1,omicron BA.1,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,51.5,32.3,65.2,omicron BA.1,omicron BA.1,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,45.3,17.8,63.5,omicron BA.1,omicron BA.1,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,<1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,43.7,36.5,50.0,omicron BA.2,omicron BA.2,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,40.2,34.2,45.7,omicron BA.2,omicron BA.2,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,39.4,24.8,51.2,omicron BA.2,omicron BA.2,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,41.9,23.4,56.0,omicron BA.2,omicron BA.2,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,<1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,49.5,44.3,54.1,omicron,omicron,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,39.4,34.4,44.0,omicron,omicron,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,43.6,33.2,52.4,omicron,omicron,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥1 month,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,47.5,34.1,58.1,omicron,omicron,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,1-6 weeks,"severe, critical, or fatal disease",severe,Qatar,≥ 18 years,general pop,90.9,78.6,96.1,omicron,omicron,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥7 weeks,"severe, critical, or fatal disease",severe,Qatar,≥ 18 years,general pop,90.9,78.6,96.1,omicron,omicron,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,1-6 weeks,"severe, critical, or fatal disease",severe,Qatar,≥ 18 years,general pop,81.8,-49.5,97.8,omicron,omicron,~19 weeks,,,,,
37,Chemaitelly,Test-negative case-control,13Mar2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥7 weeks,"severe, critical, or fatal disease",severe,Qatar,≥ 18 years,general pop,100.0,,,omicron,omicron,~19 weeks,,,,,
38,Cerqueira-Silva,Test-negative case-control,09Feb2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,7-13,infection,infection,Brazil,≥ 18 years,general pop,80.2,77.0,82.9,,gamma & delta,~5 weeks,,,,,
38,Cerqueira-Silva,Test-negative case-control,09Feb2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,30+,infection,infection,Brazil,≥ 18 years,general pop,82.6,76.9,86.9,,gamma & delta,~5 weeks,,,,,
38,Cerqueira-Silva,Test-negative case-control,09Feb2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,7-13,severe disease,severe,Brazil,≥ 18 years,general pop,91.0,88.5,93.5,,gamma & delta,~5 weeks,,,,,
38,Cerqueira-Silva,Test-negative case-control,09Feb2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,30+,severe disease,severe,Brazil,≥ 18 years,general pop,96.8,94.1,98.3,,gamma & delta,~5 weeks,,,,,
38,Cerqueira-Silva,Test-negative case-control,09Feb2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,7-13,hospitalization,severe,Brazil,≥ 18 years,general pop,91.2,88.3,93.4,,gamma & delta,~5 weeks,,,,,
38,Cerqueira-Silva,Test-negative case-control,09Feb2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,30+,hospitalization,severe,Brazil,≥ 18 years,general pop,96.7,93.9,98.2,,gamma & delta,~5 weeks,,,,,
38,Cerqueira-Silva,Test-negative case-control,09Feb2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,7-13,death,death,Brazil,≥ 18 years,general pop,92.2,87.4,95.2,,gamma & delta,~5 weeks,,,,,
38,Cerqueira-Silva,Test-negative case-control,09Feb2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,30+,death,death,Brazil,≥ 18 years,general pop,97.1,90.5,99.1,,gamma & delta,~5 weeks,,,,,
39,Hayek,Retrospective cohort,27Jan2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of primary mRNA series ≥5 months prior,7+,infection,infection,Israel,households with children,households with children,86.3,83.4,88.6,,delta,~11 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,<2 months,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,87.0,85.0,88.0,,omicron,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,≥5 months,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,31.0,-50.0,68.0,,omicron,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,<2 months,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,91.0,88.0,93.0,,omicron,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,≥4 months,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,78.0,67.0,85.0,,omicron,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,<2 months,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,97.0,96.0,97.0,,delta,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,≥4 months,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,89.0,64.0,97.0,,delta,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,<2 months,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,96.0,95.0,97.0,,delta,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,≥4 months,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,76.0,14.0,93.0,,delta,~25 weeks,,,,,
41,Regev-Yochay,"Open-label, non-randomized clinical trial",15Feb2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,8-29,infection,infection,Israel,HCW,HCW,30.0,-9.0,55.0,,omicron,~2 weeks,,,,,
41,Regev-Yochay,"Open-label, non-randomized clinical trial",15Feb2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,8-29,symptomatic disease,symptomatic,Israel,HCW,HCW,43.0,7.0,65.0,,omicron,~2 weeks,,,,,
41,Regev-Yochay,"Open-label, non-randomized clinical trial",15Feb2022,BNT162b2 (Pfizer) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,8-23,infection,infection,Israel,HCW,HCW,11.0,-43.0,43.0,,omicron,~1 week,,,,,
41,Regev-Yochay,"Open-label, non-randomized clinical trial",15Feb2022,BNT162b2 (Pfizer) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,8-23,symptomatic disease,symptomatic,Israel,HCW,HCW,31.0,-18.0,60.0,,omicron,~1 week,,,,,
42,Monge,Retrospective cohort,02Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses (or 1 dose for Ad26.COV2.S) ≥3 months prior,7-34,infection,infection,Spain,≥ 40 years,≥ 40 years,49.7,48.3,51.1,,omicron,~3 weeks,,,,,
42,Monge,Retrospective cohort,02Jun2022,mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses (or 1 dose for Ad26.COV2.S) ≥3 months prior,7-34,infection,infection,Spain,≥ 40 years,≥ 40 years,55.3,52.3,58.2,,omicron,~3 weeks,,,,,
42,Monge,Retrospective cohort,02Jun2022,AZD1222 (AstraZeneca),Pfizer,excluded,complete vaccination with 2 doses (or 1 dose for Ad26.COV2.S) ≥3 months prior,7-34,infection,infection,Spain,≥ 40 years,≥ 40 years,58.6,55.5,61.6,,omicron,~3 weeks,,,,,
42,Monge,Retrospective cohort,02Jun2022,Ad26.COV2.S (Janssen),Pfizer,excluded,complete vaccination with 2 doses (or 1 dose for Ad26.COV2.S) ≥3 months prior,7-34,infection,infection,Spain,≥ 40 years,≥ 40 years,48.0,42.5,53.7,,omicron,~3 weeks,,,,,
43,Patalon,Test-negative case-control,09Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥5 months prior,1-51,infection,infection,Israel,≥ 18 years,general pop,53.4,47.7,58.6,,omicron,~21 weeks,,,,,
43,Patalon,Test-negative case-control,09Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥5 months prior,93-142,infection,infection,Israel,≥ 18 years,general pop,3.6,0.6,6.5,,omicron,~21 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-74,infection,infection,Czech Republic,≥ 18 years,general pop,58.0,58.0,59.0,,omicron,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,75+,infection,infection,Czech Republic,≥ 18 years,general pop,24.0,22.0,26.0,,omicron,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,86.0,84.0,89.0,,omicron,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,75+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,79.0,74.0,82.0,,omicron,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-74,infection,infection,Czech Republic,≥ 18 years,general pop,61.0,60.0,62.0,,omicron,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,75+,infection,infection,Czech Republic,≥ 18 years,general pop,33.0,29.0,38.0,,omicron,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,89.0,84.0,93.0,,omicron,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,75+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,84.0,72.0,91.0,,omicron,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-74,infection,infection,Czech Republic,≥ 18 years,general pop,90.0,90.0,91.0,,delta,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,75+,infection,infection,Czech Republic,≥ 18 years,general pop,80.0,78.0,83.0,,delta,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,98.0,97.0,98.0,,delta,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,75+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,96.0,94.0,97.0,,delta,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-74,infection,infection,Czech Republic,≥ 18 years,general pop,93.0,92.0,94.0,,delta,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,75+,infection,infection,Czech Republic,≥ 18 years,general pop,91.0,83.0,96.0,,delta,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,98.0,97.0,99.0,,delta,~24 weeks,,,,,
44,Šmíd,Retrospective cohort,25Feb2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,75+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,98.0,86.0,99.8,,delta,~24 weeks,,,,,
45,Klein,Test-negative case-control,01Mar2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,16-17 years,16-17 years,81.0,59.0,91.0,,omicron,~4 weeks,,,,,
45,Klein,Test-negative case-control,01Mar2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,16-17 years,16-17 years,86.0,73.0,93.0,,omicron or delta,~4 weeks,,,,,
46,Norddahl,Retrospective cohort,01Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination 6 or more months prior,0+,infection,infection,Iceland,18-80 years,general pop,47.0,36.0,56.0,omicron,omicron,~4 weeks,,,,,
46,Norddahl,Retrospective cohort,01Mar2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination 6 or more months prior,0+,infection,infection,Iceland,18-80 years,general pop,50.0,34.0,62.0,omicron,omicron,~4 weeks,,,,,
46,Norddahl,Retrospective cohort,01Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination 6 or more months prior,0+,infection,infection,Iceland,18-80 years,general pop,52.0,28.0,69.0,delta,delta,~4 weeks,,,,,
46,Norddahl,Retrospective cohort,01Mar2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination 6 or more months prior,0+,infection,infection,Iceland,18-80 years,general pop,73.0,29.0,90.0,delta,delta,~4 weeks,,,,,
47,Butt,Retrospective cohort,04Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination 4.5 months prior,14+,symptomatic disease,symptomatic,USA,veterans,veterans,84.0,78.0,88.0,,delta,7 weeks,,,,,
47,Butt,Retrospective cohort,04Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination 4.5 months prior,14+,hospitalization,severe,USA,veterans,veterans,77.0,65.0,85.0,,delta,7 weeks,,,,,
47,Butt,Retrospective cohort,04Mar2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination 4.5 months prior,14+,symptomatic disease,symptomatic,USA,veterans,veterans,87.0,83.0,90.0,,delta,7 weeks,,,,,
47,Butt,Retrospective cohort,04Mar2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination 4.5 months prior,14+,hospitalization,severe,USA,veterans,veterans,84.0,93.0,95.0,,delta,7 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,0+,infection,infection,UK,LTCF residents,LTCF residents,71.4,49.7,83.8,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,0+,hospitalization,severe,UK,LTCF residents,LTCF residents,83.6,63.4,92.7,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,0+,death,death,UK,LTCF residents,LTCF residents,98.7,90.0,99.8,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,0+,infection,infection,UK,LTCF residents,LTCF residents,71.4,49.0,84.0,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,0+,hospitalization,severe,UK,LTCF residents,LTCF residents,93.3,82.8,97.4,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,0+,death,death,UK,LTCF residents,LTCF residents,95.3,79.4,98.9,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,0+,infection,infection,UK,LTCF staff,LTCF staff,79.3,70.0,85.7,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,0+,hospitalization,severe,UK,LTCF staff,LTCF staff,100.0,,,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,0+,infection,infection,UK,LTCF staff,LTCF staff,75.9,61.5,84.8,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,0+,hospitalization,severe,UK,LTCF staff,LTCF staff,93.4,25.2,99.4,,alpha & delta,11 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,95.0,94.0,96.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,89.0,87.0,91.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-60,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,98.0,95.0,99.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,61+,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,95.0,92.0,97.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,91.0,87.0,94.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,85.0,78.0,89.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,14-60,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,92.0,79.0,97.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,61+,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,96.0,84.0,99.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,91.0,81.0,96.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,90.0,80.0,94.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,97.0,93.0,98.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,87.0,82.0,91.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,98.0,91.0,99.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,88.0,78.0,93.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,61+,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,96.0,71.0,99.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,94.0,82.0,98.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,87.0,70.0,95.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,unvaccinated individuals,61+,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,89.0,22.0,99.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,96.0,93.0,97.0,,delta,~13 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,94.0,75.0,99.0,,delta,~13 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,75.0,-3.0,94.0,,delta,~13 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,82.0,28.0,96.0,,delta,~13 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,100.0,,,,delta,~13 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,100.0,,,,delta,~13 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,100.0,,,,delta,~13 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,84.0,-16.0,98.0,,delta,~13 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,94.0,92.0,95.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,87.0,85.0,89.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,91.0,87.0,94.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,83.0,76.0,88.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,92.0,80.0,97.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,88.0,77.0,94.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,96.0,91.0,98.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,85.0,78.0,89.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,99.0,91.0,100.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,86.0,75.0,92.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,94.0,81.0,98.0,,omicron,~20.5 weeks,,,,,
49,Baum,Retrospective cohort,05Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,87.0,68.0,95.0,,omicron,~20.5 weeks,,,,,
50,Montez-Rath,Prospective cohort,18Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,,unvaccinated individuals,21+,infection,infection,USA,dialysis patients,dialysis patients,53.0,38.0,65.0,omicron,omicron,~14 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,74.4,63.4,82.2,omicron BA.1,omicron BA.1,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,previously infected only,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100.0,30.6,100.0,omicron BA.1,omicron BA.1,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,77.2,38.5,91.5,omicron BA.1,omicron BA.1,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100.0,,,omicron BA.1,omicron BA.1,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,59.6,52.9,65.3,omicron BA.1,omicron BA.1,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,97.5,71.7,99.8,omicron BA.1,omicron BA.1,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,56.5,38.1,69.4,omicron BA.1,omicron BA.1,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100.0,-432.5,100.0,omicron BA.1,omicron BA.1,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,77.3,72.4,81.4,omicron BA.2,omicron BA.2,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,previously infected only,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100.0,82.6,100.0,omicron BA.2,omicron BA.2,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,69.8,50.1,81.7,omicron BA.2,omicron BA.2,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100.0,,,omicron BA.2,omicron BA.2,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,52.2,48.1,55.9,omicron BA.2,omicron BA.2,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,98.2,91.9,99.6,omicron BA.2,omicron BA.2,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,52.9,43.0,61.2,omicron BA.2,omicron BA.2,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100.0,-3800.0,100.0,omicron BA.2,omicron BA.2,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,76.3,71.7,80.1,omicron,omicron,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,previously infected only,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100.0,91.8,100.0,omicron,omicron,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,79.4,66.1,87.5,omicron,omicron,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100.0,-51.5,100.0,omicron,omicron,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,54.0,50.4,57.3,omicron,omicron,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,92.5,84.4,96.3,omicron,omicron,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,61.3,53.3,67.9,omicron,omicron,~19 weeks,,,,,
51,Altarawneh,Test-negative case-control,15Jun2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,82.7,-80.2,98.3,omicron,omicron,~19 weeks,,,,,
52,Tenforde,Case-control,25Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,94.0,88.0,97.0,,omicron,~20 weeks,,,,,
53,Tenforde,Case-control,25Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,95.0,91.0,97.0,,delta,~20 weeks,,,,,
53,Tenforde,Case-control,25Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,94.0,91.0,96.0,,alpha,~20 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,7-13,hospitalization,severe,UK,18-64 years,18-64 years,83.0,78.0,85.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,105+,hospitalization,severe,UK,18-64 years,18-64 years,39.0,18.0,58.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14-28,ICU admission,severe,UK,18-64 years,18-64 years,98.0,90.0,99.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,70-98,ICU admission,severe,UK,18-64 years,18-64 years,90.0,77.0,98.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,7-13,hospitalization,severe,UK,18-64 years,18-64 years,90.0,79.0,92.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,70+,hospitalization,severe,UK,18-64 years,18-64 years,75.0,56.0,83.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,14-28,ICU admission,severe,UK,18-64 years,18-64 years,97.0,64.0,100.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,35-63,ICU admission,severe,UK,18-64 years,18-64 years,97.0,72.0,99.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7-13,hospitalization,severe,UK,18-64 years,18-64 years,79.0,68.0,83.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,105+,hospitalization,severe,UK,18-64 years,18-64 years,70.0,59.0,78.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-28,ICU admission,severe,UK,18-64 years,18-64 years,99.0,90.0,100.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,70-98,ICU admission,severe,UK,18-64 years,18-64 years,89.0,74.0,96.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,7-13,hospitalization,severe,UK,18-64 years,18-64 years,89.0,78.0,92.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,70+,hospitalization,severe,UK,18-64 years,18-64 years,60.0,28.0,79.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,7-13,hospitalization,severe,UK,≥ 65 years,≥ 65 years,96.0,78.0,98.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,105+,hospitalization,severe,UK,≥ 65 years,≥ 65 years,82.0,77.0,84.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,7-13,ICU admission,severe,UK,≥ 65 years,≥ 65 years,97.0,36.0,100.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,105+,ICU admission,severe,UK,≥ 65 years,≥ 65 years,92.0,82.0,96.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,14-28,hospitalization,severe,UK,≥ 65 years,≥ 65 years,99.0,95.0,100.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,70+,hospitalization,severe,UK,≥ 65 years,≥ 65 years,90.0,75.0,96.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,14-28,ICU admission,severe,UK,≥ 65 years,≥ 65 years,99.0,84.0,100.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,35-63,ICU admission,severe,UK,≥ 65 years,≥ 65 years,98.0,90.0,99.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7-13,hospitalization,severe,UK,≥ 65 years,≥ 65 years,90.0,59.0,98.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,105+,hospitalization,severe,UK,≥ 65 years,≥ 65 years,83.0,82.0,84.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7-13,ICU admission,severe,UK,≥ 65 years,≥ 65 years,94.0,10.0,99.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,105+,ICU admission,severe,UK,≥ 65 years,≥ 65 years,82.0,70.0,90.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,7-13,hospitalization,severe,UK,≥ 65 years,≥ 65 years,90.0,18.0,99.0,,omicron,~22 weeks,,,,,
53,Stowe,Test-negative case-control,30Sep2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,14-28,hospitalization,severe,UK,≥ 65 years,≥ 65 years,92.0,64.0,96.0,,omicron,~22 weeks,,,,,
54,Gazit,Matched test-negative case control,24May2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7-13,infection,infection,Israel,≥ 60 years,≥ 60 years,57.7,55.6,59.7,,omicron,~10 weeks,,,,,
54,Gazit,Matched test-negative case control,24May2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,63-69,infection,infection,Israel,≥ 60 years,≥ 60 years,22.0,4.9,36.1,,omicron,~10 weeks,,,,,
54,Gazit,Matched test-negative case control,24May2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7-27,severe disease,severe,Israel,≥ 60 years,≥ 60 years,77.5,69.7,83.2,,omicron,~10 weeks,,,,,
54,Gazit,Matched test-negative case control,24May2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,49-69,severe disease,severe,Israel,≥ 60 years,≥ 60 years,86.5,63.4,95.0,,omicron,~10 weeks,,,,,
54,Gazit,Unmatched multiple test analysis,24May2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7-13,infection,infection,Israel,≥ 60 years,≥ 60 years,46.0,43.7,48.3,,omicron,~10 weeks,,,,,
54,Gazit,Unmatched multiple test analysis,24May2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,63-69,infection,infection,Israel,≥ 60 years,≥ 60 years,29.5,18.1,39.2,,omicron,~10 weeks,,,,,
54,Gazit,Unmatched multiple test analysis,24May2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7-27,severe disease,severe,Israel,≥ 60 years,≥ 60 years,73.3,66.3,78.9,,omicron,~10 weeks,,,,,
54,Gazit,Unmatched multiple test analysis,24May2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,49-69,severe disease,severe,Israel,≥ 60 years,≥ 60 years,86.1,73.4,92.8,,omicron,~10 weeks,,,,,
55,Arbel,Retrospective cohort,25Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7+,death,death,Israel,≥ 60 years,≥ 60 years,78.0,72.0,83.0,,omicron,~5 weeks,,,,,
56,Wang,Test-negative case-control,23Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14-179,infection,infection,USA,patients,general pop,65.0,63.0,66.0,,omicron,~23.5 weeks,,,,,
56,Wang,Test-negative case-control,23Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180+,infection,infection,USA,patients,general pop,50.0,45.0,55.0,,omicron,unknown,,,,,
56,Wang,Test-negative case-control,23Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14-179,infection,infection,USA,patients,general pop,91.0,90.0,92.0,,delta,~23.5 weeks,,,,,
56,Wang,Test-negative case-control,23Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180+,infection,infection,USA,patients,general pop,71.0,67.0,74.0,,delta,unknown,,,,,
57,Natarajan,Test-negative case-control,29Mar2022,Ad26.COV2.S (Janssen),Janssen,included,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations among adults with COVID-19 like illness,general pop,54.0,43.0,63.0,,omicron,~15 weeks,,,,,
57,Natarajan,Test-negative case-control,29Mar2022,Ad26.COV2.S (Janssen),Janssen,included,unvaccinated individuals,7+,hospitalization,severe,USA,ED/UC encounters and hospitalizations among adults with COVID-19 like illness,general pop,67.0,52.0,77.0,,omicron,~15 weeks,,,,,
57,Natarajan,Test-negative case-control,29Mar2022,Ad26.COV2.S (Janssen),Pfizer,included,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations among adults with COVID-19 like illness,general pop,79.0,74.0,82.0,,omicron,~15 weeks,,,,,
57,Natarajan,Test-negative case-control,29Mar2022,Ad26.COV2.S (Janssen),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,ED/UC encounters and hospitalizations among adults with COVID-19 like illness,general pop,78.0,70.0,84.0,,omicron,~15 weeks,,,,,
57,Natarajan,Test-negative case-control,29Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations among adults with COVID-19 like illness,general pop,83.0,82.0,84.0,,omicron,~15 weeks,,,,,
57,Natarajan,Test-negative case-control,29Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,ED/UC encounters and hospitalizations among adults with COVID-19 like illness,general pop,90.0,88.0,91.0,,omicron,~15 weeks,,,,,
58,Hansen,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-30,infection,infection,Denmark,≥ 12 years,general pop,47.9,47.4,48.2,,omicron,~2 weeks,,,,,
58,Hansen,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,121+,infection,infection,Denmark,≥ 12 years,general pop,40.5,38.9,42.2,,omicron,~20 weeks,,,,,
58,Hansen,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-30,hospitalization,severe,Denmark,≥ 12 years,general pop,88.8,87.3,90.1,,omicron,~2 weeks,,,,,
58,Hansen,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,121+,hospitalization,severe,Denmark,≥ 12 years,general pop,66.2,61.1,70.7,,omicron,~20 weeks,,,,,
58,Hansen,Retrospective cohort,30Mar2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-30,infection,infection,Denmark,≥ 12 years,general pop,47.7,47.0,48.3,,omicron,~2 weeks,,,,,
58,Hansen,Retrospective cohort,30Mar2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,121+,infection,infection,Denmark,≥ 12 years,general pop,37.9,33.4,42.0,,omicron,~18 weeks,,,,,
58,Hansen,Retrospective cohort,30Mar2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-30,hospitalization,severe,Denmark,≥ 12 years,general pop,90.2,87.3,92.5,,omicron,~2 weeks,,,,,
58,Hansen,Retrospective cohort,30Mar2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,121+,hospitalization,severe,Denmark,≥ 12 years,general pop,77.3,63.1,86.1,,omicron,~18 weeks,,,,,
61,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,Norway,≥ 18 years,general pop,75.3,72.5,77.8,,delta,~6.5 weeks,,,,,
61,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,Norway,≥ 18 years,general pop,95.6,93.1,97.2,,delta,~6.5 weeks,,,,,
61,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,7+,infection,infection,Norway,≥ 18 years,general pop,68.2,57.6,76.1,,delta,~6.5 weeks,,,,,
61,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,Norway,≥ 18 years,general pop,73.5,45.7,87.1,,delta,~6.5 weeks,,,,,
61,Starrfelt,Retrospective cohort,30Mar2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,infection,infection,Norway,≥ 18 years,general pop,84.9,71.8,91.9,,delta,~6.5 weeks,,,,,
61,Starrfelt,Retrospective cohort,30Mar2022,mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,Norway,≥ 18 years,general pop,87.1,80.1,91.6,,delta,~6.5 weeks,,,,,
59,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,Norway,≥ 18 years,general pop,75.3,72.5,77.8,,delta,~6.5 weeks,,,,,
59,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,Norway,≥ 18 years,general pop,95.6,93.1,97.2,,delta,~6.5 weeks,,,,,
59,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,7+,infection,infection,Norway,≥ 18 years,general pop,68.2,57.6,76.1,,delta,~6.5 weeks,,,,,
59,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,Norway,≥ 18 years,general pop,73.5,45.7,87.1,,delta,~6.5 weeks,,,,,
59,Starrfelt,Retrospective cohort,30Mar2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,infection,infection,Norway,≥ 18 years,general pop,84.9,71.8,91.9,,delta,~6.5 weeks,,,,,
59,Starrfelt,Retrospective cohort,30Mar2022,mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,Norway,≥ 18 years,general pop,87.1,80.1,91.6,,delta,~6.5 weeks,,,,,
60,Glatman-Freedman,Retrospective cohort,31Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,15-21,infection,infection,Israel,16-59 years,16-59 years,96.8,96.0,97.5,,delta & omicron,14 weeks,,,,,
60,Glatman-Freedman,Retrospective cohort,31Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,106-112,infection,infection,Israel,16-59 years,16-59 years,77.6,68.4,84.2,,delta & omicron,14 weeks,,,,,
60,Glatman-Freedman,Retrospective cohort,31Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,15-21,infection,infection,Israel,≥ 60 years,≥ 60 years,93.1,91.8,94.2,,delta & omicron,18 weeks,,,,,
60,Glatman-Freedman,Retrospective cohort,31Mar2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,134-140,infection,infection,Israel,≥ 60 years,≥ 60 years,61.3,52.5,68.4,,delta & omicron,18 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,complete vaccination with 2 doses of CoronaVac ≥6 months prior,8-59,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,4.9,1.5,8.1,,omicron,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,complete vaccination with 2 doses of CoronaVac ≥6 months prior,120+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,-24.8,-28.0,21.6,,omicron,~29 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,complete vaccination with 2 doses of CoronaVac ≥6 months prior,8-59,hospitalization or death,severe,Brazil,≥ 18 years,general pop,47.1,27.8,61.2,,omicron,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,complete vaccination with 2 doses of CoronaVac ≥6 months prior,120+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,20.7,10.1,30.0,,omicron,~29 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,complete vaccination with 2 doses of CoronaVac ≥6 months prior,8-59,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,53.5,52.9,54.2,,omicron,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,complete vaccination with 2 doses of CoronaVac ≥6 months prior,120+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,15.7,14.2,17.1,,omicron,~29 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,complete vaccination with 2 doses of CoronaVac ≥6 months prior,8-59,hospitalization or death,severe,Brazil,≥ 18 years,general pop,67.3,63.9,70.4,,omicron,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,complete vaccination with 2 doses of CoronaVac ≥6 months prior,120+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,62.8,59.3,65.9,,omicron,~29 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,unvaccinated individuals,8-59,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,8.6,5.6,11.5,,omicron,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,unvaccinated individuals,60+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,-2.9,-5.2,-0.6,,omicron,~29 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,unvaccinated individuals,8-59,hospitalization or death,severe,Brazil,≥ 18 years,general pop,73.6,63.9,80.7,,omicron,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,unvaccinated individuals,60+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,67.8,64.3,71.0,,omicron,~29 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,8-59,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,56.8,56.3,57.3,,omicron,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,60+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,33.8,33.2,34.4,,omicron,~29 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,8-59,hospitalization or death,severe,Brazil,≥ 18 years,general pop,86.0,84.5,87.4,,omicron,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,60+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,86.4,85.4,87.3,,omicron,~29 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,unvaccinated individuals,8-59,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,57.1,50.4,62.9,,delta,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,unvaccinated individuals,60+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,53.5,30.9,68.6,,delta,~11 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,unvaccinated individuals,8-59,hospitalization or death,severe,Brazil,≥ 18 years,general pop,75.9,67.8,81.9,,delta,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,unvaccinated individuals,60+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,75.6,52.8,87.4,,delta,~11 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,8-59,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,86.7,86.0,87.4,,delta,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,60+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,83.2,79.8,86.1,,delta,~11 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,8-59,hospitalization or death,severe,Brazil,≥ 18 years,general pop,92.3,91.0,92.9,,delta,~7 weeks,,,,,
61,Ranzani,Test-negative case-control,28Sep2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,60+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,90.8,84.8,94.4,,delta,~11 weeks,,,,,
62,Yoon,Prospective cohort,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,USA,HCW,HCW,60.0,42.0,72.0,omicron,omicron,~21 weeks,,,,,
62,Yoon,Prospective cohort,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses,7+,infection,infection,USA,HCW,HCW,60.0,40.0,73.0,omicron,omicron,~21 weeks,,,,,
62,Yoon,Prospective cohort,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,USA,HCW,HCW,91.0,84.0,95.0,delta,delta,~21 weeks,,,,,
62,Yoon,Prospective cohort,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses,7+,infection,infection,USA,HCW,HCW,86.0,69.0,94.0,delta,delta,~21 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,transplant recipients,transplant recipients,77.0,48.0,90.0,,alpha & delta,~16 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompromised,immunocompromised,92.0,85.0,95.0,,alpha & delta,~16 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompetent adults,general pop,96.0,94.0,98.0,,alpha & delta,~16 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,supplemental oxygen/oxygen support,severe,USA,transplant recipients,transplant recipients,84.0,57.0,94.0,,alpha & delta,~16 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,supplemental oxygen/oxygen support,severe,USA,immunocompromised,immunocompromised,93.0,85.0,97.0,,alpha & delta,~16 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,supplemental oxygen/oxygen support,severe,USA,immunocompetent adults,general pop,97.0,94.0,98.0,,alpha & delta,~16 weeks,,,,,
64,Buchan,Test-negative case-control,07Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,symptomatic disease,symptomatic,Canada,12-17 years,12-17 years,62.0,49.0,72.0,omicron,omicron,~3 weeks,,,,,
65,Kim,Test-negative case-control,29Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses ≥150 days prior,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,62.0,48.0,72.0,omicron,omicron,~33 weeks,,,,,
65,Kim,Test-negative case-control,29Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses ≥150 days prior,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,96.0,93.0,98.0,delta,delta,~33 weeks,,,,,
66,Plumb,Test-negative case-control,12Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14+,hospitalization,severe,USA,hospitalized adults,general pop,67.6,61.4,72.8,,omicron,~25 weeks,,,,,
66,Plumb,Test-negative case-control,12Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14+,hospitalization,severe,USA,hospitalized adults,general pop,57.8,32.1,73.8,,delta,~25 weeks,,,,,
67,Institute of Public Health,Test-negative case-control,12Apr2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,hospitalization,severe,Chile,≥ 18 years,general pop,88.3,79.5,93.3,,gamma & delta,~24 weeks,,,,,
67,Institute of Public Health,Test-negative case-control,12Apr2022,CoronaVac (Sinovac),Coronavac (Sinovac),included,unvaccinated individuals,14+,hospitalization,severe,Chile,≥ 18 years,general pop,67.2,59.1,73.7,,gamma & delta,~24 weeks,,,,,
68,Cohen,Retrospective cohort,02Aug2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7+,infection,infection,Israel,HCW,HCW,44.0,37.0,50.0,,omicron,~4 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,BNT162b2 (Pfizer),Pfizer,previously infected only,"unvaccinated individuals, previously infected",14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,56.4,53.7,59.0,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,BNT162b2 (Pfizer),Pfizer,previously infected only,"unvaccinated individuals, previously infected",70+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,43.3,25.8,56.6,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,BNT162b2 (Pfizer),Pfizer,previously infected only,"unvaccinated individuals, previously infected",14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,75.0,53.3,86.7,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),previously infected only,"unvaccinated individuals, previously infected",14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,60.5,59.1,61.9,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),previously infected only,"unvaccinated individuals, previously infected",70+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,32.6,29.4,35.7,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),previously infected only,"unvaccinated individuals, previously infected",14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,84.5,79.4,88.4,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),previously infected only,"unvaccinated individuals, previously infected",70+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,81.2,72.5,87.1,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,Ad26.COV2.S (Janssen),Janssen,previously infected only,"unvaccinated individuals, previously infected",14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,22.8,18.8,26.6,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,Ad26.COV2.S (Janssen),Janssen,previously infected only,"unvaccinated individuals, previously infected",14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,84.0,56.5,94.1,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,CoronaVac (Sinovac),CoronaVac (Sinovac),previously infected only,"unvaccinated individuals, previously infected",14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,62.7,61.0,64.3,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,CoronaVac (Sinovac),CoronaVac (Sinovac),previously infected only,"unvaccinated individuals, previously infected",70+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,37.9,35.8,40.0,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,CoronaVac (Sinovac),CoronaVac (Sinovac),previously infected only,"unvaccinated individuals, previously infected",14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,76.6,68.1,82.8,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,CoronaVac (Sinovac),CoronaVac (Sinovac),previously infected only,"unvaccinated individuals, previously infected",70+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,75.7,69.6,80.7,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,BNT162b2 (Pfizer),Pfizer,previously infected only,"unvaccinated individuals, previously infected",14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,58.1,55.3,60.6,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,BNT162b2 (Pfizer),Pfizer,previously infected only,"unvaccinated individuals, previously infected",70+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,29.8,3.3,49.0,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,BNT162b2 (Pfizer),Pfizer,previously infected only,"unvaccinated individuals, previously infected",14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,85.2,55.7,95.1,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),previously infected only,"unvaccinated individuals, previously infected",14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,61.3,59.9,62.7,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),previously infected only,"unvaccinated individuals, previously infected",70+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,36.4,33.3,39.4,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),previously infected only,"unvaccinated individuals, previously infected",14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,89.7,81.5,94.3,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),previously infected only,"unvaccinated individuals, previously infected",70+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,86.3,71.6,93.4,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,Ad26.COV2.S (Janssen),Janssen,previously infected only,"unvaccinated individuals, previously infected",14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,24.5,20.6,28.2,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,Ad26.COV2.S (Janssen),Janssen,previously infected only,"unvaccinated individuals, previously infected",70-139,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,16.2,-4.7,33.0,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,Ad26.COV2.S (Janssen),Janssen,previously infected only,"unvaccinated individuals, previously infected",14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,92.3,64.7,98.3,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,CoronaVac (Sinovac),CoronaVac (Sinovac),previously infected only,"unvaccinated individuals, previously infected",14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,62.9,61.2,64.5,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,CoronaVac (Sinovac),CoronaVac (Sinovac),previously infected only,"unvaccinated individuals, previously infected",70+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,41.1,39.1,43.1,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,CoronaVac (Sinovac),CoronaVac (Sinovac),previously infected only,"unvaccinated individuals, previously infected",14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,81.0,64.0,90.0,,omicron,~28 weeks,,,,,
69,Cerqueira-Silva ,Matched case-control,01Jul2022,CoronaVac (Sinovac),CoronaVac (Sinovac),previously infected only,"unvaccinated individuals, previously infected",70+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,84.5,74.0,90.8,,omicron,~28 weeks,,,,,
70,Magen,Target trial,13Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7-30,infection,infection,Israel,≥ 60 years,≥ 60 years,45.0,44.0,47.0,,omicron,~4 weeks,,,,,
70,Magen,Target trial,13Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,14-30,infection,infection,Israel,≥ 60 years,≥ 60 years,52.0,49.0,54.0,,omicron,~4 weeks,,,,,
70,Magen,Target trial,13Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7-30,symptomatic disease,symptomatic,Israel,≥ 60 years,≥ 60 years,55.0,53.0,58.0,,omicron,~4 weeks,,,,,
70,Magen,Target trial,13Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,14-30,symptomatic disease,symptomatic,Israel,≥ 60 years,≥ 60 years,61.0,58.0,64.0,,omicron,~4 weeks,,,,,
70,Magen,Target trial,13Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7-30,hospitalization,severe,Israel,≥ 60 years,≥ 60 years,68.0,59.0,74.0,,omicron,~4 weeks,,,,,
70,Magen,Target trial,13Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,14-30,hospitalization,severe,Israel,≥ 60 years,≥ 60 years,72.0,63.0,79.0,,omicron,~4 weeks,,,,,
70,Magen,Target trial,13Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7-30,severe disease,severe,Israel,≥ 60 years,≥ 60 years,62.0,50.0,74.0,,omicron,~4 weeks,,,,,
70,Magen,Target trial,13Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,14-30,severe disease,severe,Israel,≥ 60 years,≥ 60 years,64.0,48.0,77.0,,omicron,~4 weeks,,,,,
70,Magen,Target trial,13Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,7-30,death,death,Israel,≥ 60 years,≥ 60 years,74.0,50.0,90.0,,omicron,~4 weeks,,,,,
70,Magen,Target trial,13Apr2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥4 months prior,14-30,death,death,Israel,≥ 60 years,≥ 60 years,76.0,48.0,91.0,,omicron,~4 weeks,,,,,
71,Petrie,Prospective cohort,16Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,≥ 12 years,≥ 12 years,66.0,46.0,79.0,,omicron,~25 weeks,,,,,
71,Petrie,Prospective cohort,16Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,≥ 12 years,≥ 12 years,70.0,51.0,81.0,,omicron,~25 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,82.2,81.5,82.8,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,85.8,82.6,88.4,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Sinopharm,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,24.5,15.4,32.5,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Janssen,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,82.4,78.9,85.3,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,94.3,93.3,95.1,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,93.3,85.2,97.0,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Sinopharm,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,76.0,60.9,85.3,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Janssen,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,96.8,90.0,99.0,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,96.8,95.2,97.9,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,95.5,67.9,99.4,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Sinopharm,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,100.0,,,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),Janssen,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,100.0,,,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,88.9,86.9,90.6,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,87.7,85.1,88.4,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Sinopharm,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,69.5,52.1,80.5,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Janssen,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,82.1,73.0,88.1,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,96.5,92.5,98.3,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,97.3,92.7,99.0,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Sinopharm,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,92.0,43.0,98.9,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Janssen,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,100.0,,,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Sinopharm,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,70.7,107.9,95.9,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,100.0,,,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,100.0,,,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,mRNA-1273 (Moderna),Janssen,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,84.1,-12.6,97.8,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,82.9,81.9,83.8,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,84.1,81.2,86.5,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),Sinopharm,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,35.8,14.2,51.9,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,95.1,93.8,96.2,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,98.5,93.9,99.6,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),Sinopharm,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,84.6,38.9,96.2,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,98.4,96.5,99.3,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,100.0,,,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),Sinopharm,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,100.0,,,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Pfizer,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,83.6,82.8,84.4,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Moderna,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,84.0,81.5,86.2,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Sinopharm,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,38.9,22.2,52.0,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Janssen,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,47.2,41.2,52.6,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Pfizer,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,98.0,97.1,98.6,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Moderna,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,97.0,92.1,98.9,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Sinopharm,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,66.8,20.1,86.2,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Janssen,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,95.1,84.8,98.4,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Pfizer,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,99.2,97.4,99.7,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Moderna,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,100.0,,,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Sputnik V (Gamaleya),Janssen,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,100.0,,,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Sinopharm,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,60.6,53.4,66.7,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Pfizer,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,88.0,87.2,88.7,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Moderna,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,91.0,88.2,93.1,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Janssen,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,78.1,74.7,81.0,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Sinopharm,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,77.5,58.2,87.9,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Pfizer,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,94.6,93.3,95.6,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Moderna,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,94.8,87.6,97.9,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Janssen,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,95.3,88.7,98.0,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Sinopharm,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,91.1,36.4,98.7,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Pfizer,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,95.9,93.4,97.5,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Janssen,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,95.8,70.0,99.4,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,BBIBP-CorV (Beijing CNBG),Moderna,included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,100.0,,,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Ad26.COV2.S (Janssen),Janssen,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,78.1,74.7,81.0,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Ad26.COV2.S (Janssen),Pfizer,included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,90.9,84.6,94.6,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Ad26.COV2.S (Janssen),Janssen,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,76.7,-65.9,96.7,,delta,~20 weeks,,,,,
72,Vokó,Retrospective cohort,22Jul2022,Ad26.COV2.S (Janssen),Pfizer,included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,92.2,68.8,98.0,,delta,~20 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,0+,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,44.0,38.0,49.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,0+,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,61.0,50.0,69.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,0+,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,81.0,74.0,86.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,0+,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,32.0,24.0,38.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,0+,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,53.0,39.0,63.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,0+,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,77.0,67.0,83.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,0+,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,36.0,28.0,44.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,0+,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,57.0,40.0,69.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,0+,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,81.0,67.0,89.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,<84,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,39.0,33.0,45.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,≥84,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,37.0,31.0,43.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,<84,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,62.0,51.0,71.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,≥84,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,55.0,45.0,64.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,<84,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,80.0,72.0,86.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,≥84,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,77.0,69.0,82.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,≥7,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,51.0,43.0,58.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,≥7,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,73.0,63.0,80.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,≥7,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,88.0,82.0,92.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) (3 doses),Moderna,included,unvaccinated individuals,≥7,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,51.0,42.0,58.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) (3 doses),Moderna,included,unvaccinated individuals,≥7,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,69.0,56.0,78.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) (3 doses),Moderna,included,unvaccinated individuals,≥7,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,87.0,78.0,92.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) (2 doses) + mRNA-1273 (Moderna) (3rd dose),Moderna,included,unvaccinated individuals,≥7,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,52.0,35.0,64.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) (2 doses) + mRNA-1273 (Moderna) (3rd dose),Moderna,included,unvaccinated individuals,≥7,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,59.0,28.0,77.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) (2 doses) + mRNA-1273 (Moderna) (3rd dose),Moderna,included,unvaccinated individuals,≥7,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,83.0,54.0,94.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,≥7,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,49.0,43.0,54.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,≥7,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,69.0,61.0,76.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,≥7,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,86.0,81.0,90.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 3 doses ≥84 days ago,≥7,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,19.0,12.0,26.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 3 doses ≥84 days ago,≥7,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,31.0,20.0,41.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 3 doses ≥84 days ago,≥7,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,40.0,24.0,52.0,omicron,omicron,~15 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-30,infection,infection,Denmark,12-59 years,12-59 years,55.2,54.7,55.6,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,120+,infection,infection,Denmark,12-59 years,12-59 years,49.9,46.5,53.1,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-30,hospitalization,severe,Denmark,12-59 years,12-59 years,89.8,87.9,91.3,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,120+,hospitalization,severe,Denmark,12-59 years,12-59 years,33.3,0.9,55.1,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-30,infection,infection,Denmark,12-59 years,12-59 years,89.5,87.7,91.0,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,61-90,infection,infection,Denmark,12-59 years,12-59 years,83.5,69.4,91.1,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-30,hospitalization,severe,Denmark,12-59 years,12-59 years,94.8,85.9,98.1,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,31-60,hospitalization,severe,Denmark,12-59 years,12-59 years,68.4,41.4,83.0,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,57.6,55.8,59.4,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,120+,infection,infection,Denmark,≥ 60 years,≥ 60 years,52.8,49.3,56.0,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-30,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,94.4,93.0,95.5,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,120+,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,77.3,70.9,82.3,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,86.0,83.3,88.3,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,61-90,infection,infection,Denmark,≥ 60 years,≥ 60 years,81.2,72.9,87.0,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,31-60,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,96.6,93.9,98.1,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,91-120,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,91.4,79.8,96.4,,delta,~24 weeks,,,,,
75,Lind,Test-negative case-control,01Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,14-59,infection,infection,USA,≥ 18 years,general pop,55.0,48.0,61.0,omicron BA.1,omicron BA.1,~14 weeks,,,,,
75,Lind,Test-negative case-control,01Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,90+,infection,infection,USA,≥ 18 years,general pop,20.0,2.0,34.0,omicron BA.1,omicron BA.1,~14 weeks,,,,,
75,Lind,Test-negative case-control,01Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,≥ 18 years,general pop,47.1,22.4,63.9,omicron BA.1,omicron BA.1,~14 weeks,,,,,
75,Lind,1:1 Matched case control,01Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,≥ 18 years,general pop,58.5,52.7,63.5,omicron BA.1,omicron BA.1,~14 weeks,,,,,
75,Lind,1:1 Matched case control,01Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,≥ 18 years,general pop,35.1,-7.5,60.8,omicron BA.1,omicron BA.1,~14 weeks,,,,,
76,Widdifield,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,infection,infection,Canada,individuals with rheumatoid arthritis,individuals with rheumatoid arthritis,86.0,70.0,94.0,,alpha & delta,~9.5 weeks,,,,,
76,Widdifield,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,severe disease,severe,Canada,individuals with rheumatoid arthritis,individuals with rheumatoid arthritis,88.0,48.0,97.0,,alpha & delta,~9.5 weeks,,,,,
76,Widdifield,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,infection,infection,Canada,individuals with ankylosing spondylitis,individuals with ankylosing spondylitis,82.0,20.0,96.0,,alpha & delta,~9.5 weeks,,,,,
76,Widdifield,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,infection,infection,Canada,individuals with psoriasis,individuals with psoriasis,96.0,72.0,99.0,,alpha & delta,~9.5 weeks,,,,,
76,Widdifield,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,infection,infection,Canada,individuals with inflammatory bowel disease,individuals with inflammatory bowel disease,76.0,47.0,89.0,,alpha & delta,~9.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14-29,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,51.6,51.0,52.2,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,120+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,4.2,0.7,7.6,,omicron,~28 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14-29,severe disease,severe,Brazil,≥ 18 years,general pop,93.5,93.0,94.0,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,120+,severe disease,severe,Brazil,≥ 18 years,general pop,82.3,79.7,84.7,,omicron,~28 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with AZD1222,14-29,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,50.9,50.4,51.4,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with AZD1222,120+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,7.0,3.8,10.1,,omicron,~28 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with AZD1222,14-29,severe disease,severe,Brazil,≥ 18 years,general pop,79.0,77.3,80.6,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with AZD1222,120+,severe disease,severe,Brazil,≥ 18 years,general pop,59.4,53.3,64.7,,omicron,~28 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-29,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,44.6,43.4,45.8,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,120+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,-11.8,-35.9,8.0,,omicron,~17 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-29,severe disease,severe,Brazil,≥ 18 years,general pop,92.7,91.0,94.0,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,120+,severe disease,severe,Brazil,≥ 18 years,general pop,74.1,9.1,92.6,,omicron,~17 weeks,,,,,
78,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with BNT162b2,14-29,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,40.5,39.3,41.7,,omicron,2 weeks,,,,,
79,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with BNT162b2,120+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,9.7,-9.6,25.6,,omicron,~17 weeks,,,,,
80,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with BNT162b2,14-29,severe disease,severe,Brazil,≥ 18 years,general pop,54.6,43.9,63.2,,omicron,2 weeks,,,,,
81,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with BNT162b2,120+,severe disease,severe,Brazil,≥ 18 years,general pop,38.2,-125.0,83.0,,omicron,~17 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,67.1,65.5,68.5,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,120+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,37.4,33.8,40.9,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14-29,severe disease,severe,Scotland,≥ 18 years,general pop,98.3,87.3,99.8,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,120+,severe disease,severe,Scotland,≥ 18 years,general pop,77.8,51.4,89.9,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with BNT162b2,14-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,63.1,61.4,64.7,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with BNT162b2,120+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,28.8,23.8,33.5,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with BNT162b2,14-29,severe disease,severe,Scotland,≥ 18 years,general pop,85.2,67.3,93.3,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with BNT162b2,120+,severe disease,severe,Scotland,≥ 18 years,general pop,54.9,14.2,76.3,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,14-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,71.7,69.9,73.3,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,120+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,44.1,39.7,48.1,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,14-29,severe disease,severe,Scotland,≥ 18 years,general pop,94.4,87.7,97.5,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,120+,severe disease,severe,Scotland,≥ 18 years,general pop,76.0,59.3,85.9,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Moderna,included,complete vaccination with AZD1222,14-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,68.4,66.4,70.3,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Moderna,included,complete vaccination with AZD1222,120+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,37.1,31.5,42.2,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Moderna,included,complete vaccination with AZD1222,14-29,severe disease,severe,Scotland,≥ 18 years,general pop,95.5,67.3,99.4,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 (AstraZeneca),Moderna,included,complete vaccination with AZD1222,120+,severe disease,severe,Scotland,≥ 18 years,general pop,59.3,3.6,82.8,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 + BNT162b2 or mRNA-1273 (3 doses),Pfizer,included,unvaccinated individuals,7-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,40.6,20.9,55.4,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 + BNT162b2 or mRNA-1273 (3 doses),Pfizer,included,unvaccinated individuals,30+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,46.9,36.6,55.6,,omicron,~7 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 + BNT162b2 or mRNA-1273 (3 doses),Pfizer,included,complete vaccination with AZD1222,7-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,34.4,12.5,50.8,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 + BNT162b2 or mRNA-1273 (3 doses),Pfizer,included,complete vaccination with AZD1222,30+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,40.4,28.4,50.4,,omicron,~7 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 + BNT162b2 or mRNA-1273 (3 doses),Moderna,included,unvaccinated individuals,7-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,47.5,21.5,64.9,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 + BNT162b2 or mRNA-1273 (3 doses),Moderna,included,unvaccinated individuals,30+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,54.1,40.6,64.6,,omicron,~7 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 + BNT162b2 or mRNA-1273 (3 doses),Moderna,included,complete vaccination with AZD1222,7-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,40.8,11.4,60.5,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,AZD1222 + BNT162b2 or mRNA-1273 (3 doses),Moderna,included,complete vaccination with AZD1222,30+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,48.4,32.9,60.3,,omicron,~7 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,69.1,67.6,70.5,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,120+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,49.3,47.0,51.5,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-29,severe disease,severe,Scotland,≥ 18 years,general pop,95.3,85.1,98.5,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,120+,severe disease,severe,Scotland,≥ 18 years,general pop,78.6,64.4,87.1,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with BNT162b2,14-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,62.7,61.0,64.4,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with BNT162b2,120+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,29.1,24.8,33.2,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with BNT162b2,14-29,severe disease,severe,Scotland,≥ 18 years,general pop,78.2,27.7,93.4,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with BNT162b2,120+,severe disease,severe,Scotland,≥ 18 years,general pop,39.7,-28.6,71.7,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,14-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,71.9,70.0,73.7,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,120+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,49.3,45.1,53.2,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,14-29,severe disease,severe,Scotland,≥ 18 years,general pop,96.1,72.1,99.5,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,120+,severe disease,severe,Scotland,≥ 18 years,general pop,90.4,59.2,97.8,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Moderna,included,complete vaccination with BNT162b2,14-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,66.2,63.9,68.4,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Moderna,included,complete vaccination with BNT162b2,120+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,30.9,24.5,36.7,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Moderna,included,complete vaccination with BNT162b2,14-29,severe disease,severe,Scotland,≥ 18 years,general pop,78.3,-60.8,97.1,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer),Moderna,included,complete vaccination with BNT162b2,120+,severe disease,severe,Scotland,≥ 18 years,general pop,66.2,-60.6,92.9,,omicron,~28.5 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) + BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,61.1,43.6,73.2,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) + BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,30+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,49.0,34.3,60.4,,omicron,~7 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) + BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with BNT162b2,7-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,50.0,27.3,65.6,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) + BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with BNT162b2,30+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,33.0,13.4,48.2,,omicron,~7 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) + BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,69.2,46.5,82.3,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) + BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,30+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,55.1,33.3,69.7,,omicron,~7 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) + BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with BNT162b2,7-29,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,61.0,32.2,77.6,,omicron,2 weeks,,,,,
77,Cerqueira-Silva ,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) + BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with BNT162b2,30+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,40.4,11.3,60.0,,omicron,~7 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,8-14,symptomatic disease,symptomatic,France,≥ 18 years,general pop,64.0,63.0,64.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,90+,symptomatic disease,symptomatic,France,≥ 18 years,general pop,50.0,48.0,51.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,8-14,hospitalization,severe,France,≥ 18 years,general pop,90.0,87.0,92.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,90+,hospitalization,severe,France,≥ 18 years,general pop,93.0,92.0,94.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,8-14,ICU admission,severe,France,≥ 18 years,general pop,96.0,92.0,99.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,90+,ICU admission,severe,France,≥ 18 years,general pop,97.0,95.0,99.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,8-14,death,death,France,≥ 18 years,general pop,95.0,89.0,100.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,90+,death,death,France,≥ 18 years,general pop,93.0,91.0,96.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,8-14,symptomatic disease,symptomatic,France,≥ 18 years,general pop,84.0,79.0,88.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,90+,symptomatic disease,symptomatic,France,≥ 18 years,general pop,90.0,85.0,94.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,8-14,hospitalization,severe,France,≥ 18 years,general pop,98.0,98.0,99.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,90+,hospitalization,severe,France,≥ 18 years,general pop,99.0,99.0,100.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,8-14,ICU admission,severe,France,≥ 18 years,general pop,99.0,98.0,99.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,90+,ICU admission,severe,France,≥ 18 years,general pop,99.0,99.0,100.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,8-14,death,death,France,≥ 18 years,general pop,98.0,96.0,100.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals without prior infection,90+,death,death,France,≥ 18 years,general pop,99.0,99.0,100.0,delta,delta,~22 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,veterans,veterans,30.1,26.2,33.7,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,14+,hospitalization,severe,USA,veterans,veterans,61.4,55.0,67.1,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses ≥5 months prior,14+,death,death,USA,veterans,veterans,78.8,67.9,87.5,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,USA,veterans,veterans,47.8,45.2,50.3,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,USA,veterans,veterans,81.8,79.2,84.2,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,death,death,USA,veterans,veterans,89.6,85.0,93.6,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,veterans,veterans,37.1,32.2,41.7,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses ≥5 months prior,14+,hospitalization,severe,USA,veterans,veterans,63.5,53.7,71.6,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses ≥5 months prior,14+,death,death,USA,veterans,veterans,75.0,55.4,88.0,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,infection,infection,USA,veterans,veterans,61.9,59.4,64.4,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,hospitalization,severe,USA,veterans,veterans,87.9,85.3,90.2,,omicron,~27 weeks,,,,,
79,Sharma,Matched case-control,27Apr2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,death,death,USA,veterans,veterans,91.4,86.4,95.6,,omicron,~27 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),included,unvaccinated individuals,14-34,symptomatic disease,symptomatic,UK,40-64 years,40-64 years,51.7,38.9,61.8,omicron,omicron,~3 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),included,unvaccinated individuals,105+,symptomatic disease,symptomatic,UK,40-64 years,40-64 years,37.2,-44.1,72.6,omicron,omicron,~20 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14-34,symptomatic disease,symptomatic,UK,40-64 years,40-64 years,63.8,63.0,64.5,omicron,omicron,~3 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,105+,symptomatic disease,symptomatic,UK,40-64 years,40-64 years,30.6,26.8,34.3,omicron,omicron,~20 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),included,unvaccinated individuals,14-34,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,51.6,20.8,70.4,omicron,omicron,~3 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),included,unvaccinated individuals,70-104,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,-27.2,-131.6,30.1,omicron,omicron,~13 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),included,unvaccinated individuals,7+,hospitalization,severe,UK,≥ 65 years,≥ 65 years,82.3,64.2,91.3,omicron,omicron,~20 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14-34,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,58.1,51.6,63.8,omicron,omicron,~3 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,105+,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,23.1,15.1,30.5,omicron,omicron,~20 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,UK,≥ 65 years,≥ 65 years,90.9,88.7,92.7,omicron,omicron,~20 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),included,unvaccinated individuals,7+,hospitalization,severe,UK,≥ 65 years,≥ 65 years,80.9,15.6,95.7,delta,delta,~15 weeks,,,,,
80,Kirsebom,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,UK,≥ 65 years,≥ 65 years,93.9,92.8,94.9,delta,delta,~15 weeks,,,,,
81,Suah,Test-negative case-control,02May2022,BNT162b2 (Pfizer),Pfizer,unknown,complete vaccination with 2 doses of BNT162b2 (Pfizer) 4-6 months prior,14+,infection,infection,Malaysia,≥ 18 years,general pop,52.0,50.3,51.9,,omicron,~12 weeks,,,,,
81,Suah,Test-negative case-control,02May2022,BNT162b2 (Pfizer),Pfizer,unknown,complete vaccination with 2 doses of BNT162b2 (Pfizer) 4-6 months prior,14+,infection,infection,Malaysia,≥ 18 years,general pop,89.4,89.2,89.7,,delta,~12 weeks,,,,,
82,Carazo,Test-negative case-control,14Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,Canada,≥ 12 years,general pop,73.0,72.0,73.0,,omicron,~24 weeks,,,,,
82,Carazo,Test-negative case-control,14Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 12 years,general pop,91.0,91.0,92.0,,omicron,~24 weeks,,,,,
82,Carazo,Test-negative case-control,14Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,previously infected only,unvaccinated individuals,7+,infection,infection,Canada,≥ 12 years,general pop,68.0,67.0,68.0,,omicron,~24 weeks,,,,,
82,Carazo,Test-negative case-control,14Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,previously infected only,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 12 years,general pop,84.0,82.0,91.0,,omicron,~24 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",7+,infection,infection,USA,veterans 21+,general pop,11.0,7.0,14.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",<28,infection,infection,USA,veterans 21+,general pop,30.0,23.0,36.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",84+,infection,infection,USA,veterans 21+,general pop,-9.0,-22.0,2.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",7+,hospitalization,severe,USA,veterans 21+,general pop,50.0,41.0,57.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",<28,hospitalization,severe,USA,veterans 21+,general pop,62.0,43.0,75.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",84+,hospitalization,severe,USA,veterans 21+,general pop,45.0,18.0,63.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",7+,ICU admission or death,severe,USA,veterans 21+,general pop,88.0,68.0,96.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",28-56,ICU admission or death,severe,USA,veterans 21+,general pop,90.0,22.0,99.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",84+,ICU admission or death,severe,USA,veterans 21+,general pop,79.0,-78.0,98.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",7+,infection,infection,USA,veterans 21+,general pop,27.0,24.0,30.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",<28,infection,infection,USA,veterans 21+,general pop,40.0,35.0,44.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",84+,infection,infection,USA,veterans 21+,general pop,-23.0,-65.0,9.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",7+,hospitalization,severe,USA,veterans 21+,general pop,55.0,46.0,61.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",<28,hospitalization,severe,USA,veterans 21+,general pop,55.0,38.0,67.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",84+,hospitalization,severe,USA,veterans 21+,general pop,83.0,24.0,96.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",7+,ICU admission or death,severe,USA,veterans 21+,general pop,72.0,24.0,90.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",<28,ICU admission or death,severe,USA,veterans 21+,general pop,86.0,-17.0,98.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",28-56,ICU admission or death,severe,USA,veterans 21+,general pop,50.0,-68.0,85.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",7+,infection,infection,USA,veterans 21+,general pop,19.0,17.0,22.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",7+,hospitalization,severe,USA,veterans 21+,general pop,52.0,46.0,57.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",7+,ICU admission or death,severe,USA,veterans 21+,general pop,83.0,65.0,92.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",,infection,infection,USA,veterans 21+,general pop,73.0,70.0,76.0,,delta,~9.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",,hospitalization,severe,USA,veterans 21+,general pop,79.0,71.0,85.0,,delta,~9.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",,ICU admission or death,severe,USA,veterans 21+,general pop,90.0,21.0,99.0,,delta,~9.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",,infection,infection,USA,veterans 21+,general pop,74.0,70.0,78.0,,delta,~9.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of mRNA-1273 (Moderna) by April 30, 2021",,hospitalization,severe,USA,veterans 21+,general pop,80.0,68.0,88.0,,delta,~9.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",,infection,infection,USA,veterans 21+,general pop,73.0,71.0,76.0,,delta,~9.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",,hospitalization,severe,USA,veterans 21+,general pop,80.0,73.0,85.0,,delta,~9.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",,ICU admission or death,severe,USA,veterans 21+,general pop,94.0,52.0,99.0,,delta,~9.5 weeks,,,,,
84,Amir,Retrospective cohort,05May2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥4 months prior,0-30,hospitalization or death,severe,Israel,≥ 60 years,≥ 60 years,57.0,37.5,71.0,,omicron,~31 weeks,,,,,
84,Amir,Retrospective cohort,05May2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥4 months prior,180-210,hospitalization or death,severe,Israel,≥ 60 years,≥ 60 years,67.8,59.0,75.6,,omicron,~31 weeks,,,,,
84,Amir,Retrospective cohort,05May2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥4 months prior,0-60,hospitalization or death,severe,Israel,≥ 60 years,≥ 60 years,89.2,88.0,91.0,,omicron,~31 weeks,,,,,
85,Rennert,Propensity matched case control,07May2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,infection,infection,USA,≥ 18 years,general pop,42.8,22.7,57.6,,omicron,~16 weeks,,,,,
85,Rennert,Propensity matched case control,07May2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,infection,infection,USA,≥ 18 years,general pop,48.5,25.0,64.7,,omicron,~16 weeks,,,,,
85,Rennert,Propensity matched case control,07May2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,infection,infection,USA,18-65 years,18-65 years,74.3,42.1,88.6,,omicron,~16 weeks,,,,,
85,Rennert,Propensity matched case control,07May2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,infection,infection,USA,18-65 years,18-65 years,60.4,32.4,76.8,,omicron,~16 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,15-19,infection,infection,Italy,≥ 12 years,general pop,69.1,67.5,70.7,,alpha & delta,~26 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,75+,infection,infection,Italy,≥ 12 years,general pop,50.8,46.0,55.1,,alpha & delta,~26 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,15-19,infection,infection,Italy,≥ 12 years,general pop,59.9,56.4,63.0,,alpha & delta,~26 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,40+,infection,infection,Italy,≥ 12 years,general pop,23.4,12.1,33.3,,alpha & delta,~26 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,Ad26.COV2.S (Janssen),Janssen,excluded,unvaccinated individuals,15-19,infection,infection,Italy,≥ 12 years,general pop,52.8,47.2,57.9,,alpha & delta,~26 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,Ad26.COV2.S (Janssen),Janssen,excluded,unvaccinated individuals,40+,infection,infection,Italy,≥ 12 years,general pop,26.9,16.3,36.3,,alpha & delta,~26 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,10-14,infection,infection,Italy,≥ 12 years,general pop,28.0,0.0,48.5,,alpha & delta,~26 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,15+,infection,infection,Italy,≥ 12 years,general pop,28.8,12.9,41.8,,alpha & delta,~26 weeks,,,,,
87,Amir,Retrospective cohort,09Sept2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-60,infection,infection,Israel,12-15 years,12-15 years,80.0,76.7,83.1,,omicron,~7 weeks,,,,,
87,Amir,Retrospective cohort,09Sept2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses 120+ days prior,14-60,infection,infection,Israel,12-15 years,12-15 years,76.2,72.2,79.6,,omicron,~7 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,40.9,31.9,48.7,,omicron,~32 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,72.1,67.2,76.2,,omicron,~32 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,"previously infected before July 1, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,57.7,50.8,63.6,,omicron,~32 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,"previously infected before July 1, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,77.6,71.7,82.2,,omicron,~32 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,"previously infected between July 1 and November 30, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,84.6,70.7,91.9,,omicron,~32 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,"previously infected between July 1 and November 30, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,87.9,76.0,93.9,,omicron,~32 weeks,,,,,
88,Chin,Retrospective test-negative case control,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,43.2,42.2,47.4,,omicron,~32 weeks,,,,,
88,Chin,Retrospective test-negative case control,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,"previously infected before July 1, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,61.3,60.7,64.8,,omicron,~32 weeks,,,,,
88,Chin,Retrospective test-negative case control,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,"previously infected between July 1 and November 30, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,86.8,82.1,92.7,,omicron,~32 weeks,,,,,
89,Marra,Retrospective cohort,27May2022,CoronaVac (Sinovac),Pfizer,excluded,complete vaccination with 2 doses of CoronaVac,14+,infection,infection,Brazil,HCW,HCW,92.0,89.1,94.3,,delta,~11 weeks,,,,,
89,Marra,Retrospective cohort,27May2022,AZD1222 (AstraZeneca),Pfizer,excluded,complete vaccination with 2 doses of AZD1222,14+,infection,infection,Brazil,HCW,HCW,60.5,44.9,72.4,,delta,~11 weeks,,,,,
90,Carlsen,Retrospective cohort,01Jun2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester),infection during an infant's first 4 months of life,Norway,newborns,newborns,78.0,57.0,88.0,,omicron,~45 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,1-28,infection,infection,UK,≥ 18 years,general pop,49.6,48.3,50.8,,delta,~11 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,infection,infection,UK,≥ 18 years,general pop,49.7,47.8,51.5,,delta,~11 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,1-28,hospitalization,severe,UK,≥ 18 years,general pop,73.8,68.9,77.9,,delta,~11 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,hospitalization,severe,UK,≥ 18 years,general pop,86.1,81.9,89.4,,delta,~11 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,death,death,UK,≥ 18 years,general pop,92.6,86.5,96.0,,delta,~11 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,1-28,infection,infection,UK,≥ 18 years,general pop,49.2,48.4,50.0,,delta,~11 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,infection,infection,UK,≥ 18 years,general pop,54.8,53.3,56.3,,delta,~11 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,1-28,hospitalization,severe,UK,≥ 18 years,general pop,78.2,75.2,80.8,,delta,~11 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,hospitalization,severe,UK,≥ 18 years,general pop,83.9,80.0,87.1,,delta,~11 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,1-28,death,death,UK,≥ 18 years,general pop,77.4,66.3,84.9,,delta,~11 weeks,,,,,
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,death,death,UK,≥ 18 years,general pop,93.5,87.6,96.6,,delta,~11 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) within last 6 months,14+,symptomatic disease,symptomatic,USA,HCW,HCW,78.0,63.0,87.0,,delta,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) within last 6 months,14+,symptomatic disease,symptomatic,USA,HCW,HCW,96.0,82.0,99.0,,delta,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) within last 6 months,14+,symptomatic disease,symptomatic,USA,HCW,HCW,50.0,42.0,56.0,,omicron,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) within last 6 months,14+,symptomatic disease,symptomatic,USA,HCW,HCW,56.0,45.0,65.0,,omicron,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) within last 6 months,<56,symptomatic disease,symptomatic,USA,HCW,HCW,66.0,51.0,76.0,,omicron,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) within last 6 months,112+,symptomatic disease,symptomatic,USA,HCW,HCW,55.0,19.0,76.0,,omicron,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,HCW,HCW,93.0,78.0,98.0,,delta,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,HCW,HCW,96.0,82.0,99.0,,delta,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,HCW,HCW,54.0,23.0,73.0,,omicron,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,HCW,HCW,46.0,6.0,69.0,,omicron,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,<56,symptomatic disease,symptomatic,USA,HCW,HCW,75.0,50.0,87.0,,omicron,~32 weeks,,,,,
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,112+,symptomatic disease,symptomatic,USA,HCW,HCW,55.0,5.0,79.0,,omicron,~32 weeks,,,,,
93,Adams,Prospective test-negative case control,11Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,64.0,55.0,72.0,"omicron BA.1, B.A.2, BA.5","omicron BA.1, B.A.2, BA.5",~47 weeks,,,,,
93,Adams,Prospective test-negative case control,11Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,73.0,44.0,87.0,"omicron BA.1, B.A.2, BA.5","omicron BA.1, B.A.2, BA.5",~47 weeks,,,,,
93,Adams,Prospective test-negative case control,11Oct2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,65.0,55.0,73.0,"omicron BA.1, B.A.2, BA.5","omicron BA.1, B.A.2, BA.5",~47 weeks,,,,,
93,Adams,Prospective test-negative case control,11Oct2022,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,68.0,17.0,88.0,"omicron BA.1, B.A.2, BA.5","omicron BA.1, B.A.2, BA.5",~47 weeks,,,,,
93,Adams,Prospective test-negative case control,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,64.0,42.0,78.0,"omicron BA.1, B.A.2, BA.5","omicron BA.1, B.A.2, BA.5",~47 weeks,,,,,
93,Adams,Prospective test-negative case control,11Oct2022,Ad26.COV2.S (Janssen),Janssen,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,35.0,-54.0,73.0,"omicron BA.1, B.A.2, BA.5","omicron BA.1, B.A.2, BA.5",~47 weeks,,,,,
93,Adams,Prospective test-negative case control,11Oct2022,Ad26.COV2.S (Janssen),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,52.0,25.0,89.0,"omicron BA.1, B.A.2, BA.5","omicron BA.1, B.A.2, BA.5",~47 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 5 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,39.0,36.4,41.6,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 5 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,53.3,48.1,58.0,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 5 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,79.1,71.2,84.9,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination 5-9 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,36.4,33.3,39.4,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination 5-9 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,43.8,35.2,51.3,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination 5-9 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,78.1,67.5,85.3,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 9 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,46.5,44.1,48.7,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 9 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,63.2,56.4,69.0,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 9 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,81.6,67.8,89.4,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 5 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,39.0,36.4,41.6,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 5 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,54.0,41.6,60.8,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 5 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,85.5,73.9,92.0,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 5 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,44.6,42.5,46.6,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 5 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,52.9,45.6,59.2,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 5 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,75.2,62.9,83.4,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination at least 5 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,39.6,36.9,42.1,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination at least 5 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,53.7,45.8,60.4,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination at least 5 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,84.8,73.7,91.2,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 5 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,44.3,42.2,46.3,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 5 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,53.1,45.7,59.5,,omicron,~15 weeks,,,,omicron,~15 weeks
94,Ioannou,Target trial emulation,11Oct2022,mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination at least 5 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,75.0,62.3,83.4,,omicron,~15 weeks,,,,omicron,~15 weeks
95,Liu,Prospective cohort,12Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination 8-89 days prior,8+,hospitalization or death,severe,Australia,50-69 years,50-69 years,49.4,30.8,63.0,,omicron,~13 weeks,,,,omicron,~13 weeks
96,Muhsen,Retrospective cohort,23Jun2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,14+,infection,infection,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,36.0,31.0,40.0,,omicron,~12 weeks,,,,,
96,Muhsen,Retrospective cohort,23Jun2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,14+,mild-moderate hospitalization,severe,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,66.0,57.0,73.0,,omicron,~12 weeks,,,,,
96,Muhsen,Retrospective cohort,23Jun2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,14+,severe hospitalization,severe,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,72.0,61.0,80.0,,omicron,~12 weeks,,,,,
96,Muhsen,Retrospective cohort,23Jun2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,14+,death,death,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,76.0,58.0,87.0,,omicron,~12 weeks,,,,,
97,Carazo,Test-negative case-control,21Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,Canada,HCW,HCW,46.0,40.0,52.0,omicron BA.2,omicron BA.2,~39 weeks,,,,,
97,Carazo,Test-negative case-control,21Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,Canada,HCW,HCW,70.0,62.0,75.0,omicron BA.2,omicron BA.2,~39 weeks,,,,,
98,Ionescu,Test-negative case-control,16Jan2023,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,Canada (Quebec),12-17 years,12-17 years,60.8,40.8,74.1,,omicron,~26 weeks,,,,,
98,Ionescu,Test-negative case-control,16Jan2023,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,Canada (British Colombia),12-17 years,12-17 years,63.7,41.1,77.7,,omicron,~26 weeks,,,,,
99,Breznik,Prospective cohort,29Jun2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 3 doses,60-120,infection,infection,Canada,nursing and retirement home residents,nursing and retirement home residents,81.0,70.0,88.0,,omicron,~15 weeks,,,,,
100,Tartof,Test-negative case-control,07Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,<3 months,hospitalization,severe,USA,≥ 18 years,general pop,80.0,74.0,84.0,omicron BA.1,omicron BA.1,,,,,,
100,Tartof,Test-negative case-control,07Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥3 months,hospitalization,severe,USA,≥ 18 years,general pop,76.0,69.0,82.0,omicron BA.1,omicron BA.1,~29 weeks,,,,,
100,Tartof,Test-negative case-control,07Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,<3 months,ED admissions,symptomatic,USA,≥ 18 years,general pop,74.0,69.0,78.0,omicron BA.1,omicron BA.1,,,,,,
100,Tartof,Test-negative case-control,07Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥3 months,ED admissions,symptomatic,USA,≥ 18 years,general pop,65.0,56.0,73.0,omicron BA.1,omicron BA.1,~29 weeks,,,,,
100,Tartof,Test-negative case-control,07Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,<3 months,hospitalization,severe,USA,≥ 18 years,general pop,74.0,47.0,87.0,omicron BA.2,omicron BA.2,,,,,,
100,Tartof,Test-negative case-control,07Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥3 months,hospitalization,severe,USA,≥ 18 years,general pop,70.0,53.0,81.0,omicron BA.2,omicron BA.2,~29 weeks,,,,,
100,Tartof,Test-negative case-control,07Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,<3 months,ED admissions,symptomatic,USA,≥ 18 years,general pop,59.0,40.0,72.0,omicron BA.2,omicron BA.2,,,,,,
100,Tartof,Test-negative case-control,07Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥3 months,ED admissions,symptomatic,USA,≥ 18 years,general pop,5.0,-21.0,25.0,omicron BA.2,omicron BA.2,~29 weeks,,,,,
101,Muhsen,Prospective cohort,01Jul2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination at least 5 months prior,7+,infection,infection,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,89.0,85.0,93.0,,delta,~10 weeks,,,,,
101,Muhsen,Prospective cohort,01Jul2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination at least 5 months prior,7+,mild-moderate hospitalization,severe,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,93.0,86.0,97.0,,delta,~10 weeks,,,,,
101,Muhsen,Prospective cohort,01Jul2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination at least 5 months prior,7+,severe hospitalization,severe,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,90.0,76.0,96.0,,delta,~10 weeks,,,,,
101,Muhsen,Prospective cohort,01Jul2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination at least 5 months prior,7+,death,death,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,96.0,84.0,99.1,,delta,~10 weeks,,,,,
102,Guedalia,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination at least 5 months prior,0+,hospitalization,severe,Israel,pregnant women aged 16+,pregnant persons,48.0,37.0,57.0,,omicron BA.1,~31 weeks,,,,,
102,Guedalia,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination at least 5 months prior,0+,hospitalization with moderate disease,severe,Israel,pregnant women aged 16+,pregnant persons,92.0,26.0,99.0,,omicron BA.1,~31 weeks,,,,,
102,Guedalia,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,0+,hospitalization,severe,Israel,pregnant women aged 16+,pregnant persons,43.0,31.0,53.0,,omicron BA.1,~31 weeks,,,,,
102,Guedalia,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,0+,hospitalization with moderate disease,severe,Israel,pregnant women aged 16+,pregnant persons,97.0,72.0,100.0,,omicron BA.1,~31 weeks,,,,,
102,Guedalia,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,0+,severe disease,severe,Israel,pregnant women aged 16+,pregnant persons,94.0,43.0,99.0,,omicron BA.1,~31 weeks,,,,,
102,Guedalia,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination at least 5 months prior,0+,hospitalization,severe,Israel,pregnant women aged 16+,pregnant persons,92.0,83.0,96.0,,delta,~15.5 weeks,,,,,
102,Guedalia,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,0+,hospitalization,severe,Israel,pregnant women aged 16+,pregnant persons,97.0,95.0,99.0,,delta,~15.5 weeks,,,,,
102,Guedalia,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,0+,hospitalization with moderate disease,severe,Israel,pregnant women aged 16+,pregnant persons,99.0,93.0,100.0,,delta,~15.5 weeks,,,,,
102,Guedalia,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,0+,severe disease,severe,Israel,pregnant women aged 16+,pregnant persons,99.0,89.0,100.0,,delta,~15.5 weeks,,,,,
103,Lee,Test-negative case-control,12Jul2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,84+,infection,infection,UK,cancer patients aged 18+,immunocompromised,59.3,58.8,59.8,,delta,~12 weeks,,,,,
103,Lee,Test-negative case-control,12Jul2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,84+,symptomatic disease,symptomatic,UK,cancer patients aged 18+,immunocompromised,61.9,61.4,62.4,,delta,~12 weeks,,,,,
103,Lee,Test-negative case-control,12Jul2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,84+,hospitalization,severe,UK,cancer patients aged 18+,immunocompromised,81.1,76.8,84.6,,delta,~12 weeks,,,,,
103,Lee,Test-negative case-control,12Jul2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,84+,death,death,UK,cancer patients aged 18+,immunocompromised,94.6,92.6,96.1,,delta,~12 weeks,,,,,
103,Lee,Test-negative case-control,12Jul2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,84+,infection,infection,UK,cancer patients aged 18+,immunocompromised,58.3,57.7,58.9,,delta,~12 weeks,,,,,
103,Lee,Test-negative case-control,12Jul2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,84+,symptomatic disease,symptomatic,UK,cancer patients aged 18+,immunocompromised,63.2,62.6,63.8,,delta,~12 weeks,,,,,
103,Lee,Test-negative case-control,12Jul2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,84+,hospitalization,severe,UK,cancer patients aged 18+,immunocompromised,79.2,73.9,83.4,,delta,~12 weeks,,,,,
103,Lee,Test-negative case-control,12Jul2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,84+,death,death,UK,cancer patients aged 18+,immunocompromised,94.3,91.9,96.0,,delta,~12 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7-119,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,84.0,83.0,85.0,,omicron BA.1,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,120+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,73.0,68.0,77.0,,omicron BA.1,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7-119,hospitalization,severe,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,92.0,91.0,93.0,,omicron BA.1,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,120+,hospitalization,severe,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,85.0,81.0,89.0,,omicron BA.1,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7-119,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,56.0,51.0,61.0,,omicron BA.2,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,120+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,26.0,21.0,30.0,,omicron BA.2,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7-119,hospitalization,severe,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,69.0,58.0,76.0,,omicron BA.2,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,120+,hospitalization,severe,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,52.0,44.0,59.0,,omicron BA.2,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations in adults 50+,≥ 50 years,66.0,60.0,71.0,,omicron BA.2,~6 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,USA,ED/UC encounters and hospitalizations in adults 50+,≥ 50 years,80.0,71.0,85.0,,omicron BA.2,~6 weeks,,,,,
105,Hertz,Prospective cohort,15Aug2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥3 months prior,8-30,symptomatic disease,symptomatic,Israel,HCW,HCW,45.5,19.0,63.0,,omicron BA.1,~11 weeks,,,,,
105,Hertz,Prospective cohort,15Aug2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) ≥3 months prior,60-90,symptomatic disease,symptomatic,Israel,HCW,HCW,37.0,15.0,53.0,,omicron BA.1,~11 weeks,,,,,
106,Cerqueira-Silva ,Test-negative case-control,18Jul2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,14-30,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,63.6,62.8,64.3,,omicron,~22 weeks,,,,,
106,Cerqueira-Silva ,Test-negative case-control,18Jul2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,120+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,1.7,0.1,3.2,,omicron,~22 weeks,,,,,
106,Cerqueira-Silva ,Test-negative case-control,18Jul2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,14-30,hospitalization or death,death,Brazil,≥ 18 years,general pop,89.4,87.8,90.7,,omicron,~22 weeks,,,,,
106,Cerqueira-Silva ,Test-negative case-control,18Jul2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,120+,hospitalization or death,death,Brazil,≥ 18 years,general pop,84.1,83.2,84.9,,omicron,~22 weeks,,,,,
106,Cerqueira-Silva ,Test-negative case-control,18Jul2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,14-30,death,death,Brazil,≥ 18 years,general pop,90.2,87.6,92.3,,omicron,~22 weeks,,,,,
106,Cerqueira-Silva ,Test-negative case-control,18Jul2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,120+,death,death,Brazil,≥ 18 years,general pop,87.0,85.9,88.0,,omicron,~22 weeks,,,,,
106,Cerqueira-Silva ,Test-negative case-control,18Jul2022,CoronaVac (Sinovac),Pfizer,included,complete vaccination with 2 doses at least 4 months prior,14-30,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,62.9,62.1,63.7,,omicron,~22 weeks,,,,,
106,Cerqueira-Silva ,Test-negative case-control,18Jul2022,CoronaVac (Sinovac),Pfizer,included,complete vaccination with 2 doses at least 4 months prior,120+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,-2.9,-1.3,-4.5,,omicron,~22 weeks,,,,,
106,Cerqueira-Silva ,Test-negative case-control,18Jul2022,CoronaVac (Sinovac),Pfizer,included,complete vaccination with 2 doses at least 4 months prior,14-30,hospitalization or death,death,Brazil,≥ 18 years,general pop,71.2,67.1,74.9,,omicron,~22 weeks,,,,,
106,Cerqueira-Silva ,Test-negative case-control,18Jul2022,CoronaVac (Sinovac),Pfizer,included,complete vaccination with 2 doses at least 4 months prior,120+,hospitalization or death,death,Brazil,≥ 18 years,general pop,59.8,57.8,61.8,,omicron,~22 weeks,,,,,
107,Arashiro,Case-control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,Japan,20+ years,general pop,78.0,67.0,86.0,,omicron,~21 weeks,,,,,
107,Arashiro,Case-control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180+,symptomatic disease,symptomatic,Japan,20+ years,general pop,51.0,29.0,66.0,,omicron,~21 weeks,,,,,
108,Tartof,Test-negative case-control,03Aug2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,ED or UC visit,symptomatic,USA,12-17 years,12-17 years,87.0,72.0,94.0,omicron,omicron,~10 weeks,,,,,
108,Tartof,Test-negative case-control,03Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,ED or UC visit,symptomatic,USA,12-17 years,12-17 years,87.0,71.0,95.0,omicron,omicron,~10 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,15+,infection,infection,Colombia,≥ 16 years,general pop,72.5,59.5,81.4,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,15+,hospitalization,severe,Colombia,≥ 16 years,general pop,82.9,63.5,92.1,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,15+,death,death,Colombia,≥ 16 years,general pop,89.8,73.7,96.1,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,15+,infection,infection,Colombia,≥ 16 years,general pop,58.1,35.9,72.7,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,15+,hospitalization,severe,Colombia,≥ 16 years,general pop,67.9,35.1,84.2,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,15+,death,death,Colombia,≥ 16 years,general pop,91.9,76.2,97.2,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,Ad26.COV2.S (Janssen),Janssen,excluded,unvaccinated individuals,15+,infection,infection,Colombia,≥ 16 years,general pop,80.7,0.0,97.3,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,15+,infection,infection,Colombia,≥ 16 years,general pop,76.2,50.5,88.5,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,15+,infection,infection,Colombia,≥ 16 years,general pop,75.1,61.2,83.9,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,15+,hospitalization,severe,Colombia,≥ 16 years,general pop,91.6,72.8,97.4,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,15+,death,death,Colombia,≥ 16 years,general pop,97.3,80.5,99.6,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,15+,hospitalization,severe,Colombia,≥ 16 years,general pop,70.2,37.6,85.8,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,15+,death,death,Colombia,≥ 16 years,general pop,90.8,31.9,98.8,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,BNT162b2 (Pfizer),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,15+,infection,infection,Colombia,≥ 16 years,general pop,80.1,63.7,89.1,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,BNT162b2 (Pfizer),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,15+,hospitalization,severe,Colombia,≥ 16 years,general pop,95.3,65.7,99.4,,"mu, delta, & omicron",~26 weeks,,,,,
109,Pinto-Álvarez,Nested cohort,13Oct2022,BNT162b2 (Pfizer),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,15+,death,death,Colombia,≥ 16 years,general pop,93.4,51.3,99.1,,"mu, delta, & omicron",~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,AZD1222 (AstraZeneca),Pfizer,excluded,complete vaccination with 2 doses at least 84 days prior,14-48,infection,infection,UK,LTCF staff,LTCF staff,72.0,67.0,76.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,AZD1222 (AstraZeneca),Pfizer,excluded,complete vaccination with 2 doses at least 84 days prior,84+,infection,infection,UK,LTCF staff,LTCF staff,-12.0,-29.0,3.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses at least 84 days prior,14-48,infection,infection,UK,LTCF staff,LTCF staff,63.0,54.0,70.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses at least 84 days prior,84+,infection,infection,UK,LTCF staff,LTCF staff,-26.0,-45.0,-9.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,AZD1222 (AstraZeneca),Pfizer,previously infected only,complete vaccination with 2 doses at least 84 days prior,14-48,infection,infection,UK,LTCF staff,LTCF staff,80.0,67.0,88.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,AZD1222 (AstraZeneca),Pfizer,previously infected only,complete vaccination with 2 doses at least 84 days prior,84+,infection,infection,UK,LTCF staff,LTCF staff,-8.0,-41.0,18.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,previously infected only,complete vaccination with 2 doses at least 84 days prior,14-48,infection,infection,UK,LTCF staff,LTCF staff,75.0,52.0,87.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,previously infected only,complete vaccination with 2 doses at least 84 days prior,84+,infection,infection,UK,LTCF staff,LTCF staff,-36.0,-83.0,-1.0,,omicron,~26 weeks,,,,,
111,Low,Retrospective cohort,10Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥3 months prior,14+,symptomatic disease,symptomatic,Malaysia,≥ 18 years,general pop,99.0,99.0,100.0,,delta,~14 weeks,,,,,
111,Low,Retrospective cohort,10Aug2022,CoronaVac (Sinovac),Pfizer,excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥3 months prior,14+,symptomatic disease,symptomatic,Malaysia,≥ 18 years,general pop,94.0,94.0,95.0,,delta,~14 weeks,,,,,
111,Low,Retrospective cohort,10Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥3 months prior,14+,symptomatic disease,symptomatic,Malaysia,≥ 18 years,general pop,92.0,90.0,94.0,,delta,~14 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,infection,infection,USA,immunocompromised adults,immunocompromised adults,50.0,31.0,64.0,,omicron,~22 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,infection,infection,USA,immunocompetent adults,general pop,35.0,29.0,41.0,,omicron,~22 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,≥ 18 years,general pop,89.0,84.0,93.0,,omicron,~22 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,infection,infection,USA,immunocompromised adults,immunocompromised adults,60.0,42.0,73.0,,omicron,~22 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,infection,infection,USA,immunocompetent adults,general pop,57.0,51.0,62.0,,omicron,~22 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,≥ 18 years,general pop,92.0,86.0,96.0,,omicron,~22 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompromised adults,immunocompromised adults,87.0,74.0,93.0,,omicron,~22 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompetent adults,general pop,92.0,87.0,95.0,,omicron,~22 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ICU admission,severe,USA,≥ 18 years,general pop,91.0,75.0,97.0,,omicron,~22 weeks,,,,,
113,Kim,Retrospective cohort,17Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-29,infection,infection,South Korea,12-18 years,12-18 years,56.3,50.0,61.7,,delta & omicron,~6 weeks,,,,,
113,Kim,Retrospective cohort,17Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,30-59,infection,infection,South Korea,12-18 years,12-18 years,55.2,47.3,61.9,,delta & omicron,~6 weeks,,,,,
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,severe disease,severe,"Hong Kong, SAR",18-50 years,18-50 years,76.1,24.8,92.4,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,severe disease,severe,"Hong Kong, SAR",51-64 years,51-64 years,90.5,72.6,96.7,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,severe disease,severe,"Hong Kong, SAR",≥ 65 years,≥ 65 years,86.7,74.8,93.0,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,death,death,"Hong Kong, SAR",18-50 years,18-50 years,82.1,35.5,95.0,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,death,death,"Hong Kong, SAR",51-64 years,51-64 years,98.1,92.3,99.5,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,death,death,"Hong Kong, SAR",≥ 65 years,≥ 65 years,97.5,95.1,98.7,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,severe disease,severe,"Hong Kong, SAR",18-50 years,18-50 years,81.0,10.7,96.0,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,severe disease,severe,"Hong Kong, SAR",51-64 years,51-64 years,84.6,62.0,93.7,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,severe disease,severe,"Hong Kong, SAR",≥ 65 years,≥ 65 years,83.6,79.0,90.1,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,death,death,"Hong Kong, SAR",18-50 years,18-50 years,89.5,46.0,97.9,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,death,death,"Hong Kong, SAR",51-64 years,51-64 years,97.0,90.3,99.1,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,death,death,"Hong Kong, SAR",≥ 65 years,≥ 65 years,94.2,91.5,96.1,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,severe disease,severe,"Hong Kong, SAR",18-50 years,18-50 years,56.9,-256.0,94.8,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,severe disease,severe,"Hong Kong, SAR",51-64 years,51-64 years,91.7,37.5,98.9,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,severe disease,severe,"Hong Kong, SAR",≥ 65 years,≥ 65 years,92.8,70.8,98.2,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,death,death,"Hong Kong, SAR",18-50 years,18-50 years,66.3,-218.8,96.4,,omicron BA.2,18 weeks,,,,,
114,Yan,Case-control,18Aug2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,death,death,"Hong Kong, SAR",≥ 65 years,≥ 65 years,95.8,90.6,98.1,,omicron BA.2,18 weeks,,,,,
115,Powell,Test-negative case-control,22Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-104,symptomatic disease,symptomatic,UK,11-17 years,11-17 years,62.9,60.5,65.1,,omicron,~23 weeks,,,,,
115,Powell,Test-negative case-control,22Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,105-174,symptomatic disease,symptomatic,UK,11-17 years,11-17 years,33.6,14.6,48.3,,omicron,~23 weeks,,,,,
115,Powell,Test-negative case-control,22Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-104,symptomatic disease,symptomatic,UK,11-17 years,11-17 years,96.0,92.2,97.9,,delta,~13 weeks,,,,,
116,Cheng,Retrospective cohort,11Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,"Hong Kong, SAR",≥18 years with chronic kidney disease,≥18 years with chronic kidney disease,77.0,72.0,82.0,,omicron,~45 weeks,,,,,
116,Cheng,Retrospective cohort,11Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,"Hong Kong, SAR",≥18 years with chronic kidney disease,≥18 years with chronic kidney disease,85.0,73.0,92.0,,omicron,~45 weeks,,,,,
116,Cheng,Retrospective cohort,11Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,death,death,"Hong Kong, SAR",≥18 years with chronic kidney disease,≥18 years with chronic kidney disease,95.0,78.0,99.0,,omicron,~45 weeks,,,,,
116,Cheng,Retrospective cohort,11Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,infection,infection,"Hong Kong, SAR",≥18 years with chronic kidney disease,≥18 years with chronic kidney disease,61.0,48.0,72.0,,omicron,~45 weeks,,,,,
116,Cheng,Retrospective cohort,11Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,hospitalization,severe,"Hong Kong, SAR",≥18 years with chronic kidney disease,≥18 years with chronic kidney disease,65.0,5.0,87.0,,omicron,~45 weeks,,,,,
116,Cheng,Retrospective cohort,11Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,death,death,"Hong Kong, SAR",≥18 years with chronic kidney disease,≥18 years with chronic kidney disease,97.0,92.0,99.0,,omicron,~45 weeks,,,,,
117,Wan,Case-control,17Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,54.2,52.4,55.9,,omicron BA.2,~23 weeks,,,,,
117,Wan,Case-control,17Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,91.4,89.5,92.9,,omicron BA.2,~23 weeks,,,,,
117,Wan,Case-control,17Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,ICU admission,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,86.3,71.5,93.4,,omicron BA.2,~23 weeks,,,,,
117,Wan,Case-control,17Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,infection,infection,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,19.8,17.2,22.3,,omicron BA.2,~23 weeks,,,,,
117,Wan,Case-control,17Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,hospitalization,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,85.4,83.2,87.3,,omicron BA.2,~23 weeks,,,,,
117,Wan,Case-control,17Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,ICU admission,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,94.8,85.8,98.1,,omicron BA.2,~23 weeks,,,,,
117,Wan,Case-control,17Aug2022,BNT162b2 (Pfizer),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,infection,infection,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,12.1,-15.8,33.3,,omicron BA.2,~23 weeks,,,,,
117,Wan,Case-control,17Aug2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,39.9,36.6,42.9,,omicron BA.2,~23 weeks,,,,,
117,Wan,Case-control,17Aug2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,89.5,85.9,92.2,,omicron BA.2,~23 weeks,,,,,
117,Wan,Case-control,17Aug2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,ICU admission,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,95.9,70.3,99.4,,omicron BA.2,~23 weeks,,,,,
118,Tsang,Prospective cohort,12Dec2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,"Hong Kong, SAR",≥ 5 years,general pop,41.4,23.2,55.2,,omicron BA.2,~12 weeks,,,,,
118,Tsang,Prospective cohort,12Dec2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,"Hong Kong, SAR",≥ 5 years,general pop,50.9,31.0,65.0,,omicron BA.2,~12 weeks,,,,,
118,Tsang,Prospective cohort,12Dec2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,infection,infection,"Hong Kong, SAR",≥ 5 years,general pop,32.4,9.0,49.8,,omicron BA.2,~12 weeks,,,,,
118,Tsang,Prospective cohort,12Dec2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,"Hong Kong, SAR",≥ 5 years,general pop,41.6,15.0,59.8,,omicron BA.2,~12 weeks,,,,,
118,Tsang,Prospective cohort,12Dec2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,"Hong Kong, SAR",≥ 5 years,general pop,31.3,-1.0,53.3,,omicron BA.2,~12 weeks,,,,,
118,Tsang,Prospective cohort,12Dec2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,"Hong Kong, SAR",≥ 5 years,general pop,55.8,22.9,74.6,,omicron BA.2,~12 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,15-60,infection,infection,Singapore,≥ 30 years,≥ 30 years,31.7,30.0,33.4,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,121-330,infection,infection,Singapore,≥ 30 years,≥ 30 years,-2.8,-5.4,0.3,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,15-60,severe disease,severe,Singapore,≥ 30 years,≥ 30 years,85.2,80.2,88.9,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,121-330,severe disease,severe,Singapore,≥ 30 years,≥ 30 years,87.3,84.2,89.8,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,15-60,infection,infection,Singapore,≥ 30 years,≥ 30 years,41.3,39.4,43.1,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,121-330,infection,infection,Singapore,≥ 30 years,≥ 30 years,14.6,11.0,18.0,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,15-60,severe disease,severe,Singapore,≥ 30 years,≥ 30 years,97.5,89.7,99.4,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,121-330,severe disease,severe,Singapore,≥ 30 years,≥ 30 years,89.0,78.9,94.2,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,15-60,infection,infection,Singapore,≥ 30 years,≥ 30 years,34.9,33.0,36.8,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,121-330,infection,infection,Singapore,≥ 30 years,≥ 30 years,3.69,0.03,7.21,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,15-60,severe disease,severe,Singapore,≥ 30 years,≥ 30 years,87.3,72.8,94.1,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,121-330,severe disease,severe,Singapore,≥ 30 years,≥ 30 years,84.4,73.4,90.9,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,15-60,infection,infection,Singapore,≥ 30 years,≥ 30 years,35.6,32.8,38.3,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,121-330,infection,infection,Singapore,≥ 30 years,≥ 30 years,9.70,2.70,16.3,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,15-60,severe disease,severe,Singapore,≥ 30 years,≥ 30 years,100.0,-inf,100.0,,omicron,~45 weeks,,,,,
119,Ng,Retrospective cohort,26Aug2022,mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,121-330,severe disease,severe,Singapore,≥ 30 years,≥ 30 years,86.3,44.7,96.6,,omicron,~45 weeks,,,,,
120,Cocchio,Retrospective cohort,20Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-34,infection,infection,Italy,12-17 years,12-17 years,72.0,70.0,73.0,,omicron,~16 weeks,,,,,
120,Cocchio,Retrospective cohort,20Aug2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,35-69,infection,infection,Italy,12-17 years,12-17 years,30.0,27.0,33.0,,omicron,~16 weeks,,,,,
120,Cocchio,Retrospective cohort,20Aug2022,mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14-34,infection,infection,Italy,12-17 years,12-17 years,71.0,66.0,74.0,,omicron,~16 weeks,,,,,
120,Cocchio,Retrospective cohort,20Aug2022,mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,35-69,infection,infection,Italy,12-17 years,12-17 years,32.0,26.0,38.0,,omicron,~16 weeks,,,,,
121,Suphanchaimat,Test-negative case-control,05Jul2022,CoronaVac (Sinovac),AZD1222 (AstraZeneca),included,unvaccinated individuals,30-59,infection,infection,Thailand,≥ 18 years,general pop,99.1,93.6,99.9,,delta,~6 weeks,,,,,
121,Suphanchaimat,Test-negative case-control,05Jul2022,CoronaVac (Sinovac),AZD1222 (AstraZeneca),included,unvaccinated individuals,60-89,infection,infection,Thailand,≥ 18 years,general pop,97.9,91.4,99.5,,delta,~11 weeks,,,,,
121,Suphanchaimat,Test-negative case-control,05Jul2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,15-29,infection,infection,Thailand,≥ 18 years,general pop,97.2,79.8,99.6,,delta,~2 weeks,,,,,
121,Suphanchaimat,Test-negative case-control,05Jul2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,90+,infection,infection,Thailand,≥ 18 years,general pop,98.7,90.6,99.8,,delta,~19 weeks,,,,,
122,Barraza,Retrospective cohort,05Aug2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,hospitalization with SARI,severe,Chile,≥ 18 years,general pop,84.0,71.0,91.2,,"gamma, delta & omicron",~47 weeks,,,,,
122,Barraza,Retrospective cohort,05Aug2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,14+,hospitalization with SARI,severe,Chile,≥ 18 years,general pop,96.2,83.5,99.1,,"gamma, delta & omicron",~21 weeks,,,,,
122,Barraza,Retrospective cohort,05Aug2022,CoronaVac (Sinovac),CoronaVac (Sinovac),included,unvaccinated individuals,14+,hospitalization with SARI,severe,Chile,≥ 18 years,general pop,69.1,53.6,79.4,,"gamma, delta & omicron",~47 weeks,,,,,
123,Kim,Matched case-control,29Aug2022,AZD1222 (AstraZeneca),Pfizer,excluded,complete vaccination with 2 doses of AZD1222,14+,infection,infection,South Korea,HCW,HCW,48.3,30.0,72.5,,omicron,~15 weeks,,,,,
123,Kim,Matched case-control,29Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of any mRNA,14+,infection,infection,South Korea,HCW,HCW,53.1,13.2,74.7,,omicron,~15 weeks,,,,,
124,Huang,Matched case-control,09Sept2022,Ad5-nCoV (CanSino),Ad5-nCoV (CanSino),excluded,unvaccinated individuals,13-24 weeks,infection,infection,China,≥ 3 years,general pop,16.0,1.5,28.4,,omicron,23 weeks,,,,,
125,Mallah,Test-negative case-control,10Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,infection,infection,Spain,≥ 11 years,general pop,88.0,85.0,90.0,,alpha & delta,~5 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8+,symptomatic disease,symptomatic,Singapore,≥ 80 years,80+ years,22.2,19.6,24.7,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8-30,symptomatic disease,symptomatic,Singapore,≥ 80 years,80+ years,35.0,31.0,40.0,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,60+,symptomatic disease,symptomatic,Singapore,≥ 80 years,80+ years,16.0,12.0,20.0,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8+,hospitalization,severe,Singapore,≥ 80 years,80+ years,55.0,51.8,58.3,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8-30,hospitalization,severe,Singapore,≥ 80 years,80+ years,58.0,50.0,64.0,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,60+,hospitalization,severe,Singapore,≥ 80 years,80+ years,52.0,47.0,57.0,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8+,severe disease,severe,Singapore,≥ 80 years,80+ years,63.0,56.3,68.5,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8-30,severe disease,severe,Singapore,≥ 80 years,80+ years,58.0,42.0,69.0,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,60+,severe disease,severe,Singapore,≥ 80 years,80+ years,57.0,46.0,66.0,,omicron,~13 weeks,,,,,
127,Chatzilena,Test-negative case-control,07Dec2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,UK,≥ 18 years,general pop,30.9,6.0,50.0,,omicron,~42 weeks,,,,,
127,Chatzilena,Test-negative case-control,07Dec2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,≤3 months,hospitalization,severe,UK,≥ 18 years,general pop,31.0,-15.0,59.0,,omicron,~42 weeks,,,,,
127,Chatzilena,Test-negative case-control,07Dec2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,>3 months,hospitalization,severe,UK,≥ 18 years,general pop,33.9,8.0,52.0,,omicron,~42 weeks,,,,,
128,Collie,Test-negative case-control,14Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14-27,hospitalization,severe,South Africa,≥ 18 years,general pop,81.6,68.1,89.4,,omicron BA.1 or BA.2,~23 weeks,,,,,
128,Collie,Test-negative case-control,14Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,3-4 months,hospitalization,severe,South Africa,≥ 18 years,general pop,50.0,4.4,73.0,,omicron BA.1 or BA.2,~23 weeks,,,,,
128,Collie,Test-negative case-control,14Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,1-2 months,hospitalization,severe,South Africa,≥ 18 years,general pop,68.8,59.5,76.0,,omicron BA.4 or BA.5,~23 weeks,,,,,
128,Collie,Test-negative case-control,14Sep2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,3-4 months,hospitalization,severe,South Africa,≥ 18 years,general pop,46.8,35.3,56.2,,omicron BA.4 or BA.5,~23 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,65.0,41.0,79.0,,omicron,~18 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7-119,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,79.0,59.0,89.0,,omicron,~15 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,120+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,-124.0,-414.0,2.0,,omicron,~18 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,76.0,27.0,92.0,,omicron,~18 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7-119,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,86.0,28.0,97.0,,omicron,~15 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,120+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,-53.0,-1254.0,83.0,,omicron,~18 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,81.0,33.0,95.0,,omicron,~18 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,97.0,79.0,100.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination at least 120 days prior,<60,infection,infection,Argentina,≥ 50 years,≥ 50 years,36.0,33.0,39.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination at least 120 days prior,60+,infection,infection,Argentina,≥ 50 years,≥ 50 years,8.0,-4.0,19.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination at least 120 days prior,<60,hospitalization,severe,Argentina,≥ 50 years,≥ 50 years,78.0,65.0,86.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination at least 120 days prior,60+,hospitalization,severe,Argentina,≥ 50 years,≥ 50 years,86.0,23.0,97.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination at least 120 days prior,<60,death,death,Argentina,≥ 50 years,≥ 50 years,80.0,68.0,97.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Pfizer,included,complete vaccination at least 120 days prior,60+,death,death,Argentina,≥ 50 years,≥ 50 years,75.0,-17.0,95.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,BBIBP-CorV (Beijing CNBG),Pfizer,included,complete vaccination at least 120 days prior,<60,infection,infection,Argentina,≥ 50 years,≥ 50 years,38.0,31.0,45.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,BBIBP-CorV (Beijing CNBG),Pfizer,included,complete vaccination at least 120 days prior,60+,infection,infection,Argentina,≥ 50 years,≥ 50 years,36.0,16.0,50.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,BBIBP-CorV (Beijing CNBG),Pfizer,included,complete vaccination at least 120 days prior,<60,hospitalization,severe,Argentina,≥ 50 years,≥ 50 years,78.0,49.0,91.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,BBIBP-CorV (Beijing CNBG),Pfizer,included,complete vaccination at least 120 days prior,<60,death,death,Argentina,≥ 50 years,≥ 50 years,73.0,49.0,85.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,BBIBP-CorV (Beijing CNBG),Pfizer,included,complete vaccination at least 120 days prior,60+,death,death,Argentina,≥ 50 years,≥ 50 years,76.0,-85.0,97.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Pfizer,included,complete vaccination at least 120 days prior,<60,infection,infection,Argentina,≥ 50 years,≥ 50 years,34.0,31.0,37.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Pfizer,included,complete vaccination at least 120 days prior,60+,infection,infection,Argentina,≥ 50 years,≥ 50 years,-2.0,16.0,10.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Pfizer,included,complete vaccination at least 120 days prior,<60,hospitalization,severe,Argentina,≥ 50 years,≥ 50 years,76.0,68.0,83.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Pfizer,included,complete vaccination at least 120 days prior,60+,hospitalization,severe,Argentina,≥ 50 years,≥ 50 years,66.0,16.0,86.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Pfizer,included,complete vaccination at least 120 days prior,<60,death,death,Argentina,≥ 50 years,≥ 50 years,88.0,83.0,92.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Pfizer,included,complete vaccination at least 120 days prior,60+,death,death,Argentina,≥ 50 years,≥ 50 years,84.0,46.0,95.0,,omicron,~18 weeks,,,,,
131,Florea,Prospective cohort,22Sep2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination,14+,infection,infection,USA,"immunocompetent, ≥ 18 years","immunocompetent, ≥ 18 years",61.3,60.5,62.2,,delta & omicron,~16 weeks,,,,,
131,Florea,Prospective cohort,22Sep2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination,<1 month,infection,infection,USA,"immunocompetent, ≥ 18 years","immunocompetent, ≥ 18 years",67.1,66.1,68.0,,delta & omicron,,,,,,
131,Florea,Prospective cohort,22Sep2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination,2-<3 months,infection,infection,USA,"immunocompetent, ≥ 18 years","immunocompetent, ≥ 18 years",30.5,21.3,38.6,,delta & omicron,,,,,,
131,Florea,Prospective cohort,22Sep2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination,14+,hospitalization,severe,USA,"immunocompetent, ≥ 18 years","immunocompetent, ≥ 18 years",89.0,86.2,91.2,,delta & omicron,~16 weeks,,,,,
131,Florea,Prospective cohort,22Sep2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination,<1 month,hospitalization,severe,USA,"immunocompetent, ≥ 18 years","immunocompetent, ≥ 18 years",91.0,86.9,94.0,,delta & omicron,,,,,,
131,Florea,Prospective cohort,22Sep2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination,2-<3 months,hospitalization,severe,USA,"immunocompetent, ≥ 18 years","immunocompetent, ≥ 18 years",78.7,54.5,90.0,,delta & omicron,,,,,,
131,Florea,Prospective cohort,22Sep2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination,14+,death,death,USA,"immunocompetent, ≥ 18 years","immunocompetent, ≥ 18 years",96.0,68.0,99.5,,delta & omicron,~16 weeks,,,,,
132,Chiew,Retrospective cohort,28Sep2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,8+,infection,infection,Singapore,12-17 years,12-17 years,56.0,53.0,58.0,,omicron,~12 weeks,,,,,
132,Chiew,Retrospective cohort,28Sep2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,8-14,infection,infection,Singapore,12-17 years,12-17 years,59.0,56.0,62.0,,omicron,,,,,,
132,Chiew,Retrospective cohort,28Sep2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,60+,infection,infection,Singapore,12-17 years,12-17 years,40.0,34.0,45.0,,omicron,~12 weeks,,,,,
132,Chiew,Retrospective cohort,28Sep2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,8+,hospitalization,severe,Singapore,12-17 years,12-17 years,94.0,86.0,97.0,,omicron,~12 weeks,,,,,
132,Chiew,Retrospective cohort,28Sep2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,8-14,hospitalization,severe,Singapore,12-17 years,12-17 years,96.0,87.0,99.0,,omicron,,,,,,
132,Chiew,Retrospective cohort,28Sep2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,60+,hospitalization,severe,Singapore,12-17 years,12-17 years,84.0,14.0,97.0,,omicron,~12 weeks,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,<2 months,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,83.0,82.0,84.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,8+ months,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,17.0,7.0,26.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,<2 months,hospitalization,severe,USA,≥ 18 years,general pop,89.0,88.0,90.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,8+ months,hospitalization,severe,USA,≥ 18 years,general pop,31.0,17.0,43.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,<2 months,hospitalization,severe,USA,"immunocompromised, ≥ 18 years","immunocompromised, ≥ 18 years",78.0,73.0,82.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,6+ months,hospitalization,severe,USA,"immunocompromised, ≥ 18 years","immunocompromised, ≥ 18 years",29.0,13.0,42.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,USA,"immunocompromised, ≥ 18 years","immunocompromised, ≥ 18 years",48.0,29.0,62.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,<2 months,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,96.0,95.0,96.0,,delta,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,4-<6 monhts,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,88.0,62.0,96.0,,delta,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,<2 months,hospitalization,severe,USA,≥ 18 years,general pop,96.0,95.0,96.0,,delta,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,2+ months,hospitalization,severe,USA,≥ 18 years,general pop,92.0,90.0,93.0,,delta,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7-119,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,56.0,45.0,65.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,120+,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,28.0,24.0,33.0,,omicron BA.4 or BA.5,~45 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7-119,hospitalization,severe,USA,≥ 18 years,general pop,54.0,23.0,72.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,120+,hospitalization,severe,USA,≥ 18 years,general pop,33.0,24.0,41.0,,omicron BA.4 or BA.5,~45 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7-119,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,72.0,61.0,80.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,120+,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,29.0,23.0,34.0,,omicron BA.4 or BA.5,~45 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7-119,hospitalization,severe,USA,≥ 18 years,general pop,73.0,50.0,86.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,120+,hospitalization,severe,USA,≥ 18 years,general pop,38.0,27.0,46.0,,omicron BA.4 or BA.5,~45 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,Any mRNA - heterologous,Any mRNA - heterologous,included,unvaccinated individuals,7-119,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,70.0,52.0,81.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,Any mRNA - heterologous,Any mRNA - heterologous,included,unvaccinated individuals,120+,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,38.0,29.0,46.0,,omicron BA.4 or BA.5,~45 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,Any mRNA - heterologous,Any mRNA - heterologous,included,unvaccinated individuals,120+,hospitalization,severe,USA,≥ 18 years,general pop,23.0,-2.0,42.0,,omicron BA.4 or BA.5,~45 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,7-59,ED or UC encounters,symptomatic,USA,≥ 50 years,≥ 50 years,60.0,50.0,68.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,60+,ED or UC encounters,symptomatic,USA,≥ 50 years,≥ 50 years,46.0,36.0,54.0,,omicron BA.4 or BA.5,~18.5 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,7-59,hospitalization,severe,USA,≥ 50 years,≥ 50 years,44.0,18.0,62.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,60+,hospitalization,severe,USA,≥ 50 years,≥ 50 years,53.0,37.0,66.0,,omicron BA.4 or BA.5,~18.5 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-59,ED or UC encounters,symptomatic,USA,≥ 50 years,≥ 50 years,67.0,56.0,76.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,60+,ED or UC encounters,symptomatic,USA,≥ 50 years,≥ 50 years,49.0,38.0,58.0,,omicron BA.4 or BA.5,~18.5 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-59,hospitalization,severe,USA,≥ 50 years,≥ 50 years,73.0,55.0,84.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,60+,hospitalization,severe,USA,≥ 50 years,≥ 50 years,56.0,34.0,71.0,,omicron BA.4 or BA.5,~18.5 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,Any mRNA - heterologous (3 doses),Any mRNA - heterologous (4th dose),included,unvaccinated individuals,7-59,ED or UC encounters,symptomatic,USA,≥ 50 years,≥ 50 years,52.0,32.0,66.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,Any mRNA - heterologous (3 doses),Any mRNA - heterologous (4th dose),included,unvaccinated individuals,60+,ED or UC encounters,symptomatic,USA,≥ 50 years,≥ 50 years,45.0,28.0,59.0,,omicron BA.4 or BA.5,~18.5 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,Any mRNA - heterologous (3 doses),Any mRNA - heterologous (4th dose),included,unvaccinated individuals,7-59,hospitalization,severe,USA,≥ 50 years,≥ 50 years,65.0,36.0,80.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,Any mRNA - heterologous (3 doses),Any mRNA - heterologous (4th dose),included,unvaccinated individuals,60+,hospitalization,severe,USA,≥ 50 years,≥ 50 years,52.0,22.0,71.0,,omicron BA.4 or BA.5,~18.5 weeks,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination at least 150 days prior,7-119,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,46.0,39.0,58.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination at least 150 days prior,7-119,hospitalization,severe,USA,≥ 18 years,general pop,57.0,35.0,72.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,receipt of 3 doses at least 150 days prior,7-119,ED or UC encounters,symptomatic,USA,≥ 65 years,≥ 65 years,35.0,28.0,41.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,receipt of 3 doses at least 150 days prior,7-119,hospitalization,severe,USA,≥ 65 years,≥ 65 years,37.0,25.0,46.0,,omicron BA.4 or BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,receipt of 3 doses at least 84 days prior,<84,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,23.0,17.0,29.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,receipt of 3 doses at least 84 days prior,168+,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,-24.0,-41.0,-9.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,receipt of 3 doses at least 84 days prior,<84,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,36.0,26.0,44.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,receipt of 3 doses at least 84 days prior,168+,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,-15.0,-49.0,11.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,receipt of 3 doses at least 84 days prior,<84,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,37.0,24.0,48.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,receipt of 3 doses at least 84 days prior,168+,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,6.0,-29.0,32.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,<84,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,49.0,44.0,54.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,168+,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,18.0,5.0,28.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,<84,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,69.0,61.0,75.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,168+,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,44.0,24.0,59.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,<84,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,82.0,77.0,86.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,168+,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,74.0,62.0,82.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,<84,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,38.0,32.0,43.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,84+,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,34.0,28.0,39.0,,omicron BA.1/BA.2/BA.4/BA.5,~42 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,<84,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,59.0,48.0,68.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,84+,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,51.0,42.0,60.0,,omicron BA.1/BA.2/BA.4/BA.5,~42 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,<84,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,77.0,68.0,83.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,84+,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,72.0,64.0,78.0,,omicron BA.1/BA.2/BA.4/BA.5,~42 weeks,,,,,
136,Lin,Retrospective cohort,26Sep20222,BNT162b2 (Pfizer),Pfizer,included,complete vaccination at least 120 days prior,1 month,infection,infection,USA,≥ 5 years,≥ 5 years,51.6,48.9,54.1,,omicron,~ 2 weeks,"Persons vaccinated between January 1 and June 3, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,BNT162b2 (Pfizer),Pfizer,included,complete vaccination at least 120 days prior,3 months,infection,infection,USA,≥ 5 years,≥ 5 years,16.5,14.1,18.8,,omicron,~10 weeks,"Persons vaccinated between January 1 and June 3, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,BNT162b2 (Pfizer),Moderna,included,complete vaccination at least 120 days prior,1 month,infection,infection,USA,≥ 5 years,≥ 5 years,60.4,51.7,67.5,,omicron,~ 2 weeks,"Persons vaccinated between January 1 and June 3, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,BNT162b2 (Pfizer),Moderna,included,complete vaccination at least 120 days prior,4 months,infection,infection,USA,≥ 5 years,≥ 5 years,21.8,11.2,31.2,,omicron,~14 weeks,"Persons vaccinated between January 1 and June 3, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,mRNA-1273 (Moderna),Pfizer,included,complete vaccination at least 120 days prior,1 month,infection,infection,USA,≥ 5 years,≥ 5 years,61.3,55.9,66.1,,omicron,~ 2 weeks,"Persons vaccinated between January 1 and June 3, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,mRNA-1273 (Moderna),Pfizer,included,complete vaccination at least 120 days prior,4 months,infection,infection,USA,≥ 5 years,≥ 5 years,16.4,2.1,28.6,,omicron,~14 weeks,"Persons vaccinated between January 1 and June 3, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,mRNA-1273 (Moderna),Moderna,included,complete vaccination at least 120 days prior,1 month,infection,infection,USA,≥ 5 years,≥ 5 years,55.3,51.7,58.6,,omicron,~ 2 weeks,"Persons vaccinated between January 1 and June 3, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,mRNA-1273 (Moderna),Moderna,included,complete vaccination at least 120 days prior,3 months,infection,infection,USA,≥ 5 years,≥ 5 years,22.3,19.0,25.4,,omicron,~10 weeks,"Persons vaccinated between January 1 and June 3, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,Ad26.COV2.S (Janssen),Pfizer,included,complete vaccination at least 120 days prior,1 month,infection,infection,USA,≥ 5 years,≥ 5 years,38.2,29.8,45.5,,omicron,~ 2 weeks,"Persons vaccinated after Dec 15, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,Ad26.COV2.S (Janssen),Pfizer,included,complete vaccination at least 120 days prior,2 months,infection,infection,USA,≥ 5 years,≥ 5 years,20.7,13.0,27.8,,omicron,~14 weeks,"Persons vaccinated after Dec 15, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,Ad26.COV2.S (Janssen),Moderna,included,complete vaccination at least 120 days prior,1 month,infection,infection,USA,≥ 5 years,≥ 5 years,46.4,39.1,52.9,,omicron,~ 2 weeks,"Persons vaccinated after Dec 15, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,Ad26.COV2.S (Janssen),Moderna,included,complete vaccination at least 120 days prior,2 months,infection,infection,USA,≥ 5 years,≥ 5 years,4.8,0.0,12.4,,omicron,~14 weeks,"Persons vaccinated after Dec 15, 2022. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,BNT162b2 (Pfizer),Pfizer,included,complete vaccination at least 120 days prior,1 month,infection,infection,USA,≥ 5 years,≥ 5 years,60.1,64.3,70.4,,delta,~ 2 weeks,"Persons vaccinated before September 22, 2021. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,BNT162b2 (Pfizer),Pfizer,included,complete vaccination at least 120 days prior,2 months,infection,infection,USA,≥ 5 years,≥ 5 years,53.1,50.2,55.9,,delta,~6 weeks,"Persons vaccinated before September 22, 2021. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,BNT162b2 (Pfizer),Moderna,included,complete vaccination at least 120 days prior,1 month,infection,infection,USA,≥ 5 years,≥ 5 years,68.2,62.4,73.1,,delta,~ 2 weeks,"Persons vaccinated before September 22, 2021. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,BNT162b2 (Pfizer),Moderna,included,complete vaccination at least 120 days prior,2 months,infection,infection,USA,≥ 5 years,≥ 5 years,64.1,60.8,67.2,,delta,~6 weeks,"Persons vaccinated before September 22, 2021. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,mRNA-1273 (Moderna),Pfizer,included,complete vaccination at least 120 days prior,1 month,infection,infection,USA,≥ 5 years,≥ 5 years,66.8,64.1,69.3,,delta,~ 2 weeks,"Persons vaccinated before September 22, 2021. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,mRNA-1273 (Moderna),Pfizer,included,complete vaccination at least 120 days prior,2 months,infection,infection,USA,≥ 5 years,≥ 5 years,58.3,55.8,60.7,,delta,~6 weeks,"Persons vaccinated before September 22, 2021. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,mRNA-1273 (Moderna),Moderna,included,complete vaccination at least 120 days prior,1 month,infection,infection,USA,≥ 5 years,≥ 5 years,61.6,57.4,65.5,,delta,~ 2 weeks,"Persons vaccinated before September 22, 2021. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
136,Lin,Retrospective cohort,26Sep20222,mRNA-1273 (Moderna),Moderna,included,complete vaccination at least 120 days prior,2 months,infection,infection,USA,≥ 5 years,≥ 5 years,52.8,48.7,56.6,,delta,~6 weeks,"Persons vaccinated before September 22, 2021. The study includes additional VE estimates for individuals vaccinated during different time periods",,,,
137,McConeghy,Target trial emulation,30Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,receipt of 3 doses at least 120 days prior,0-60,infection,infection,USA,nursing home residents,nursing home residents,25.8,1.2,44.3,,delta,~6.5 weeks,,,,,
137,McConeghy,Target trial emulation,30Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,receipt of 3 doses at least 120 days prior,0-60,hospitalization,severe,USA,nursing home residents,nursing home residents,60.1,-18.8,91.5,,delta,~6.5 weeks,,,,,
137,McConeghy,Target trial emulation,30Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,receipt of 3 doses at least 120 days prior,0-60,death,death,USA,nursing home residents,nursing home residents,89.6,45.0,100.0,,delta,~6.5 weeks,,,,,
137,McConeghy,Target trial emulation,30Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,receipt of 3 doses at least 120 days prior,0-60,hospitalization or death,severe,USA,nursing home residents,nursing home residents,73.9,36.1,92.2,,delta,~6.5 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-30,infection,infection,USA,≥ 18 years,general pop,85.8,82.7,88.3,omicron BA.1,omicron BA.1,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,>150,infection,infection,USA,≥ 18 years,general pop,54.9,35.6,68.4,omicron BA.1,omicron BA.1,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,14-30,infection,infection,USA,≥ 18 years,general pop,81.0,77.0,54.4,omicron BA.1,omicron BA.1,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,>150,infection,infection,USA,≥ 18 years,general pop,50.0,28.4,65.1,omicron BA.1,omicron BA.1,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,hospitalization,severe,USA,≥ 18 years,general pop,97.5,96.3,98.3,omicron BA.1,omicron BA.1,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,14+,hospitalization,severe,USA,≥ 18 years,general pop,88.8,83.3,92.5,omicron BA.1,omicron BA.1,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-30,infection,infection,USA,≥ 18 years,general pop,61.0,27.6,79.0,omicron BA.2,omicron BA.2,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,>150,infection,infection,USA,≥ 18 years,general pop,-24.9,-32.3,-16.7,omicron BA.2,omicron BA.2,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,14-30,infection,infection,USA,≥ 18 years,general pop,63.6,32.3,80.4,omicron BA.2,omicron BA.2,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,>150,infection,infection,USA,≥ 18 years,general pop,-13.6,-23.4,-2.5,omicron BA.2,omicron BA.2,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,hospitalization,severe,USA,≥ 18 years,general pop,82.0,64.5,90.8,omicron BA.2,omicron BA.2,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,14+,hospitalization,severe,USA,≥ 18 years,general pop,75.0,47.6,88.1,omicron BA.2,omicron BA.2,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,14-30,infection,infection,USA,≥ 18 years,general pop,64.3,50.7,74.2,omicron BA.2,omicron BA.2,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,>90,infection,infection,USA,≥ 18 years,general pop,17.2,-45.3,62.6,omicron BA.2,omicron BA.2,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,14-30,infection,infection,USA,≥ 18 years,general pop,64.3,52.0,73.5,omicron BA.2,omicron BA.2,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,>90,infection,infection,USA,≥ 18 years,general pop,66.1,22.1,85.3,omicron BA.2,omicron BA.2,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,14+,hospitalization,severe,USA,≥ 18 years,general pop,96.4,88.4,98.9,omicron BA.2,omicron BA.2,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,14+,hospitalization,severe,USA,≥ 18 years,general pop,85.5,59.7,94.9,omicron BA.2,omicron BA.2,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-30,infection,infection,USA,≥ 18 years,general pop,82.7,44.2,94.7,omicron BA.2.12.1,omicron BA.2.12.1,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,>150,infection,infection,USA,≥ 18 years,general pop,-26.8,-34.6,-18.0,omicron BA.2.12.1,omicron BA.2.12.1,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,14-30,infection,infection,USA,≥ 18 years,general pop,85.2,52.2,95.4,omicron BA.2.12.1,omicron BA.2.12.1,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,>150,infection,infection,USA,≥ 18 years,general pop,-9.1,-20.3,3.5,omicron BA.2.12.1,omicron BA.2.12.1,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,14-30,infection,infection,USA,≥ 18 years,general pop,64.4,48.6,75.4,omicron BA.2.12.1,omicron BA.2.12.1,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,>90,infection,infection,USA,≥ 18 years,general pop,14.0,-48.4,61.9,omicron BA.2.12.1,omicron BA.2.12.1,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,14-30,infection,infection,USA,≥ 18 years,general pop,72.1,60.8,80.2,omicron BA.2.12.1,omicron BA.2.12.1,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,>90,infection,infection,USA,≥ 18 years,general pop,68.0,25.3,86.3,omicron BA.2.12.1,omicron BA.2.12.1,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-30,infection,infection,USA,≥ 18 years,general pop,72.6,-54.7,96.6,omicron BA.4,omicron BA.4,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,>150,infection,infection,USA,≥ 18 years,general pop,-16.4,-35.8,8.2,omicron BA.4,omicron BA.4,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,14-30,infection,infection,USA,≥ 18 years,general pop,71.8,-55.7,96.5,omicron BA.4,omicron BA.4,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,>150,infection,infection,USA,≥ 18 years,general pop,-13.1,-36.3,15.6,omicron BA.4,omicron BA.4,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,14-30,infection,infection,USA,≥ 18 years,general pop,75.7,34.7,91.0,omicron BA.4,omicron BA.4,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,>90,infection,infection,USA,≥ 18 years,general pop,6.3,-66.3,70.4,omicron BA.4,omicron BA.4,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,14-30,infection,infection,USA,≥ 18 years,general pop,80.8,49.6,92.7,omicron BA.4,omicron BA.4,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,>90,infection,infection,USA,≥ 18 years,general pop,42.4,-48.5,82.9,omicron BA.4,omicron BA.4,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-30,infection,infection,USA,≥ 18 years,general pop,90.6,30.6,98.7,omicron BA.5,omicron BA.5,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,>150,infection,infection,USA,≥ 18 years,general pop,-17.9,-29.6,-4.2,omicron BA.5,omicron BA.5,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,14-30,infection,infection,USA,≥ 18 years,general pop,91.0,33.6,98.8,omicron BA.5,omicron BA.5,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,>150,infection,infection,USA,≥ 18 years,general pop,-17.1,-31.4,0.2,omicron BA.5,omicron BA.5,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,14-30,infection,infection,USA,≥ 18 years,general pop,30.8,-9.2,56.5,omicron BA.5,omicron BA.5,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,>90,infection,infection,USA,≥ 18 years,general pop,5.0,-56.9,61.1,omicron BA.5,omicron BA.5,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,14-30,infection,infection,USA,≥ 18 years,general pop,43.2,12.4,63.1,omicron BA.5,omicron BA.5,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,>90,infection,infection,USA,≥ 18 years,general pop,48.4,-24.2,79.8,omicron BA.5,omicron BA.5,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,hospitalization,severe,USA,≥ 18 years,general pop,72.4,23.9,90.0,omicron BA.4 or BA.5,omicron BA.4 or BA.5,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,14+,hospitalization,severe,USA,≥ 18 years,general pop,87.5,51.8,96.8,omicron BA.4 or BA.5,omicron BA.4 or BA.5,~39 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,14+,hospitalization,severe,USA,≥ 18 years,general pop,88.5,51.8,97.2,omicron BA.4 or BA.5,omicron BA.4 or BA.5,~15 weeks,,,,,
138,Tseng,Test-negative case-control,12Jan2023,mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,14+,hospitalization,severe,USA,≥ 18 years,general pop,72.2,-7.4,92.9,omicron BA.4 or BA.5,omicron BA.4 or BA.5,~15 weeks,,,,,
139,Risk,Test-negative case-control,08Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,0-3 months,infection,infection,USA,12-17 years,12-17 years,56.3,36.5,70.6,,delta & omicron,~9 weeks,This study does not adjust for calendar time,,,,
140,Buchan,Test-negative case-control,22Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,60.0,55.0,65.0,omicron,omicron,~19 weeks,~7.1% of participants received one dose of AZD1222 as part of their primary series ,,,,
140,Buchan,Test-negative case-control,22Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,severe disease,severe,Canada,≥ 18 years,general pop,95.0,87.0,98.0,omicron,omicron,~19 weeks,~7.1% of participants received one dose of AZD1222 as part of their primary series ,,,,
140,Buchan,Test-negative case-control,22Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,65.0,55.0,72.0,omicron,omicron,~19 weeks,~7.1% of participants received one dose of AZD1222 as part of their primary series ,,,,
140,Buchan,Test-negative case-control,22Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,severe disease,severe,Canada,≥ 18 years,general pop,93.0,74.0,98.0,omicron,omicron,~19 weeks,~7.1% of participants received one dose of AZD1222 as part of their primary series ,,,,
140,Buchan,Test-negative case-control,22Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,97.0,96.0,98.0,delta,delta,~19 weeks,~7.1% of participants received one dose of AZD1222 as part of their primary series ,,,,
140,Buchan,Test-negative case-control,22Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,severe disease,severe,Canada,≥ 18 years,general pop,99.0,98.0,99.0,delta,delta,~19 weeks,~7.1% of participants received one dose of AZD1222 as part of their primary series ,,,,
140,Buchan,Test-negative case-control,22Sep2022,BNT162b2 (Pfizer) (3 doses),Moderna,included,unvaccinated individuals,7+,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,97.0,95.0,98.0,delta,delta,~19 weeks,~7.1% of participants received one dose of AZD1222 as part of their primary series ,,,,
140,Buchan,Test-negative case-control,22Sep2022,BNT162b2 (Pfizer) (3 doses),Moderna,included,unvaccinated individuals,7+,severe disease,severe,Canada,≥ 18 years,general pop,100.0,98.0,100.0,delta,delta,~19 weeks,~7.1% of participants received one dose of AZD1222 as part of their primary series ,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) + CoronaVac (Sinovac) +  BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 20 years,general pop,74.1,54.8,85.2,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) + CoronaVac (Sinovac) +  BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,14+,death,death,Chile,≥ 20 years,general pop,87.7,76.1,93.7,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) (3 doses),Pfizer,excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 20 years,general pop,86.3,83.2,88.8,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) (3 doses),Pfizer,excluded,unvaccinated individuals,14+,death,death,Chile,≥ 20 years,general pop,81.0,76.8,84.0,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) + CoronaVac (Sinovac) +  AZD1222 (AstraZeneca) (3 doses),Pfizer,excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 20 years,general pop,75.0,63.4,83.0,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) + CoronaVac (Sinovac) +  AZD1222 (AstraZeneca) (3 doses),Pfizer,excluded,unvaccinated individuals,14+,death,death,Chile,≥ 20 years,general pop,79.3,73.8,83.7,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 20 years,general pop,77.0,69.6,83.0,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14+,death,death,Chile,≥ 20 years,general pop,90.8,89.4,92.0,,omicron,~24 weeks,,,,,
142,Mimura,Retrospective cohort,08Oct2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Pfizer,excluded,unvaccinated individuals,14+,infection,infection,Japan,16-64 years,16-64 years,56.5,46.0,65.0,omicron,omicron,~15 weeks,,,,,
142,Mimura,Retrospective cohort,08Oct2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Pfizer,excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,Japan,16-64 years,16-64 years,71.8,60.1,80.1,omicron,omicron,~15 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,81.0,75.0,85.0,,omicron BA.5,~9 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Pfizer,excluded,complete vaccination with 2 doses,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,53.0,43.0,65.0,,omicron BA.5,~9 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Pfizer,excluded,complete vaccination with 3 doses,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,47.0,35.0,57.0,,omicron BA.5,~9 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Pfizer,excluded,unvaccinated individuals,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,82.0,77.0,85.0,,omicron BA.5,~9 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or any mRNA primary series + any mRNA first booster,Pfizer,excluded,complete vaccination with 2 doses,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,56.0,47.0,63.0,,omicron BA.5,~9 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or any mRNA primary series + any mRNA first booster,Pfizer,excluded,complete vaccination with 3 doses,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,49.0,41.0,56.0,,omicron BA.5,~9 weeks,,,,,
144,UKHSA,Retrospective cohort,03Nov2022,BNT162b2 (Pfizer),Pfizer,unknown,complete vaccination with 3 doses at least 25-39 weeks prior,14-28,hospitalization,severe,UK,≥ 75 years,≥ 75 years,58.8,54.1,63.0,,omicron,~26 weeks,A minority of individuals received AZD1222 as a booster vaccine.,,,,
144,UKHSA,Retrospective cohort,03Nov2022,BNT162b2 (Pfizer),Pfizer,unknown,complete vaccination with 3 doses at least 25-39 weeks prior,140+,hospitalization,severe,UK,≥ 75 years,≥ 75 years,10.8,-6.2,25.1,,omicron,~26 weeks,A minority of individuals received AZD1222 as a booster vaccine.,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-180,infection,infection,"Hong Kong, SAR",60-79 years,60-79 years,-0.1,-2.6,2.3,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-180,hospitalization,severe,"Hong Kong, SAR",60-79 years,60-79 years,90.4,88.7,91.8,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-180,severe disease,severe,"Hong Kong, SAR",60-79 years,60-79 years,89.3,79.1,94.5,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-180,death,death,"Hong Kong, SAR",60-79 years,60-79 years,97.9,95.3,99.1,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-180,infection,infection,"Hong Kong, SAR",≥ 80 years,≥ 80 years,73.8,70.6,76.6,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-180,hospitalization,severe,"Hong Kong, SAR",≥ 80 years,≥ 80 years,90.5,87.0,93.1,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14-180,severe disease,severe,"Hong Kong, SAR",≥ 80 years,≥ 80 years,78.7,40.3,92.4,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14-180,death,death,"Hong Kong, SAR",≥ 80 years,≥ 80 years,96.1,91.2,98.3,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,infection,infection,"Hong Kong, SAR",60-79 years,60-79 years,-9.3,-39.0,14.0,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,hospitalization,severe,"Hong Kong, SAR",60-79 years,60-79 years,81.9,79.7,83.8,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,severe disease,severe,"Hong Kong, SAR",60-79 years,60-79 years,85.2,75.8,91.0,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,death,death,"Hong Kong, SAR",60-79 years,60-79 years,96.1,93.5,97.7,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,infection,infection,"Hong Kong, SAR",≥ 80 years,≥ 80 years,49.2,45.5,52.6,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,hospitalization,severe,"Hong Kong, SAR",≥ 80 years,≥ 80 years,87.3,84.3,89.7,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,severe disease,severe,"Hong Kong, SAR",≥ 80 years,≥ 80 years,88.8,64.4,96.5,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,death,death,"Hong Kong, SAR",≥ 80 years,≥ 80 years,93.7,89.5,96.2,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,infection,infection,"Hong Kong, SAR",60-79 years,60-79 years,49.4,47.8,50.9,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,hospitalization,severe,"Hong Kong, SAR",60-79 years,60-79 years,94.0,55.5,99.2,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,infection,infection,"Hong Kong, SAR",≥ 80 years,≥ 80 years,62.7,10.1,84.5,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),CoronaVac (Sinovac),excluded,unvaccinated individuals,14-180,hospitalization,severe,"Hong Kong, SAR",≥ 80 years,≥ 80 years,85.0,-10.9,98.0,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14-180,infection,infection,"Hong Kong, SAR",60-79 years,60-79 years,-0.1,-2.6,2.3,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14-180,hospitalization,severe,"Hong Kong, SAR",60-79 years,60-79 years,85.5,82.3,88.2,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14-180,severe disease,severe,"Hong Kong, SAR",60-79 years,60-79 years,92.2,74.9,97.6,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14-180,death,death,"Hong Kong, SAR",60-79 years,60-79 years,97.3,92.1,99.1,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,14-180,infection,infection,"Hong Kong, SAR",≥ 80 years,≥ 80 years,55.8,48.5,62.1,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-180,hospitalization,severe,"Hong Kong, SAR",≥ 80 years,≥ 80 years,88.8,82.0,93.0,,omicron BA.2,~24 weeks,,,,,
145,Wan,Case-control,17Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,14-180,death,death,"Hong Kong, SAR",≥ 80 years,≥ 80 years,94.0,80.7,98.2,,omicron BA.2,~24 weeks,,,,,
146,John,Retrospective cohort,19Oct2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses,14+,infection,infection,USA,patients with liver cirrhosis ≥ 18 years,immunocompromised,96.0,73.0,99.0,,delta & omicron,~28 weeks,,,,,
146,John,Retrospective cohort,19Oct2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses,14+,symptomatic disease,symptomatic,USA,patients with liver cirrhosis ≥ 18 years,immunocompromised,91.0,29.0,99.0,,delta & omicron,~28 weeks,,,,,
146,John,Retrospective cohort,19Oct2022,mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses,14+,"moderate, severe, or critical disease","moderate, severe, or critical disease",USA,patients with liver cirrhosis ≥ 18 years,immunocompromised,100.0,94.0,100.0,,delta & omicron,~28 weeks,,,,,
146,John,Retrospective cohort,19Oct2022,mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses,14+,severe or critical disease,severe,USA,patients with liver cirrhosis ≥ 18 years,immunocompromised,100.0,97.0,100.0,,delta & omicron,~28 weeks,,,,,
146,John,Retrospective cohort,19Oct2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,14+,infection,infection,USA,patients with liver cirrhosis ≥ 18 years,immunocompromised,61.0,16.0,82.0,,delta & omicron,~28 weeks,,,,,
146,John,Retrospective cohort,19Oct2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,14+,symptomatic disease,symptomatic,USA,patients with liver cirrhosis ≥ 18 years,immunocompromised,56.0,-21.0,84.0,,delta & omicron,~28 weeks,,,,,
146,John,Retrospective cohort,19Oct2022,BNT162b2 (Pfizer),Moderna,included,complete vaccination with 2 doses,14+,"moderate, severe, or critical disease","moderate, severe, or critical disease",USA,patients with liver cirrhosis ≥ 18 years,immunocompromised,38.0,-248.0,89.0,,delta & omicron,~28 weeks,,,,,
146,John,Retrospective cohort,19Oct2022,BNT162b2 (Pfizer),Moderna,included,complete vaccination with 2 doses,14+,severe or critical disease,severe,USA,patients with liver cirrhosis ≥ 18 years,immunocompromised,100.0,93.0,100.0,,delta & omicron,~28 weeks,,,,,
147,Consonni,Retrospective cohort,19Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7-29,infection,infection,Italy,HCW,HCW,57.0,35.0,71.0,,omicron,~30 weeks,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",,,,
147,Consonni,Retrospective cohort,19Oct2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,120+,infection,infection,Italy,HCW,HCW,1.0,0.0,32.0,,omicron,~30 weeks,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",,,,
147,Consonni,Retrospective cohort,19Oct2022,BNT162b2 (Pfizer),Pfizer,previously infected only,unvaccinated individuals,7-29,infection,infection,Italy,HCW,HCW,71.0,23.0,89.0,,omicron,~30 weeks,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",,,,
147,Consonni,Retrospective cohort,19Oct2022,mRNA-1273 (Moderna),Pfizer,previously infected only,unvaccinated individuals,120+,infection,infection,Italy,HCW,HCW,20.0,0.0,72.0,,omicron,~30 weeks,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",,,,
148,Embi,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,ED or UC visit with COVID-like illness,symptomatic,USA,immunocompetent adults ≥ 18 years,general pop,93.0,92.0,94.0,,delta,~11 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED or UC visit with COVID-like illness,symptomatic,USA,immunocompetent adults ≥ 18 years,general pop,95.0,94.0,96.0,,delta,~11 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 18 years,general pop,95.0,94.0,96.0,,delta,~11 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 18 years,general pop,96.0,95.0,97.0,,delta,~11 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,ED or UC visit with COVID-like illness,symptomatic,USA,immunocompromised adults ≥ 18 years,immunocompromised,74.0,62.0,82.0,,delta,~15 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED or UC visit with COVID-like illness,symptomatic,USA,immunocompromised adults ≥ 18 years,immunocompromised,77.0,58.0,87.0,,delta,~15 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,76.0,69.0,82.0,,delta,~15 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,87.0,79.0,92.0,,delta,~15 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses,7+,ED or UC visit with COVID-like illness,symptomatic,USA,immunocompetent adults ≥ 18 years,general pop,74.0,70.0,78.0,,delta,~11 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,7+,ED or UC visit with COVID-like illness,symptomatic,USA,immunocompetent adults ≥ 18 years,general pop,69.0,60.0,76.0,,delta,~11 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 18 years,general pop,77.0,70.0,83.0,,delta,~11 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 18 years,general pop,71.0,57.0,81.0,,delta,~11 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with 2 doses,7+,ED or UC visit with COVID-like illness,symptomatic,USA,immunocompromised adults ≥ 18 years,immunocompromised,51.0,29.0,66.0,,delta,~15 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,7+,ED or UC visit with COVID-like illness,symptomatic,USA,immunocompromised adults ≥ 18 years,immunocompromised,47.0,3.0,71.0,,delta,~15 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,40.0,21.0,55.0,,delta,~15 weeks,,,,,
148,Embi,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,57.0,33.0,73.0,,delta,~15 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7-89,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,75.0,71.0,79.0,,omicron BA.1,,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,90+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,49.0,41.0,7.0,,omicron BA.1,~31 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,32.0,16.0,46.0,,omicron BA.2/BA.2.12.1,~44 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,90+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,32.0,15.0,45.0,,omicron BA.2/BA.2.12.1,~44 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,35.0,21.0,47.0,,omicron BA.4/BA.5,~51 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,90+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,36.0,22.0,47.0,,omicron BA.4/BA.5,~51 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,33.0,22.0,42.0,,omicron BA.2/BA.2.12.1/BA.4/BA.5,~51 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,90+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,32.0,21.0,42.0,,omicron BA.2/BA.2.12.1/BA.4/BA.5,~51 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,43.0,27.0,56.0,,omicron BA.2/BA.2.12.1/BA.4/BA.5,~22 weeks,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-120,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,79.0,74.0,84.0,,omicron BA.1/BA.2,,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,120+,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,41.0,23.0,55.0,,omicron BA.1/BA.2,~28 weeks,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,61.0,29.0,78.0,,omicron BA.1/BA.2,~11 weeks,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7-120,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,61.0,29.0,78.0,,omicron BA.1/BA.2,,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-120,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,60.0,12.0,81.0,,omicron BA.4/BA.5,,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,120+,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,29.0,3.0,48.0,,omicron BA.4/BA.5,~39 weeks,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,60.0,36.0,75.0,,omicron BA.4/BA.5,~22 weeks,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7-120,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,61.0,37.0,76.0,,omicron BA.4/BA.5,,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,<3 months,ED visit,symptomatic,USA,≥ 18 years,general pop,71.0,18.0,90.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~52 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥6 months,ED visit,symptomatic,USA,≥ 18 years,general pop,37.0,8.0,57.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~52 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,<3 months,UC visit,symptomatic,USA,≥ 18 years,general pop,59.0,35.0,74.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~52 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥6 months,UC visit,symptomatic,USA,≥ 18 years,general pop,11.0,-7.0,26.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~52 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,<3 months,Outpatient care visit,symptomatic,USA,≥ 18 years,general pop,55.0,41.0,65.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~52 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,≥6 months,Outpatient care visit,symptomatic,USA,≥ 18 years,general pop,6.0,-7.0,17.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~52 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,3-5 months,Hospitalization,severe,USA,≥ 18 years,general pop,72.0,13.0,91.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~52 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,≥6 months,hospitalization,severe,USA,≥ 18 years,general pop,38.0,-31.0,71.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~52 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,<3 months,ED visit for ARI,symptomatic,USA,≥ 50 years,≥ 50 years,65.0,35.0,82.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~19 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,≥3 months,ED visit for ARI,symptomatic,USA,≥ 50 years,≥ 50 years,78.0,50.0,91.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~19 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,<3 months,UC visit for ARI,symptomatic,USA,≥ 50 years,≥ 50 years,35.0,10.0,54.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~19 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,≥3 months,UC visit for ARI,symptomatic,USA,≥ 50 years,≥ 50 years,20.0,-23.0,48.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~19 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,<3 months,outpatient care visit for ARI,symptomatic,USA,≥ 50 years,≥ 50 years,28.0,10.0,43.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~19 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,BNT162b2 (Pfizer) (3 doses),Pfizer,included,unvaccinated individuals,≥3 months,outpatient care visit for ARI,symptomatic,USA,≥ 50 years,≥ 50 years,11.0,-18.0,34.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~19 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,Sputnik V (Gamaleya),Pfizer,included,unvaccinated individuals,<3 months,hospitalization for ARI,severe,USA,≥ 50 years,≥ 50 years,66.0,20.0,85.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~19 weeks,,,,,
151,Tartof,Test-negative case-control,25Oct2022,Sputnik V (Gamaleya),Pfizer,included,unvaccinated individuals,≥3 months,hospitalization for ARI,severe,USA,≥ 50 years,≥ 50 years,33.0,-112.0,79.0,omicron BA.4/BA.5,omicron BA.4/BA.5,~19 weeks,,,,,
152,Moghnieh,Retrospective case cohort,22Sept2022,Sputnik V (Gamaleya),Pfizer,included,unvaccinated individuals,7-60,infection,infection,Lebanon,≥ 18 years,general pop,57.0,23.2,75.5,omicron,omicron,~19 weeks,,,,,
152,Moghnieh,Retrospective case cohort,22Sept2022,BNT162b2 (Pfizer),Pfizer,excluded,unvaccinated individuals,7-60,infection,infection,Lebanon,≥ 18 years,general pop,53.7,13.3,74.7,omicron,omicron,~19 weeks,,,,,
152,Moghnieh,Retrospective case cohort,22Sept2022,BNT162b2 (Pfizer),Pfizer,previously infected only,unvaccinated individuals,7-60,infection,infection,Lebanon,≥ 18 years,general pop,90.5,71.6,97.8,omicron,omicron,~19 weeks,,,,,
152,Moghnieh,Retrospective case cohort,22Sept2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7-60,infection,infection,Lebanon,≥ 18 years,general pop,63.7,-9.1,91.6,omicron,omicron,~19 weeks,,,,,
152,Moghnieh,Retrospective case cohort,22Sept2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7-60,infection,infection,Lebanon,≥ 18 years,general pop,48.6,-92.2,92.1,omicron,omicron,~19 weeks,,,,,
152,Moghnieh,Retrospective case cohort,22Sept2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,previously infected only,unvaccinated individuals,7-60,infection,infection,Lebanon,≥ 18 years,general pop,84.1,19.6,99.1,omicron,omicron,~19 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,120-179,severe disease,severe,Canada,50-59 years,50-59 years,96.0,93.0,97.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180-239,severe disease,severe,Canada,50-59 years,50-59 years,98.0,93.0,99.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,50-59 years,50-59 years,97.0,77.0,100.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,60-119,severe disease,severe,Canada,60-69 years,60-69 years,95.0,96.0,96.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180-239,severe disease,severe,Canada,60-69 years,60-69 years,90.0,79.0,95.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,60-69 years,60-69 years,96.0,93.0,98.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,60-119,severe disease,severe,Canada,60-69 years,60-69 years,95.0,77.0,99.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,70-79 years,70-79 years,96.0,96.0,97.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180-239,severe disease,severe,Canada,70-79 years,70-79 years,91.0,85.0,95.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,70-79 years,70-79 years,96.0,94.0,97.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,60-119,severe disease,severe,Canada,70-79 years,70-79 years,93.0,87.0,96.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,80+ years,80+ years,92.0,90.0,93.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180-239,severe disease,severe,Canada,80+ years,80+ years,87.0,80.0,91.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,80+ years,80+ years,94.0,92.0,95.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,120+,severe disease,severe,Canada,80+ years,80+ years,92.0,78.0,97.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,120-179,severe disease,severe,Canada,50-59 years,50-59 years,77.0,50.0,89.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180-239,severe disease,severe,Canada,50-59 years,50-59 years,75.0,60.0,84.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,50-59 years,50-59 years,95.0,82.0,98.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,60-119,severe disease,severe,Canada,60-69 years,60-69 years,94.0,53.0,99.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180-239,severe disease,severe,Canada,60-69 years,60-69 years,69.0,55.0,78.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,60-69 years,60-69 years,88.0,78.0,94.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,60-119,severe disease,severe,Canada,60-69 years,60-69 years,81.0,70.0,88.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,70-79 years,70-79 years,86.0,37.0,97.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180-239,severe disease,severe,Canada,70-79 years,70-79 years,59.0,44.0,70.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,70-79 years,70-79 years,85.0,77.0,90.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,60-119,severe disease,severe,Canada,70-79 years,70-79 years,86.0,80.0,90.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,≥ 80 years,≥ 80 years,76.0,27.0,92.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,180-239,severe disease,severe,Canada,≥ 80 years,≥ 80 years,52.0,36.0,64.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,7-59,severe disease,severe,Canada,≥ 80 years,≥ 80 years,86.0,79.0,90.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,unvaccinated individuals,120+,severe disease,severe,Canada,≥ 80 years,≥ 80 years,80.0,72.0,85.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,50-59 years,50-59 years,79.0,72.0,84.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses,60-119,severe disease,severe,Canada,50-59 years,50-59 years,57.0,35.0,72.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,50-59 years,50-59 years,89.0,69.0,96.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 2 doses,240+,severe disease,severe,Canada,50-59 years,50-59 years,77.0,-1.0,95.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,60-69 years,60-69 years,87.0,83.0,90.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses,120+,severe disease,severe,Canada,60-69 years,60-69 years,62.0,45.0,75.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,60-69 years,60-69 years,83.0,74.0,89.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 2 doses,240+,severe disease,severe,Canada,60-69 years,60-69 years,69.0,47.0,82.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,70-79 years,70-79 years,83.0,79.0,86.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses,120+,severe disease,severe,Canada,70-79 years,70-79 years,45.0,24.0,59.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,70-79 years,70-79 years,80.0,74.0,85.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 2 doses,240+,severe disease,severe,Canada,70-79 years,70-79 years,69.0,57.0,78.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,≥ 80 years,≥ 80 years,77.0,72.0,80.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses,240+,severe disease,severe,Canada,≥ 80 years,≥ 80 years,48.0,33.0,60.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,≥ 80 years,≥ 80 years,82.0,78.0,86.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with 2 doses,120+,severe disease,severe,Canada,≥ 80 years,≥ 80 years,75.0,68.0,81.0,,omicron,~37 weeks,,,,,
154,Chemaitelly,Retrospective cohort,01Nov2022,BNT162b2 (Pfizer) (3 doses),Pfizer,previously infected only,complete vaccination with 2 doses prior to first infection,91+ (90+ days post primary Omicron infection),reinfection,reinfection,Qatar,≥18 years with prior breakthrough Omicron infection,≥18 years with prior breakthrough Omicron infection,-38.0,-65.0,-15.0,,omicron,~50 weeks,,,,,
154,Chemaitelly,Retrospective cohort,01Nov2022,BNT162b2 (Pfizer) (3 doses),Pfizer,previously infected only,unvaccinated individuals,91+ (90+ days post primary Omicron infection),reinfection,reinfection,Qatar,≥18 years with prior breakthrough Omicron infection,≥18 years with prior breakthrough Omicron infection,47.0,37.0,56.0,,omicron,~50 weeks,,,,,
155,Hazan,Retrospective cohort,02Nov2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses,7+,infection,infection,Israel,≥ 12 years,≥ 12 years,57.0,56.0,88.0,,delta & omicron,~31 weeks,,,,,
155,Hazan,Retrospective cohort,02Nov2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses,7+,ED visit,symptomatic,Israel,≥ 12 years,≥ 12 years,67.0,59.0,73.0,,delta & omicron,~31 weeks,,,,,
156,Canetti,Prospective cohort,09Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,7-35,infection,infection,Israel,HCW,HCW,52.0,45.0,58.0,,omicron BA.1/BA.2,~24 weeks,,,,,
156,Canetti,Prospective cohort,09Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,103-81,infection,infection,Israel,HCW,HCW,-2.0,-27.0,17.0,,omicron BA.1/BA.2,~24 weeks,,,,,
157,Jorgensen,Test-negative case-control,08Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14+,infection,infection,Canada,infants <6 months,infants <6 months,73.0,61.0,80.0,,omicron,~35 weeks,,,,,
157,Jorgensen,Test-negative case-control,08Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14+,hospitalization,severe,Canada,infants <6 months,infants <6 months,81.0,58.0,92.0,,omicron,~35 weeks,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,14-28,infection,infection,Italy,≥ 80 years,≥ 80 years,28.5,24.7,32.1,,omicron,,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,28-56,infection,infection,Italy,≥ 80 years,≥ 80 years,7.6,-14.1,18.3,,omicron,,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,14-28,severe disease,severe,Italy,≥ 80 years,≥ 80 years,43.2,30.6,54.9,,omicron,,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,28-56,severe disease,severe,Italy,≥ 80 years,≥ 80 years,27.2,8.3,42.9,,omicron,,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,14+,infection,infection,Italy,≥ 80 years,≥ 80 years,12.8,-1.1,19.4,,omicron,~19 weeks,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,14+,severe disease,severe,Italy,≥ 80 years,≥ 80 years,33.1,21.2,43.0,,omicron,~19 weeks,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,BNT162b2 (Pfizer) (3 doses),Moderna,excluded,complete vaccination with 3 doses at least 4 months prior,14+,infection,infection,Italy,≥ 80 years,≥ 80 years,22.6,13.5,30.0,,omicron,~19 weeks,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,BNT162b2 (Pfizer) (3 doses),Moderna,excluded,complete vaccination with 3 doses at least 4 months prior,14+,severe disease,severe,Italy,≥ 80 years,≥ 80 years,38.5,16.4,55.0,,omicron,~19 weeks,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses at least 6 months prior,7+,infection,infection,Qatar,all ages,general pop,44.0,42.9,45.2,,omicron,~54 weeks,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses at least 6 months prior,7+,"severe, critical, or fatal disease",severe,Qatar,all ages,general pop,79.4,52.8,91.0,,omicron,~54 weeks,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses at least 6 months prior,7+,infection,infection,Qatar,all ages,general pop,29.1,26.4,31.6,,omicron,~54 weeks,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses at least 6 months prior,7+,infection,infection,Qatar,all ages,general pop,41.1,40.0,42.1,,omicron,~54 weeks,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses at least 6 months prior,7-37,infection,infection,Qatar,all ages,general pop,57.1,55.9,58.3,,omicron,,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses at least 6 months prior,308+,infection,infection,Qatar,all ages,general pop,-20.3,-55.0,29.0,,omicron,~54 weeks,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses at least 6 months prior,7+,"severe, critical, or fatal disease",severe,Qatar,all ages,general pop,80.5,55.7,91.4,,omicron,~54 weeks,,,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer bivalent,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,18-49 years,18-49 years,41.0,31.0,49.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer bivalent,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,50.0,35.0,61.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer bivalent,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,32.0,9.0,49.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer bivalent,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,18-49 years,18-49 years,43.0,39.0,46.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer bivalent,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,25.0,17.0,33.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer bivalent,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,19.0,8.0,29.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Pfizer bivalent,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,28.0,20.0,34.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Pfizer bivalent,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,23.0,15.0,30.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,AZD1222 primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,-7.9,-80.2,64.4,,omicron BA.1/BA.2,~14 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,AZD1222 primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,51.6,-49.9,100.0,,omicron BA.1/BA.2,~13 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,AZD1222 + BNT162b2 (heterologous) primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,16.5,6.9,26.1,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + mRNA-1273 (Moderna) (heterologous),Moderna,excluded,AZD1222 + mRNA-1273 (heterologous) primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,19.9,7.8,31.9,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + mRNA-1273 (Moderna) (heterologous),Moderna,excluded,AZD1222 + mRNA-1273 (heterologous) primary,14-75,hospitalization,severe,Denmark,≥ 18 years,general pop,36.0,-141.4,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Moderna,excluded,BNT162b2 primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,51.8,18.0,85.6,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,mRNA-1273 primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,33.2,-6.8,73.2,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,mRNA-1273 + BNT162b2 primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,-92.2,-458.0,100.0,,omicron BA.1/BA.2,~26 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,0.8,-1.0,2.6,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,hospitalization,severe,Denmark,≥ 18 years,general pop,88.7,84.2,93.2,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,ICU admission,severe,Denmark,≥ 18 years,general pop,64.1,25.2,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,death,death,Denmark,≥ 18 years,general pop,96.8,92.6,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,4.2,0.2,8.2,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,hospitalization,severe,Denmark,≥ 18 years,general pop,89.3,80.8,97.9,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,death,death,Denmark,≥ 18 years,general pop,99.0,96.9,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,previously infected only,BNT162b2 primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,13.4,5.5,21.2,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,previously infected only,mRNA-1273 primary,14-75,infection,infection,Denmark,≥ 18 years,general pop,11.2,-4.8,27.3,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,AZD1222 primary,14-75,infection,infection,Finland,≥ 18 years,general pop,62.8,52.9,72.7,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,AZD1222 primary,14-75,hospitalization,severe,Finland,≥ 18 years,general pop,95.5,88.5,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,AZD1222 primary,14-75,infection,infection,Finland,≥ 18 years,general pop,77.7,67.9,87.4,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,AZD1222 primary,14-75,death,death,Finland,≥ 18 years,general pop,73.7,18.8,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,AZD1222 + BNT162b2 (heterologous) primary,14-75,infection,infection,Finland,≥ 18 years,general pop,42.7,35.8,49.6,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,AZD1222 + BNT162b2 (heterologous) primary,14-75,hospitalization,severe,Finland,≥ 18 years,general pop,86.6,65.1,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,AZD1222 + BNT162b2 (heterologous) primary,14-75,ICU admission,severe,Finland,≥ 18 years,general pop,52.8,-42.8,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,AZD1222 + BNT162b2 (heterologous) primary,14-75,death,death,Finland,≥ 18 years,general pop,-11.9,-186.4,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + mRNA-1273 (Moderna) (heterologous),Moderna,excluded,AZD1222 + mRNA-1273 (heterologous) primary,14-75,infection,infection,Finland,≥ 18 years,general pop,55.1,42.9,67.2,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Moderna,excluded,BNT162b2 primary,14-75,infection,infection,Finland,≥ 18 years,general pop,36.2,21.9,50.4,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Moderna,excluded,BNT162b2 primary,14-75,hospitalization,severe,Finland,≥ 18 years,general pop,34.6,-85.8,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Moderna,excluded,BNT162b2 primary,14-75,ICU admission,severe,Finland,≥ 18 years,general pop,41.4,-47.7,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Moderna,excluded,BNT162b2 primary,14-75,death,death,Finland,≥ 18 years,general pop,99.3,98.2,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,mRNA-1273 primary,14-75,infection,infection,Finland,≥ 18 years,general pop,44.2,34.5,53.8,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer) + mRNA-1273 (Moderna) (heterologous),Moderna,excluded,BNT162b2 primary + mRNA-1273,14-75,infection,infection,Finland,≥ 18 years,general pop,46.0,-29.9,100.0,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,BNT162b2 primary + mRNA-1273,14-75,infection,infection,Finland,≥ 18 years,general pop,-17.1,-136.0,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer) + mRNA-1273 (Moderna) (heterologous),Pfizer,excluded,BNT162b2 primary + mRNA-1273,14-75,infection,infection,Finland,≥ 18 years,general pop,47.8,27.7,68.0,,omicron BA.1/BA.2,~15 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna) + BNT162b2 (Pfizer) (heterologous),Moderna,excluded,BNT162b2 primary + mRNA-1273,14-75,infection,infection,Finland,≥ 18 years,general pop,32.1,-37.0,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,infection,infection,Finland,≥ 18 years,general pop,39.5,37.2,41.8,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,hospitalization,severe,Finland,≥ 18 years,general pop,77.9,65.2,90.6,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,death,death,Finland,≥ 18 years,general pop,80.9,69.5,92.4,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,infection,infection,Finland,≥ 18 years,general pop,47.9,41.5,54.3,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,hospitalization,severe,Finland,≥ 18 years,general pop,76.5,36.5,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,death,death,Finland,≥ 18 years,general pop,87.8,60.7,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,previously infected only,BNT162b2 primary,14-75,infection,infection,Finland,≥ 18 years,general pop,38.7,-0.9,78.4,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,previously infected only,mRNA-1273 primary,14-75,infection,infection,Finland,≥ 18 years,general pop,64.4,9.6,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,AZD1222 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,-8.6,-79.8,62.6,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,AZD1222 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,-66.6,-240.0,100.0,,omicron BA.1/BA.2,~15 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,AZD1222 + BNT162b2 (heterologous) primary,14-75,infection,infection,Norway,≥ 18 years,general pop,60.9,57.8,64.1,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + mRNA-1273 (Moderna) (heterologous),Moderna,excluded,AZD1222 + mRNA-1273 (heterologous) primary,14-75,infection,infection,Norway,≥ 18 years,general pop,50.1,19.1,81.0,,omicron BA.1/BA.2,~15 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Moderna,excluded,BNT162b2 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,67.8,66.3,69.2,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Moderna,excluded,BNT162b2 primary,14-75,hospitalization,severe,Norway,≥ 18 years,general pop,94.6,90.0,99.3,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,mRNA-1273 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,62.3,59.5,65.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,mRNA-1273 primary,14-75,hospitalization,severe,Norway,≥ 18 years,general pop,88.5,70.8,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 + BNT162b2 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,69.7,47.4,92.0,,omicron BA.1/BA.2,~14 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 + BNT162b2 primary,14-75,hospitalization,severe,Norway,≥ 18 years,general pop,95.5,86.1,100.0,,omicron BA.1/BA.2,~14 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 + BNT162b2 primary,14-75,ICU admission,severe,Norway,≥ 18 years,general pop,75.5,16.8,100.0,,omicron BA.1/BA.2,~14 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,mRNA-1273 + BNT162b2 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,66.7,56.0,77.4,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer) + mRNA-1273 (Moderna) (heterologous),Pfizer,excluded,mRNA-1273 + BNT162b2 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,65.1,48.7,81.5,,omicron BA.1/BA.2,~14 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna) + BNT162b2 (Pfizer) (heterologous),Moderna,excluded,mRNA-1273 + BNT162b2 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,69.8,56.1,83.5,,omicron BA.1/BA.2,~11 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,69.8,69.2,70.5,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,hospitalization,severe,Norway,≥ 18 years,general pop,80.1,70.8,89.3,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,ICU admission,severe,Norway,≥ 18 years,general pop,83.7,79.0,88.4,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,65.1,62.8,67.4,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,hospitalization,severe,Norway,≥ 18 years,general pop,94.4,85.5,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,ICU admission,severe,Norway,≥ 18 years,general pop,94.0,80.2,100.0,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,previously infected only,BNT162b2 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,59.7,41.9,77.5,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,previously infected only,mRNA-1273 primary,14-75,infection,infection,Norway,≥ 18 years,general pop,53.9,17.6,90.3,,omicron BA.1/BA.2,~17 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,AZD1222 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,26.3,20.2,32.5,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Pfizer,excluded,AZD1222 primary,14-75,hospitalization,severe,Sweden,≥ 18 years,general pop,87.8,80.9,94.7,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,AZD1222 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,38.8,34.2,43.3,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca),Moderna,excluded,AZD1222 primary,14-75,hospitalization,severe,Sweden,≥ 18 years,general pop,95.2,90.2,100.0,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,AZD1222 + BNT162b2 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,9.7,4.1,15.3,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,AZD1222 + BNT162b2 primary,14-75,hospitalization,severe,Sweden,≥ 18 years,general pop,63.2,12.1,100.0,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,AZD1222 (AstraZeneca) + mRNA-1273 (Moderna) (heterologous),Moderna,excluded,AZD1222 + mRNA-1273 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,8.1,-13.3,29.4,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Moderna,excluded,BNT162b2 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,37.4,34.7,40.2,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Moderna,excluded,BNT162b2 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,88.7,83.6,93.8,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,mRNA-1273 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,20.2,14.3,26.1,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Pfizer,excluded,mRNA-1273 primary,14-75,hospitalization,severe,Sweden,≥ 18 years,general pop,89.6,79.7,99.6,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer) + mRNA-1273 (Moderna) (heterologous),Moderna,excluded,mRNA-1273 + BNT162b2 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,64.3,14.1,100.0,,omicron BA.1/BA.2,~12 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna) + BNT162b2 (Pfizer) (heterologous),Pfizer,excluded,mRNA-1273 + BNT162b2 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,49.1,-29.0,100.0,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer) + mRNA-1273 (Moderna) (heterologous),Pfizer,excluded,mRNA-1273 + BNT162b2 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,55.4,-14.1,100.0,,omicron BA.1/BA.2,~13 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,23.0,21.3,24.8,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,excluded,BNT162b2 primary,14-75,hospitalization,severe,Sweden,≥ 18 years,general pop,83.7,79.0,88.4,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,31.0,25.5,36.6,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,excluded,mRNA-1273 primary,14-75,hospitalization,severe,Sweden,≥ 18 years,general pop,76.3,59.5,93.1,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,BNT162b2 (Pfizer),Pfizer,previously infected only,BNT162b2 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,29.1,23.6,34.6,,omicron BA.1/BA.2,~16 weeks,,,,,
161,Andersson,Retrospective cohort,29Nov2022,mRNA-1273 (Moderna),Moderna,previously infected only,mRNA-1273 primary,14-75,infection,infection,Sweden,≥ 18 years,general pop,38.7,19.7,57.6,,omicron BA.1/BA.2,~16 weeks,,,,,
162,UKHSA,Test-negative case-control,01Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) & AZD1222 (AstraZeneca) (2 or 3 doses),Pfizer bivalent,included,complete vaccination with ≥ 2 doses at least 6 months prior,14+,hospitalization,severe,UK,≥ 50 years,≥ 50 years,57.0,48.0,65.0,,omicron BA.5/BQ.1,~10 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
163,Florentino,Test-negative case-control,01Dec2022,CoronaVac (Sinovac),Pfizer,included,complete vaccination with 2 doses of CoronaVac,14+,symptomatic disease,symptomatic,Brazil,15-49 years,15-49 years,37.7,28.9,45.3,,omicron BA.1/BA.2,~34 weeks,,,,,
163,Florentino,Test-negative case-control,01Dec2022,CoronaVac (Sinovac),Pfizer,included,complete vaccination with 2 doses of CoronaVac,14+,severe disease,severe,Brazil,15-49 years,15-49 years,68.4,52.6,78.9,,omicron BA.1/BA.2,~34 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,-70.1,-72.5,-67.8,,omicron,~44 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,-43.7,-52.4,-35.3,,omicron,~44 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,-49.8,-52.6,-47.1,,omicron,~44 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,-61.9,-69.9,-54.2,,omicron,~44 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,45.1,43.6,46.6,,delta,~17 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,34.2,26.2,41.3,,delta,~17 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,47.6,45.5,49.7,,delta,~17 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,14+,infection,infection,USA,≥ 18 years,general pop,36.2,29.0,42.6,,delta,~17 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,1st month,infection,infection,USA,≥ 18 years,general pop,-22.0,-24.9,-19.1,,delta & omicron,~4 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,8th month,infection,infection,USA,≥ 18 years,general pop,45.7,40.3,50.6,,delta & omicron,~30 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,1st month,infection,infection,USA,≥ 18 years,general pop,-44.1,-56.4,-32.7,,delta & omicron,~4 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,8th month,infection,infection,USA,≥ 18 years,general pop,89.7,72.5,96.1,,delta & omicron,~30 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,1st month,infection,infection,USA,≥ 18 years,general pop,-15.2,-18.5,-11.9,,delta & omicron,~4 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,8th month,infection,infection,USA,≥ 18 years,general pop,76.5,70.9,81.1,,delta & omicron,~30 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,1st month,infection,infection,USA,≥ 18 years,general pop,-64.8,-76.5,-53.9,,delta & omicron,~4 weeks,,,,,
164,Fu,Retrospective cohort,10Dec2022,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,8th month,infection,infection,USA,≥ 18 years,general pop,83.9,66.2,92.3,,delta & omicron,~30 weeks,,,,,
165,Canetti,"Open-label, non-randomized clinical trial",12Dec2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,8+,infection,infection,Israel,HCW ≥ 18 years,HCW,2.8,-37.7,31.5,,omicron BA.1,~13 weeks,,,,,
165,Canetti,"Open-label, non-randomized clinical trial",12Dec2022,BNT162b2 (Pfizer) (3 doses),Pfizer,excluded,complete vaccination with 3 doses at least 4 months prior,8+,symptomatic disease,symptomatic,Israel,HCW ≥ 18 years,HCW,71.0,42.6,86.6,,omicron BA.1,~13 weeks,,,,,
165,Canetti,"Open-label, non-randomized clinical trial",12Dec2022,BNT162b2 (Pfizer) (3 doses),Moderna,excluded,complete vaccination with 3 doses at least 4 months prior,8+,infection,infection,Israel,HCW ≥ 18 years,HCW,24.6,-10.8,49.1,,omicron BA.1,~13 weeks,,,,,
165,Canetti,"Open-label, non-randomized clinical trial",12Dec2022,BNT162b2 (Pfizer) (3 doses),Moderna,excluded,complete vaccination with 3 doses at least 4 months prior,8+,symptomatic disease,symptomatic,Israel,HCW ≥ 18 years,HCW,89.3,63.2,98.3,,omicron BA.1,~13 weeks,,,,,
166,Tenforde,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Pfizer bivalent,included,unvaccinated individuals,7+,ED or UC encounters for COVID-like illness,symptomatic,USA,immuncompetent adults ≥ 18 years,general pop,56.0,49.0,62.0,,omicron BA.5,~9 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
166,Tenforde,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Pfizer bivalent,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 18 years,general pop,57.0,41.0,69.0,,omicron BA.5,~9 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
167,Surie,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Pfizer bivalent,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 65 years,≥ 65 years,84.0,64.0,93.0,,omicron BA.5/BQ.1/BQ.1.1,~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
167,Surie,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Pfizer bivalent,included,≥2 doses of monovalent mRNA vaccine ≥2 mos. prior ,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 65 years,≥ 65 years,73.0,52.0,85.0,,omicron BA.5/BQ.1/BQ.1.1,~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
167,Surie,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Pfizer bivalent,included,≥2 doses of monovalent mRNA vaccine 6-11 mos. prior ,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 65 years,≥ 65 years,78.0,57.0,89.0,,omicron BA.5/BQ.1/BQ.1.1,~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
167,Surie,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Pfizer bivalent,included,≥2 doses of monovalent mRNA vaccine ≥12 mos. prior ,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 65 years,≥ 65 years,83.0,63.0,92.0,,omicron BA.5/BQ.1/BQ.1.1,~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
168,Strestha,Prospective cohort,19Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses,7+,infection,infection,USA,employees of Cleveland Clinic Health System,HCW,57.0,54.0,59.0,,omicron BA.1,~20 weeks,,,,,
169,Cegolon,Retrospective cohort,30Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,14+,infection,infection,Italy,HCW ≥ 18 years,HCW,53.0,-8.0,79.0,,"omicron BA.1, BA.2, BA.4/BA.5",~39 weeks,,,,,
169,Cegolon,Retrospective cohort,30Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,previously infected only,unvaccinated individuals,14+,infection,infection,Italy,HCW ≥ 18 years,HCW,42.0,19.0,58.0,,"omicron BA.1, BA.2, BA.4/BA.5",~39 weeks,,,,,
170,Mimura,Retrospective cohort,24Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses (14 days post dose 2 to 13 days post dose 3),2-3 weeks,infection,infection,Japan,≥16 years,≥16 years,63.6,56.4,69.5,,omicron BA.1,~21 weeks,,,,,
170,Mimura,Retrospective cohort,24Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses (14 days post dose 2 to 13 days post dose 3),≥10 weeks,infection,infection,Japan,≥16 years,≥16 years,54.5,3.0,78.7,,omicron BA.1,~21 weeks,,,,,
170,Mimura,Retrospective cohort,24Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses (14 days post dose 2 to 13 days post dose 3),2-3 weeks,symptomatic disease,symptomatic,Japan,≥16 years,≥16 years,66.5,58.7,72.8,,omicron BA.1,~21 weeks,,,,,
170,Mimura,Retrospective cohort,24Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses (14 days post dose 2 to 13 days post dose 3),≥10 weeks,symptomatic disease,symptomatic,Japan,≥16 years,≥16 years,58.5,-1.6,83.0,,omicron BA.1,~21 weeks,,,,,
170,Mimura,Retrospective cohort,24Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses (14 days post dose 2 to 13 days post dose 3),2-3 weeks,infection,infection,Japan,≥16 years,≥16 years,52.9,41.1,62.3,,omicron BA.2,~21 weeks,,,,,
170,Mimura,Retrospective cohort,24Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses (14 days post dose 2 to 13 days post dose 3),≥10 weeks,infection,infection,Japan,≥16 years,≥16 years,40.1,15.1,57.7,,omicron BA.2,~21 weeks,,,,,
170,Mimura,Retrospective cohort,24Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses (14 days post dose 2 to 13 days post dose 3),2-3 weeks,symptomatic disease,symptomatic,Japan,≥16 years,≥16 years,59.6,47.9,68.6,,omicron BA.2,~21 weeks,,,,,
170,Mimura,Retrospective cohort,24Nov2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses (14 days post dose 2 to 13 days post dose 3),≥10 weeks,symptomatic disease,symptomatic,Japan,≥16 years,≥16 years,44.0,17.1,62.2,,omicron BA.2,~21 weeks,,,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) or AZD1222 (AstraZeneca) (3 doses),Pfizer,included,unvaccinated individuals,14-89,pneumonia requiring invasive ventilation,severe,Thailand,≥ 18 years,general pop,99.0,92.6,99.8,,"omicron BA.1, BA.2",~15 weeks,,,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) or AZD1222 (AstraZeneca) (3 doses),Pfizer,included,unvaccinated individuals,180+,pneumonia requiring invasive ventilation,severe,Thailand,≥ 18 years,general pop,100.0,99.6,100.3,,"omicron BA.1, BA.2",~15 weeks,,,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) or AZD1222 (AstraZeneca) (3 doses),Pfizer,included,unvaccinated individuals,14+,death,death,Thailand,≥ 18 years,general pop,99.2,94.4,99.9,,"omicron BA.1, BA.2",~15 weeks,,,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,CoronaVac (Sinovac),AZD1222 (AstraZeneca),included,unvaccinated individuals,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥ 18 years,general pop,94.9,61.9,99.3,,"omicron BA.1, BA.2",~15 weeks,,,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,CoronaVac (Sinovac),Pfizer,included,unvaccinated individuals,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥ 18 years,general pop,100.0,9.9,100.0,,"omicron BA.1, BA.2",~15 weeks,,,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,BBIBP-CorV (Beijing CNBG),Pfizer,included,unvaccinated individuals,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥ 18 years,general pop,81.3,36.0,94.5,,"omicron BA.1, BA.2",~15 weeks,,,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥ 18 years,general pop,85.8,74.0,92.3,,"omicron BA.1, BA.2",~15 weeks,,,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥ 18 years,general pop,87.7,46.6,97.2,,"omicron BA.1, BA.2",~15 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,93.0,92.0,93.0,,omicron BA.1,~14.5 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,93.0,92.0,94.0,,omicron BA.1,~14.5 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,91-179,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,87.0,84.0,89.0,,omicron BA.1,~14.5 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,70.0,67.0,73.0,,omicron BA.1,~14.5 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,96.0,93.0,98.0,,omicron BA.1,unknown,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,96.0,92.0,98.0,,omicron BA.1,unknown,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,85.0,72.0,92.0,,omicron BA.1,unknown,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,75.0,71.0,79.0,,omicron BA.2,~28 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,85.0,81.0,88.0,,omicron BA.2,~28 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,180-269,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,66.0,48.0,78.0,,omicron BA.2,~28 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,38.0,26.0,48.0,,omicron BA.2,~28 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,84.0,81.0,87.0,,omicron BA.2,~9 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,82.0,78.0,86.0,,omicron BA.2,~9 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,91-179,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,85.0,69.0,93.0,,omicron BA.2,~9 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,61.0,52.0,68.0,,omicron BA.2,~9 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,59.0,53.0,64.0,,omicron BA.4/BA.5,~49 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,82.0,68.0,90.0,,omicron BA.4/BA.5,~49 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,270-359,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,56.0,45.0,66.0,,omicron BA.4/BA.5,~49 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,31.0,22.0,40.0,,omicron BA.4/BA.5,~49 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,68.0,63.0,72.0,,omicron BA.4/BA.5,~30 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,80.0,76.0,83.0,,omicron BA.4/BA.5,~30 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,unvaccinated individuals,270-359,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,75.0,-9.0,94.0,,omicron BA.4/BA.5,~30 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,47.0,39.0,53.0,,omicron BA.4/BA.5,~30 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Pfizer,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,74.0,68.0,78.0,,omicron BA.4/BA.5,~10 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Pfizer,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,73.0,67.0,78.0,,omicron BA.4/BA.5,~10 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Pfizer,excluded,unvaccinated individuals,91-179,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,57.0,11.0,79.0,,omicron BA.4/BA.5,~10 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Pfizer,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,56.0,48.0,63.0,,omicron BA.4/BA.5,~10 weeks,,,,,
173,Arbel,Retrospective cohort,03Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (≥2 doses),Pfizer bivalent,included,≥2 doses of monovalent mRNA vaccine,14+,hospitalization,severe,Israel,≥ 65 years,≥ 65 years,81.0,58.0,92.0,,omicron BA.5,~10 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
173,Arbel,Retrospective cohort,03Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (≥2 doses),Pfizer bivalent,included,≥2 doses of monovalent mRNA vaccine,14+,death,death,Israel,≥ 65 years,≥ 65 years,86.0,-3.0,98.0,,omicron BA.5,~10 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
174,Lewis,Test-negative case-control,31Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination at least 150 days prior,7+,hospitalization,severe,USA,≥ 18 years,general pop,66.0,55.0,74.0,,"omicron BA.1, BA.2",~26 weeks,,,,,
174,Lewis,Test-negative case-control,31Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,≥ 18 years,general pop,81.0,75.0,86.0,,"omicron BA.1, BA.2",~26 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 1","≥ 18 years, Social Vulnerability Index Quartile 1",78.0,76.0,80.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 1","≥ 18 years, Social Vulnerability Index Quartile 1",88.0,85.0,91.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 2","≥ 18 years, Social Vulnerability Index Quartile 2",80.0,77.0,82.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 2","≥ 18 years, Social Vulnerability Index Quartile 2",89.0,87.0,92.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 3","≥ 18 years, Social Vulnerability Index Quartile 3",80.0,77.0,83.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 3","≥ 18 years, Social Vulnerability Index Quartile 3",87.0,83.0,90.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 4","≥ 18 years, Social Vulnerability Index Quartile 4",76.0,72.0,80.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 4","≥ 18 years, Social Vulnerability Index Quartile 4",82.0,76.0,86.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 1","≥ 18 years, Social Vulnerability Index Quartile 1",96.0,95.0,96.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 1","≥ 18 years, Social Vulnerability Index Quartile 1",97.0,95.0,98.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 2","≥ 18 years, Social Vulnerability Index Quartile 2",95.0,93.0,96.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 2","≥ 18 years, Social Vulnerability Index Quartile 2",98.0,96.0,99.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 3","≥ 18 years, Social Vulnerability Index Quartile 3",95.0,93.0,97.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 3","≥ 18 years, Social Vulnerability Index Quartile 3",94.0,90.0,97.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 4","≥ 18 years, Social Vulnerability Index Quartile 4",93.0,89.0,95.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 4","≥ 18 years, Social Vulnerability Index Quartile 4",94.0,88.0,97.0,,delta,~11.5 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,23.0,-72.0,65.0,,omicron,~27 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,57.0,20.0,76.0,,omicron,~27 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,97.0,60.0,100.0,,delta,~9 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,87.0,-86.0,99.0,,delta,~9 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,53.0,10.0,76.0,,omicron or delta,~27 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,55.0,21.0,74.0,,omicron or delta,~27 weeks,,,,,
177,Tamandiou,Test-negative case-control,12Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with primary series plus any mRNA booster dose received 6-7 months prior,7-30,symptomatic disease,symptomatic,France,≥ 60 years,≥ 60 years,39.3,37.8,40.7,,"omicron BA.2, BA.4, BA.5",~30 weeks,,,,,
177,Tamandiou,Test-negative case-control,12Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Pfizer,included,complete vaccination with primary series plus any mRNA booster dose received 6-7 months prior,180-210,symptomatic disease,symptomatic,France,≥ 60 years,≥ 60 years,-32.6,-39.1,26.4,,"omicron BA.2, BA.4, BA.5",~30 weeks,,,,,
178,Villar,Prospective cohort,17Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,0+,infection,infection,Multiple,pregnant women,pregnant women,32.0,20.0,42.0,,omicron,~46 weeks,,,,,
178,Villar,Prospective cohort,17Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,0+,moderate disease,symptomatic,Multiple,pregnant women,pregnant women,54.0,34.0,68.0,,omicron,~46 weeks,,,,,
178,Villar,Prospective cohort,17Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,0+,severe disease or death,severe,Multiple,pregnant women,pregnant women,81.0,47.0,93.0,,omicron,~46 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Denmark,≥ 50 years,≥ 50 years,74.1,66.3,82.0,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Denmark,≥ 50 years,≥ 50 years,87.5,79.3,95.7,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Denmark,≥ 50 years,≥ 50 years,73.0,66.1,79.9,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Denmark,≥ 50 years,≥ 50 years,79.8,70.5,89.1,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Denmark,≥ 50 years,≥ 50 years,75.5,34.2,100.0,,omicron BA.4/BA.5,~11 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Finland,≥ 50 years,≥ 50 years,91.2,79.9,100.0,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Finland,≥ 50 years,≥ 50 years,39.8,-30.7,100.0,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Finland,≥ 50 years,≥ 50 years,85.8,67.5,100.0,,omicron BA.4/BA.5,~8 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Finland,≥ 50 years,≥ 50 years,33.6,-58.7,100.0,,omicron BA.4/BA.5,~8 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Finland,≥ 50 years,≥ 50 years,53.6,35.6,71.6,,omicron BA.4/BA.5,~17 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Finland,≥ 50 years,≥ 50 years,60.9,43.3,78.5,,omicron BA.4/BA.5,~17 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Norway,≥ 50 years,≥ 50 years,76.6,61.0,92.3,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Norway,≥ 50 years,≥ 50 years,57.3,-33.5,100.0,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Norway,≥ 50 years,≥ 50 years,67.9,54.7,81.1,,omicron BA.4/BA.5,~9 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Norway,≥ 50 years,≥ 50 years,84.7,61.9,100.0,,omicron BA.4/BA.5,~9 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Norway,≥ 50 years,≥ 50 years,69.3,61.6,77.0,,omicron BA.4/BA.5,~19 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Norway,≥ 50 years,≥ 50 years,60.9,43.3,78.5,,omicron BA.4/BA.5,~19 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Sweden,≥ 50 years,≥ 50 years,78.7,63.5,94.0,,omicron BA.4/BA.5,~4 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer bivalent,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Sweden,≥ 50 years,≥ 50 years,80.5,55.4,100.0,,omicron BA.4/BA.5,~4 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Sweden,≥ 50 years,≥ 50 years,64.9,57.7,72.2,,omicron BA.4/BA.5,~13 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Pfizer,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Sweden,≥ 50 years,≥ 50 years,53.7,22.5,84.9,,omicron BA.4/BA.5,~13 weeks,,,,,
180,Alkadi,Test-negative case-control,26Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,unknown,unvaccinated individuals,0+,infection,infection,Qatar,≥ 18 years on chronic hemodialysis,≥ 18 years on chronic hemodialysis,70.1,23.3,89.0,,"non-VOC, alpha & delta",~13.5 weeks,,,,,
181,Heidarzadeh,Test-negative case-control,23Dec2022,AZD1222 (AstraZeneca),AZD1222 (AstraZeneca),included,unvaccinated individuals,0+,hospitalization (severe),severe,Iran,≥ 5 years,≥ 5 years,94.0,46.0,99.2,,alpha & delta,~4.5 weeks,,,,,
181,Heidarzadeh,Test-negative case-control,23Dec2022,BBIBP-CorV (Beijing CNBG),BBIBP-CorV (Beijing CNBG),included,unvaccinated individuals,0+,hospitalization (severe),severe,Iran,≥ 5 years,≥ 5 years,96.0,92.0,98.0,,alpha & delta,~4.5 weeks,,,,,
181,Heidarzadeh,Test-negative case-control,23Dec2022,BBIBP-CorV (Beijing CNBG),BBIBP-CorV (Beijing CNBG),included,unvaccinated individuals,0+,death,death,Iran,≥ 5 years,≥ 5 years,58.0,-6.0,83.0,,alpha & delta,~4.5 weeks,,,,,
182,Lin,Retrospective cohort,19Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses of BNT162b2 or mRNA-1273,1 mo,infection,infection,USA,5-11 years,5-11 years,24.4,14.4,33.2,,omicron (all lineages),~31 weeks,,,,,
182,Lin,Retrospective cohort,19Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,included,complete vaccination with 2 doses of BNT162b2 or mRNA-1273,5 mos,infection,infection,USA,5-11 years,5-11 years,19.3,6.9,30.0,,omicron (all lineages),~31 weeks,,,,,
182,Lin,Retrospective cohort,19Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer bivalent,included,complete vaccination with 2 doses of BNT162b2 or mRNA-1273,1 mo,infection,infection,USA,5-11 years,5-11 years,76.7,45.7,90.0,,omicron (all lineages),~10 weeks,,,,,
182,Lin,Retrospective cohort,19Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer bivalent,included,complete vaccination with 2 doses of BNT162b2 or mRNA-1273,2 mos,infection,infection,USA,5-11 years,5-11 years,47.3,-17.9,76.4,,omicron (all lineages),~10 weeks,,,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Pfizer bivalent,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,14+,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,52.0,48.0,56.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Pfizer bivalent,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,14-59,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,51.0,43.0,58.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Pfizer bivalent,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,60-119,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,52.0,48.0,56.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Pfizer bivalent,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,14+,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,49.0,41.0,55.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Pfizer bivalent,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,14-59,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,50.0,36.0,61.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Pfizer bivalent,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,60-119,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,48.0,39.0,55.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14+,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,43.0,36.0,49.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14-59,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,54.0,43.0,63.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",60-119,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,39.0,30.0,46.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14+,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,37.0,28.0,44.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14-59,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,55.0,42.0,65.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",60-119,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,32.0,21.0,40.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14+,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,40.0,28.0,50.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14-59,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,45.0,25.0,60.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",60-119,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,38.0,24.0,50.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14+,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,43.0,29.0,55.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14-59,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,50.0,24.0,68.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Pfizer bivalent,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",60-119,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,42.0,26.0,54.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2 (Pfizer), mRNA-1273 (Moderna) or Ad26.COV2.S (Janssen)",Pfizer,included,complete primary vaccination,15-99,hospitalization,severe,USA,≥ 12 years,≥ 12 years,15.8,-39.5,49.1,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2 (Pfizer), mRNA-1273 (Moderna) or Ad26.COV2.S (Janssen)",Pfizer,included,complete primary vaccination,15-99,hospitalization or death,severe,USA,≥ 12 years,≥ 12 years,4.2,-50.1,38.8,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose)",Pfizer,included,complete primary + first booster vaccination (3 doses),15-99,hospitalization,severe,USA,≥ 12 years,≥ 12 years,28.0,-3.2,49.8,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose)",Pfizer,included,complete primary + first booster vaccination (3 doses),15-99,hospitalization or death,severe,USA,≥ 12 years,≥ 12 years,32.2,4.5,51.8,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2 (Pfizer), mRNA-1273 (Moderna) or Ad26.COV2.S (Janssen)",Pfizer bivalent,included,complete primary vaccination,15-99,hospitalization,severe,USA,≥ 12 years,≥ 12 years,54.0,-6.3,80.1,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data assessing monovalent vs. bivalent vaccines.",,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2 (Pfizer), mRNA-1273 (Moderna) or Ad26.COV2.S (Janssen)",Pfizer bivalent,included,complete primary vaccination,15-99,hospitalization or death,severe,USA,≥ 12 years,≥ 12 years,54.0,-0.3,78.9,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data assessing monovalent vs. bivalent vaccines.",,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose)",Pfizer bivalent,included,complete primary + first booster vaccination (3 doses),15-99,hospitalization,severe,USA,≥ 12 years,≥ 12 years,61.9,43.6,74.3,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose)",Pfizer bivalent,included,complete primary + first booster vaccination (3 doses),15-99,hospitalization or death,severe,USA,≥ 12 years,≥ 12 years,64.0,47.0,75.5,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose) + BNT162b2 or mRNA-1273 (4th dose)",Pfizer bivalent,included,complete primary + first and second booster vaccination (4 doses),15-99,hospitalization,severe,USA,≥ 12 years,≥ 12 years,55.7,12.0,77.7,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose) + BNT162b2 or mRNA-1273 (4th dose)",Pfizer bivalent,included,complete primary + first and second booster vaccination (4 doses),15-99,hospitalization or death,severe,USA,≥ 12 years,≥ 12 years,63.1,27.3,81.2,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
185,Ellingson,Prospective cohort,26Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,previously infected only,unvaccinated individuals,7+,infection,infection,USA,frontline workers,general pop,46.0,25.0,61.0,,omicron,~25.5 weeks,,,,,
186,Niesen,Test-negative case-control,28Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Pfizer,excluded,complete vaccination with 2 doses of any mRNA,314-339 days post dose 2,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,89.6,86.9,91.7,,delta,~16 weeks,,,,,
186,Niesen,Test-negative case-control,28Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of any mRNA,314-339 days post dose 2,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,89.1,82.9,93.0,,delta,~16 weeks,,,,,
187,Tartof,Test-negative case-control,28Jan2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,ED/UC visit,symptomatic,USA,5-11 years,5-11 years,77.0,53.0,88.0,,"omicron BA.1, BA.2, BA.4/BA.5",~11 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,<90,infection,infection,Thailand,≥ 18 years,general pop,60.0,42.0,73.0,,"omicron BA.1, BA.2",~37 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,>90,infection,infection,Thailand,≥ 18 years,general pop,51.0,27.0,67.0,,"omicron BA.1, BA.2",~37 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac),Pfizer,excluded,unvaccinated individuals,7+,moderate to critical disease,symptomatic,Thailand,≥ 18 years,general pop,76.0,52.0,88.0,,"omicron BA.1, BA.2",~37 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,<90,infection,infection,Thailand,≥ 18 years,general pop,41.0,16.0,58.0,,"omicron BA.1, BA.2",~37 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,>90,infection,infection,Thailand,≥ 18 years,general pop,26.0,-12.0,52.0,,"omicron BA.1, BA.2",~37 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,AZD1222 (AstraZeneca),Pfizer,excluded,unvaccinated individuals,7+,moderate to critical disease,symptomatic,Thailand,≥ 18 years,general pop,58.0,28.0,75.0,,"omicron BA.1, BA.2",~37 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,<90,infection,infection,Thailand,≥ 18 years,general pop,50.0,15.0,71.0,,"omicron BA.1, BA.2",~37 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,>90,infection,infection,Thailand,≥ 18 years,general pop,54.0,31.0,69.0,,"omicron BA.1, BA.2",~37 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac),AZD1222 (AstraZeneca),excluded,unvaccinated individuals,7+,moderate to critical disease,symptomatic,Thailand,≥ 18 years,general pop,69.0,36.0,85.0,,"omicron BA.1, BA.2",~37 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac) (primary) + BNT162b2 (Pfizer) 1st booster,Pfizer,excluded,unvaccinated individuals,<90,infection,infection,Thailand,≥ 18 years,general pop,58.0,36.0,71.0,,"omicron BA.1, BA.2",~19 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac) (primary) + BNT162b2 (Pfizer) 1st booster,Pfizer,excluded,unvaccinated individuals,>90,infection,infection,Thailand,≥ 18 years,general pop,65.0,36.0,80.0,,"omicron BA.1, BA.2",~19 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac) (primary) + BNT162b2 (Pfizer) 1st booster,Pfizer,excluded,unvaccinated individuals,7+,moderate to critical disease,symptomatic,Thailand,≥ 18 years,general pop,57.0,7.0,80.0,,"omicron BA.1, BA.2",~19 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac) (primary) + AZD1222 (AstraZeneca) 1st booster,Pfizer,excluded,unvaccinated individuals,<90,infection,infection,Thailand,≥ 18 years,general pop,67.0,51.0,78.0,,"omicron BA.1, BA.2",~19 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac) (primary) + AZD1222 (AstraZeneca) 1st booster,Pfizer,excluded,unvaccinated individuals,>90,infection,infection,Thailand,≥ 18 years,general pop,49.0,15.0,70.0,,"omicron BA.1, BA.2",~19 weeks,,,,,
188,Sritipsukho,Test-negative case-control,30Jan2023,CoronaVac (Sinovac) (primary) + AZD1222 (AstraZeneca) 1st booster,Pfizer,excluded,unvaccinated individuals,7+,moderate to critical disease,symptomatic,Thailand,≥ 18 years,general pop,82.0,59.0,92.0,,"omicron BA.1, BA.2",~19 weeks,,,,,
189,Lai,Retrospective cohort,30Jan2023,BNT162b2 (Pfizer),Pfizer,included,complete vaccination with BNT162b2 at least 6 months prior,14+,death,death,China,≥ 18 years with multimorbidity,≥ 18 years with multimorbidity,95.0,84.0,98.0,,omicron BA.2,~18 weeks,,,,,
189,Lai,Retrospective cohort,30Jan2023,CoronaVac (Sinovac),CoronaVac (Sinovac),included,complete vaccination with CoronaVac at least 6 months prior,14+,death,death,China,≥ 18 years with multimorbidity,≥ 18 years with multimorbidity,92.0,88.0,95.0,,omicron BA.2,~18 weeks,,,,,
190,Weng,Retrospective cohort,01Feb2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,14+,infection,infection,USA,≥ 12 years,≥ 12 years,79.9,44.3,93.5,,omicron BA.1,~17 weeks,,,,,
190,Weng,Retrospective cohort,01Feb2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,infection,infection,USA,≥ 12 years,≥ 12 years,71.2,24.0,90.8,,omicron BA.1,~17 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,infection,infection,Taiwan,≥ 20 years,general pop,46.3,42.9,49.6,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,BNT162b2 (Pfizer),Pfizer,included,unvaccinated individuals,7+,moderate to severe disease,symptomatic,Taiwan,≥ 20 years,general pop,82.5,72.4,88.9,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,infection,infection,Taiwan,≥ 20 years,general pop,44.5,42.1,46.8,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,moderate to severe disease,symptomatic,Taiwan,≥ 20 years,general pop,80.8,77.1,83.8,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,MVC-COV1901 (Medigen),MVC-COV1901 (Medigen),included,unvaccinated individuals,7+,infection,infection,Taiwan,≥ 20 years,general pop,39.9,34.7,44.6,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,MVC-COV1901 (Medigen),MVC-COV1901 (Medigen),included,unvaccinated individuals,7+,moderate to severe disease,symptomatic,Taiwan,≥ 20 years,general pop,66.1,52.9,75.5,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,infection,infection,Taiwan,≥ 20 years,general pop,47.7,42.9,52.2,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,mRNA-1273 (Moderna),Pfizer,included,unvaccinated individuals,7+,moderate to severe disease,symptomatic,Taiwan,≥ 20 years,general pop,90.3,82.6,94.5,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,7+,infection,infection,Taiwan,≥ 20 years,general pop,49.0,45.7,52.2,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,7+,moderate to severe disease,symptomatic,Taiwan,≥ 20 years,general pop,83.5,72.9,90.0,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,7+,infection,infection,Taiwan,≥ 20 years,general pop,42.4,40.2,44.6,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,AZD1222 (AstraZeneca),Moderna,included,unvaccinated individuals,7+,moderate to severe disease,symptomatic,Taiwan,≥ 20 years,general pop,69.7,63.9,74.6,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,7+,infection,infection,Taiwan,≥ 20 years,general pop,42.7,40.0,45.4,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,AZD1222 (AstraZeneca),Pfizer,included,unvaccinated individuals,7+,moderate to severe disease,symptomatic,Taiwan,≥ 20 years,general pop,69.9,61.9,76.2,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,AZD1222 (AstraZeneca) + mRNA-1273 (Moderna) (heterologous),Moderna,included,unvaccinated individuals,7+,infection,infection,Taiwan,≥ 20 years,general pop,39.9,33.9,45.4,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
191,Huang,Test-negative case-control,01Feb2023,AZD1222 (AstraZeneca) + mRNA-1273 (Moderna) (heterologous),Moderna,included,unvaccinated individuals,7+,moderate to severe disease,symptomatic,Taiwan,≥ 20 years,general pop,91.4,65.5,97.9,,"omicron BA.1, BA.2, BA.4/BA.5",~37 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,infection,infection,USA,veterans,veterans,64.0,63.0,65.0,omicron,omicron,~20 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,hospitalization,severe,USA,veterans,veterans,89.0,88.0,91.0,omicron,omicron,~20 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,death,death,USA,veterans,veterans,94.0,90.0,96.0,omicron,omicron,~20 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,infection,infection,USA,veterans,veterans,90.0,88.0,92.0,delta,delta,~20 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,hospitalization,severe,USA,veterans,veterans,94.0,90.0,96.0,delta,delta,~20 weeks,,,,,
24,Young-Xu,Matched test-negative case control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,death,death,USA,veterans,veterans,96.0,87.0,99.0,delta,delta,~20 weeks,,,,,
26,Thompson,Test-negative case-control,21Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,94.0,93.0,95.0,omicron,omicron,~18 weeks,,,,,
26,Thompson,Test-negative case-control,21Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,90.0,80.0,94.0,omicron,omicron,~18 weeks,,,,,
26,Thompson,Test-negative case-control,21Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,94.0,93.0,94.0,delta,delta,~18 weeks,,,,,
26,Thompson,Test-negative case-control,21Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,94.0,93.0,95.0,delta,delta,~18 weeks,,,,,
29,Tenforde,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompromised hospitalized adults,immunocompromised hospitalized adults,88.0,81.0,93.0,,delta,~16 weeks,,,,,
29,Tenforde,Test-negative case-control,28Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,97.0,95.0,99.0,,delta,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,infection,infection,USA,nursing home residents,LTCF residents,37.7,25.4,44.2,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,hospitalization,severe,USA,nursing home residents,LTCF residents,74.4,44.6,86.2,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,death,death,USA,nursing home residents,LTCF residents,87.9,75.9,93.9,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,hospitalization or death,severe,USA,nursing home residents,LTCF residents,80.3,65.7,88.5,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,infection,infection,USA,residents of Veterans Affairs community living centers,residents of Veterans Affairs community living centers,57.7,43.5,67.8,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,hospitalization,severe,USA,residents of Veterans Affairs community living centers,residents of Veterans Affairs community living centers,64.1,41.3,76.0,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,death,death,USA,residents of Veterans Affairs community living centers,residents of Veterans Affairs community living centers,46.6,-34.6,94.8,,delta & omicron,~10 weeks,,,,,
30,McConeghy,Nested target trial emulation,07Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,7+,hospitalization or death,severe,USA,residents of Veterans Affairs community living centers,residents of Veterans Affairs community living centers,63.8,41.4,76.1,,delta & omicron,~10 weeks,,,,,
33,Roberts,Test-negative case-control,31Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,14+,infection,infection,USA,≥ 18 years,general pop,87.3,85.0,89.2,,"non-VOC, alpha, & delta",~20 weeks,,,,,
33,Roberts,Test-negative case-control,31Jan2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses of primary mRNA series ≥6 months prior,14+,severe disease,severe,USA,≥ 18 years,general pop,94.0,89.5,96.6,,"non-VOC, alpha, & delta",~20 weeks,,,,,
36,Lauring,Test-negative case-control,09Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,USA,≥ 18 years,general pop,86.0,77.0,91.0,omicron,omicron,~3 weeks,,,,,
36,Lauring,Test-negative case-control,09Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,USA,≥ 18 years,general pop,94.0,92.0,95.0,delta,delta,~25 weeks,,,,,
36,Lauring,Test-negative case-control,09Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompromised,immunocompromised,87.0,78.0,92.0,delta,delta,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<2 months,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,87.0,85.0,88.0,,omicron,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥5 months,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,31.0,-50.0,68.0,,omicron,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<2 months,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,91.0,88.0,93.0,,omicron,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥4 months,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,78.0,67.0,85.0,,omicron,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<2 months,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,97.0,96.0,97.0,,delta,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥4 months,ED or UC visit,symptomatic,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,89.0,64.0,97.0,,delta,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<2 months,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,96.0,95.0,97.0,,delta,~25 weeks,,,,,
40,Ferdinands,Test-negative case-control,11Feb2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥4 months,hospitalization,severe,USA,ED encounters and hospital admissions,ED encounters and hospital admissions,76.0,14.0,93.0,,delta,~25 weeks,,,,,
42,Monge,Retrospective cohort,02Jun2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination with 2 doses (or 1 dose for Ad26.COV2.S) ≥3 months prior,7-34,infection,infection,Spain,≥ 40 years,≥ 40 years,49.7,48.3,51.1,,omicron,~3 weeks,,,,,
42,Monge,Retrospective cohort,02Jun2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses (or 1 dose for Ad26.COV2.S) ≥3 months prior,7-34,infection,infection,Spain,≥ 40 years,≥ 40 years,55.3,52.3,58.2,,omicron,~3 weeks,,,,,
42,Monge,Retrospective cohort,02Jun2022,AZD1222 (AstraZeneca),Moderna,excluded,complete vaccination with 2 doses (or 1 dose for Ad26.COV2.S) ≥3 months prior,7-34,infection,infection,Spain,≥ 40 years,≥ 40 years,58.6,55.5,61.6,,omicron,~3 weeks,,,,,
42,Monge,Retrospective cohort,02Jun2022,Ad26.COV2.S (Janssen),Moderna,excluded,complete vaccination with 2 doses (or 1 dose for Ad26.COV2.S) ≥3 months prior,7-34,infection,infection,Spain,≥ 40 years,≥ 40 years,48.0,42.5,53.7,,omicron,~3 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,0+,infection,infection,UK,LTCF residents,LTCF residents,71.4,49.7,83.8,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,0+,hospitalization,severe,UK,LTCF residents,LTCF residents,83.6,63.4,92.7,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,0+,death,death,UK,LTCF residents,LTCF residents,98.7,90.0,99.8,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,0+,infection,infection,UK,LTCF staff,LTCF staff,79.3,70.0,85.7,,alpha & delta,11 weeks,,,,,
48,Shrotri,Prospective cohort,12Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,0+,hospitalization,severe,UK,LTCF staff,LTCF staff,100.0,,,,alpha & delta,11 weeks,,,,,
50,Montez-Rath,Prospective cohort,18Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,,unvaccinated individuals,21+,infection,infection,USA,dialysis patients,dialysis patients,53.0,38.0,65.0,omicron,omicron,~14 weeks,,,,,
52,Tenforde,Case-control,25Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,94.0,88.0,97.0,,omicron,~20 weeks,,,,,
53,Tenforde,Case-control,25Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,95.0,91.0,97.0,,delta,~20 weeks,,,,,
53,Tenforde,Case-control,25Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,94.0,91.0,96.0,,alpha,~20 weeks,,,,,
56,Wang,Test-negative case-control,23Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-179,infection,infection,USA,patients,general pop,65.0,63.0,66.0,,omicron,~23.5 weeks,,,,,
56,Wang,Test-negative case-control,23Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180+,infection,infection,USA,patients,general pop,50.0,45.0,55.0,,omicron,unknown,,,,,
56,Wang,Test-negative case-control,23Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14-179,infection,infection,USA,patients,general pop,91.0,90.0,92.0,,delta,~23.5 weeks,,,,,
56,Wang,Test-negative case-control,23Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180+,infection,infection,USA,patients,general pop,71.0,67.0,74.0,,delta,unknown,,,,,
57,Natarajan,Test-negative case-control,29Mar2022,Ad26.COV2.S (Janssen),Moderna,included,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations among adults with COVID-19 like illness,general pop,79.0,74.0,82.0,,omicron,~15 weeks,,,,,
57,Natarajan,Test-negative case-control,29Mar2022,Ad26.COV2.S (Janssen),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,ED/UC encounters and hospitalizations among adults with COVID-19 like illness,general pop,78.0,70.0,84.0,,omicron,~15 weeks,,,,,
57,Natarajan,Test-negative case-control,29Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations among adults with COVID-19 like illness,general pop,83.0,82.0,84.0,,omicron,~15 weeks,,,,,
57,Natarajan,Test-negative case-control,29Mar2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,ED/UC encounters and hospitalizations among adults with COVID-19 like illness,general pop,90.0,88.0,91.0,,omicron,~15 weeks,,,,,
62,Yoon,Prospective cohort,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,infection,infection,USA,HCW,HCW,60.0,42.0,72.0,omicron,omicron,~21 weeks,,,,,
62,Yoon,Prospective cohort,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses,7+,infection,infection,USA,HCW,HCW,60.0,40.0,73.0,omicron,omicron,~21 weeks,,,,,
62,Yoon,Prospective cohort,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,infection,infection,USA,HCW,HCW,91.0,84.0,95.0,delta,delta,~21 weeks,,,,,
62,Yoon,Prospective cohort,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses,7+,infection,infection,USA,HCW,HCW,86.0,69.0,94.0,delta,delta,~21 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,transplant recipients,transplant recipients,77.0,48.0,90.0,,alpha & delta,~16 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompromised,immunocompromised,92.0,85.0,95.0,,alpha & delta,~16 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompetent adults,general pop,96.0,94.0,98.0,,alpha & delta,~16 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,supplemental oxygen/oxygen support,severe,USA,transplant recipients,transplant recipients,84.0,57.0,94.0,,alpha & delta,~16 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,supplemental oxygen/oxygen support,severe,USA,immunocompromised,immunocompromised,93.0,85.0,97.0,,alpha & delta,~16 weeks,,,,,
63,Kwon,Test-negative case-control,06Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,supplemental oxygen/oxygen support,severe,USA,immunocompetent adults,general pop,97.0,94.0,98.0,,alpha & delta,~16 weeks,,,,,
65,Kim,Test-negative case-control,29Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses ≥150 days prior,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,62.0,48.0,72.0,omicron,omicron,~33 weeks,,,,,
65,Kim,Test-negative case-control,29Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses ≥150 days prior,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,96.0,93.0,98.0,delta,delta,~33 weeks,,,,,
66,Plumb,Test-negative case-control,12Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,hospitalization,severe,USA,hospitalized adults,general pop,67.6,61.4,72.8,,omicron,~25 weeks,,,,,
66,Plumb,Test-negative case-control,12Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,hospitalization,severe,USA,hospitalized adults,general pop,57.8,32.1,73.8,,delta,~25 weeks,,,,,
71,Petrie,Prospective cohort,16Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,≥ 12 years,≥ 12 years,66.0,46.0,79.0,,omicron,~25 weeks,,,,,
71,Petrie,Prospective cohort,16Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,≥ 12 years,≥ 12 years,70.0,51.0,81.0,,omicron,~25 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<84,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,39.0,33.0,45.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥84,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,37.0,31.0,43.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<84,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,62.0,51.0,71.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥84,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,55.0,45.0,64.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<84,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,80.0,72.0,86.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,≥84,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,77.0,69.0,82.0,omicron,omicron,~34 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,≥7,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,49.0,43.0,54.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,≥7,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,69.0,61.0,76.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,≥7,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,86.0,81.0,90.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses ≥84 days ago,≥7,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,19.0,12.0,26.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses ≥84 days ago,≥7,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,31.0,20.0,41.0,omicron,omicron,~15 weeks,,,,,
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses ≥84 days ago,≥7,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,40.0,24.0,52.0,omicron,omicron,~15 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-30,infection,infection,Denmark,12-59 years,12-59 years,55.2,54.7,55.6,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,120+,infection,infection,Denmark,12-59 years,12-59 years,49.9,46.5,53.1,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-30,hospitalization,severe,Denmark,12-59 years,12-59 years,89.8,87.9,91.3,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,120+,hospitalization,severe,Denmark,12-59 years,12-59 years,33.3,0.9,55.1,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-30,infection,infection,Denmark,12-59 years,12-59 years,89.5,87.7,91.0,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,61-90,infection,infection,Denmark,12-59 years,12-59 years,83.5,69.4,91.1,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-30,hospitalization,severe,Denmark,12-59 years,12-59 years,94.8,85.9,98.1,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,31-60,hospitalization,severe,Denmark,12-59 years,12-59 years,68.4,41.4,83.0,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,57.6,55.8,59.4,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,120+,infection,infection,Denmark,≥ 60 years,≥ 60 years,52.8,49.3,56.0,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-30,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,94.4,93.0,95.5,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,120+,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,77.3,70.9,82.3,,omicron,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,86.0,83.3,88.3,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,61-90,infection,infection,Denmark,≥ 60 years,≥ 60 years,81.2,72.9,87.0,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,31-60,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,96.6,93.9,98.1,,delta,~24 weeks,,,,,
74,Gram,Retrospective cohort,20Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,91-120,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,91.4,79.8,96.4,,delta,~24 weeks,,,,,
75,Lind,Test-negative case-control,01Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses ≥5 months prior,14-59,infection,infection,USA,≥ 18 years,general pop,55.0,48.0,61.0,omicron BA.1,omicron BA.1,~14 weeks,,,,,
75,Lind,Test-negative case-control,01Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses ≥5 months prior,90+,infection,infection,USA,≥ 18 years,general pop,20.0,2.0,34.0,omicron BA.1,omicron BA.1,~14 weeks,,,,,
75,Lind,Test-negative case-control,01Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,≥ 18 years,general pop,47.1,22.4,63.9,omicron BA.1,omicron BA.1,~14 weeks,,,,,
75,Lind,1:1 Matched case control,01Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,≥ 18 years,general pop,58.5,52.7,63.5,omicron BA.1,omicron BA.1,~14 weeks,,,,,
75,Lind,1:1 Matched case control,01Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,≥ 18 years,general pop,35.1,-7.5,60.8,omicron BA.1,omicron BA.1,~14 weeks,,,,,
76,Widdifield,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,infection,infection,Canada,individuals with rheumatoid arthritis,individuals with rheumatoid arthritis,86.0,70.0,94.0,,alpha & delta,~9.5 weeks,,,,,
76,Widdifield,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,severe disease,severe,Canada,individuals with rheumatoid arthritis,individuals with rheumatoid arthritis,88.0,48.0,97.0,,alpha & delta,~9.5 weeks,,,,,
76,Widdifield,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,infection,infection,Canada,individuals with ankylosing spondylitis,individuals with ankylosing spondylitis,82.0,20.0,96.0,,alpha & delta,~9.5 weeks,,,,,
76,Widdifield,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,infection,infection,Canada,individuals with psoriasis,individuals with psoriasis,96.0,72.0,99.0,,alpha & delta,~9.5 weeks,,,,,
76,Widdifield,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,infection,infection,Canada,individuals with inflammatory bowel disease,individuals with inflammatory bowel disease,76.0,47.0,89.0,,alpha & delta,~9.5 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,8-14,symptomatic disease,symptomatic,France,≥ 18 years,general pop,64.0,63.0,64.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,symptomatic disease,symptomatic,France,≥ 18 years,general pop,50.0,48.0,51.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,8-14,hospitalization,severe,France,≥ 18 years,general pop,90.0,87.0,92.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,hospitalization,severe,France,≥ 18 years,general pop,93.0,92.0,94.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,8-14,ICU admission,severe,France,≥ 18 years,general pop,96.0,92.0,99.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,ICU admission,severe,France,≥ 18 years,general pop,97.0,95.0,99.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,8-14,death,death,France,≥ 18 years,general pop,95.0,89.0,100.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,death,death,France,≥ 18 years,general pop,93.0,91.0,96.0,omicron,omicron,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,8-14,symptomatic disease,symptomatic,France,≥ 18 years,general pop,84.0,79.0,88.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,symptomatic disease,symptomatic,France,≥ 18 years,general pop,90.0,85.0,94.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,8-14,hospitalization,severe,France,≥ 18 years,general pop,98.0,98.0,99.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,hospitalization,severe,France,≥ 18 years,general pop,99.0,99.0,100.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,8-14,ICU admission,severe,France,≥ 18 years,general pop,99.0,98.0,99.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,ICU admission,severe,France,≥ 18 years,general pop,99.0,99.0,100.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,8-14,death,death,France,≥ 18 years,general pop,98.0,96.0,100.0,delta,delta,~22 weeks,,,,,
78,Castillo,Test-negative case-control,21Apr2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,death,death,France,≥ 18 years,general pop,99.0,99.0,100.0,delta,delta,~22 weeks,,,,,
82,Carazo,Test-negative case-control,14Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,infection,infection,Canada,≥ 12 years,general pop,73.0,72.0,73.0,,omicron,~24 weeks,,,,,
82,Carazo,Test-negative case-control,14Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 12 years,general pop,91.0,91.0,92.0,,omicron,~24 weeks,,,,,
82,Carazo,Test-negative case-control,14Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,infection,infection,Canada,≥ 12 years,general pop,68.0,67.0,68.0,,omicron,~24 weeks,,,,,
82,Carazo,Test-negative case-control,14Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 12 years,general pop,84.0,82.0,91.0,,omicron,~24 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",7+,infection,infection,USA,veterans 21+,general pop,19.0,17.0,22.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",7+,hospitalization,severe,USA,veterans 21+,general pop,52.0,46.0,57.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",7+,ICU admission or death,severe,USA,veterans 21+,general pop,83.0,65.0,92.0,,omicron,~19.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",,infection,infection,USA,veterans 21+,general pop,73.0,71.0,76.0,,delta,~9.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",,hospitalization,severe,USA,veterans 21+,general pop,80.0,73.0,85.0,,delta,~9.5 weeks,,,,,
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,"complete vaccination with 2 doses of BNT162b2 or mRNA-1273 by April 30, 2021",,ICU admission or death,severe,USA,veterans 21+,general pop,94.0,52.0,99.0,,delta,~9.5 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,15-19,infection,infection,Italy,≥ 12 years,general pop,69.1,67.5,70.7,,alpha & delta,~26 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,75+,infection,infection,Italy,≥ 12 years,general pop,50.8,46.0,55.1,,alpha & delta,~26 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,AZD1222 (AstraZeneca),Moderna,excluded,unvaccinated individuals,10-14,infection,infection,Italy,≥ 12 years,general pop,28.0,0.0,48.5,,alpha & delta,~26 weeks,,,,,
86,Fano,Retrospective cohort,18May2022,AZD1222 (AstraZeneca),Moderna,excluded,unvaccinated individuals,15+,infection,infection,Italy,≥ 12 years,general pop,28.8,12.9,41.8,,alpha & delta,~26 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,40.9,31.9,48.7,,omicron,~32 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,72.1,67.2,76.2,,omicron,~32 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,"previously infected before July 1, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,57.7,50.8,63.6,,omicron,~32 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,"previously infected before July 1, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,77.6,71.7,82.2,,omicron,~32 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,"previously infected between July 1 and November 30, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,84.6,70.7,91.9,,omicron,~32 weeks,,,,,
88,Chin,Retrospective cohort,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,"previously infected between July 1 and November 30, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,87.9,76.0,93.9,,omicron,~32 weeks,,,,,
88,Chin,Retrospective test-negative case control,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,43.2,42.2,47.4,,omicron,~32 weeks,,,,,
88,Chin,Retrospective test-negative case control,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,"previously infected before July 1, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,61.3,60.7,64.8,,omicron,~32 weeks,,,,,
88,Chin,Retrospective test-negative case control,26Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,"previously infected between July 1 and November 30, 2021",unvaccinated individuals,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,86.8,82.1,92.7,,omicron,~32 weeks,,,,,
90,Carlsen,Retrospective cohort,01Jun2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester),infection during an infant's first 4 months of life,Norway,newborns,newborns,78.0,57.0,88.0,,omicron,~45 weeks,,,,,
93,Adams,Prospective test-negative case control,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,64.0,42.0,78.0,"omicron BA.1, B.A.2, BA.5","omicron BA.1, B.A.2, BA.5",~47 weeks,,,,,
93,Adams,Prospective test-negative case control,11Oct2022,Ad26.COV2.S (Janssen),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,52.0,25.0,89.0,"omicron BA.1, B.A.2, BA.5","omicron BA.1, B.A.2, BA.5",~47 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 5 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,39.0,36.4,41.6,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 5 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,53.3,48.1,58.0,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 5 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,79.1,71.2,84.9,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination 5-9 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,36.4,33.3,39.4,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination 5-9 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,43.8,35.2,51.3,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination 5-9 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,78.1,67.5,85.3,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 9 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,46.5,44.1,48.7,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 9 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,63.2,56.4,69.0,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 9 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,81.6,67.8,89.4,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination at least 5 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,39.6,36.9,42.1,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination at least 5 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,53.7,45.8,60.4,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,BNT162b2 (Pfizer),Moderna,excluded,complete vaccination at least 5 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,84.8,73.7,91.2,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 5 months prior,10+,infection,infection,USA,veterans ≥ 18 years,veterans,44.3,42.2,46.3,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 5 months prior,10+,hospitalization,severe,USA,veterans ≥ 18 years,veterans,53.1,45.7,59.5,,omicron,~15 weeks,,,,,
94,Ioannou,Target trial emulation,11Oct2022,mRNA-1273 (Moderna),Moderna,excluded,complete vaccination at least 5 months prior,10+,death,death,USA,veterans ≥ 18 years,veterans,75.0,62.3,83.4,,omicron,~15 weeks,,,,,
97,Carazo,Test-negative case-control,21Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,infection,infection,Canada,HCW,HCW,46.0,40.0,52.0,omicron BA.2,omicron BA.2,~39 weeks,,,,,
97,Carazo,Test-negative case-control,21Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,Canada,HCW,HCW,70.0,62.0,75.0,omicron BA.2,omicron BA.2,~39 weeks,,,,,
99,Breznik,Prospective cohort,29Jun2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 3 doses,60-120,infection,infection,Canada,nursing and retirement home residents,nursing and retirement home residents,81.0,70.0,88.0,,omicron,~15 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7-119,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,84.0,83.0,85.0,,omicron BA.1,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,120+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,73.0,68.0,77.0,,omicron BA.1,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7-119,hospitalization,severe,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,92.0,91.0,93.0,,omicron BA.1,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,120+,hospitalization,severe,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,85.0,81.0,89.0,,omicron BA.1,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7-119,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,56.0,51.0,61.0,,omicron BA.2,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,120+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,26.0,21.0,30.0,,omicron BA.2,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7-119,hospitalization,severe,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,69.0,58.0,76.0,,omicron BA.2,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,120+,hospitalization,severe,USA,ED/UC encounters and hospitalizations in adults 18+,general pop,52.0,44.0,59.0,,omicron BA.2,~20 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,ED/UC encounters and hospitalizations in adults 50+,≥ 50 years,66.0,60.0,71.0,,omicron BA.2,~6 weeks,,,,,
104,Link-Gelles,Test-negative case-control,15Jul2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,USA,ED/UC encounters and hospitalizations in adults 50+,≥ 50 years,80.0,71.0,85.0,,omicron BA.2,~6 weeks,,,,,
107,Arashiro,Case-control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,Japan,20+ years,general pop,78.0,67.0,86.0,,omicron,~21 weeks,,,,,
107,Arashiro,Case-control,03Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180+,symptomatic disease,symptomatic,Japan,20+ years,general pop,51.0,29.0,66.0,,omicron,~21 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,AZD1222 (AstraZeneca),Moderna,excluded,complete vaccination with 2 doses at least 84 days prior,14-48,infection,infection,UK,LTCF staff,LTCF staff,72.0,67.0,76.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,AZD1222 (AstraZeneca),Moderna,excluded,complete vaccination with 2 doses at least 84 days prior,84+,infection,infection,UK,LTCF staff,LTCF staff,-12.0,-29.0,3.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses at least 84 days prior,14-48,infection,infection,UK,LTCF staff,LTCF staff,63.0,54.0,70.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses at least 84 days prior,84+,infection,infection,UK,LTCF staff,LTCF staff,-26.0,-45.0,-9.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,AZD1222 (AstraZeneca),Moderna,previously infected only,complete vaccination with 2 doses at least 84 days prior,14-48,infection,infection,UK,LTCF staff,LTCF staff,80.0,67.0,88.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,AZD1222 (AstraZeneca),Moderna,previously infected only,complete vaccination with 2 doses at least 84 days prior,84+,infection,infection,UK,LTCF staff,LTCF staff,-8.0,-41.0,18.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,previously infected only,complete vaccination with 2 doses at least 84 days prior,14-48,infection,infection,UK,LTCF staff,LTCF staff,75.0,52.0,87.0,,omicron,~26 weeks,,,,,
110,Stirrup,Prospective cohort,29Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,previously infected only,complete vaccination with 2 doses at least 84 days prior,84+,infection,infection,UK,LTCF staff,LTCF staff,-36.0,-83.0,-1.0,,omicron,~26 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompromised adults,immunocompromised adults,87.0,74.0,93.0,,omicron,~22 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,immunocompetent adults,general pop,92.0,87.0,95.0,,omicron,~22 weeks,,,,,
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ICU admission,severe,USA,≥ 18 years,general pop,91.0,75.0,97.0,,omicron,~22 weeks,,,,,
115,Powell,Test-negative case-control,22Aug2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,14-104,symptomatic disease,symptomatic,UK,11-17 years,11-17 years,62.9,60.5,65.1,,omicron,~23 weeks,,,,,
115,Powell,Test-negative case-control,22Aug2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,105-174,symptomatic disease,symptomatic,UK,11-17 years,11-17 years,33.6,14.6,48.3,,omicron,~23 weeks,,,,,
115,Powell,Test-negative case-control,22Aug2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,14-104,symptomatic disease,symptomatic,UK,11-17 years,11-17 years,96.0,92.2,97.9,,delta,~13 weeks,,,,,
123,Kim,Matched case-control,29Aug2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,complete vaccination with 2 doses of any mRNA,14+,infection,infection,South Korea,HCW,HCW,53.1,13.2,74.7,,omicron,~15 weeks,,,,,
125,Mallah,Test-negative case-control,10Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,infection,infection,Spain,≥ 11 years,general pop,88.0,85.0,90.0,,alpha & delta,~5 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8+,symptomatic disease,symptomatic,Singapore,≥ 80 years,80+ years,22.2,19.6,24.7,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8-30,symptomatic disease,symptomatic,Singapore,≥ 80 years,80+ years,35.0,31.0,40.0,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,60+,symptomatic disease,symptomatic,Singapore,≥ 80 years,80+ years,16.0,12.0,20.0,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8+,hospitalization,severe,Singapore,≥ 80 years,80+ years,55.0,51.8,58.3,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8-30,hospitalization,severe,Singapore,≥ 80 years,80+ years,58.0,50.0,64.0,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,60+,hospitalization,severe,Singapore,≥ 80 years,80+ years,52.0,47.0,57.0,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8+,severe disease,severe,Singapore,≥ 80 years,80+ years,63.0,56.3,68.5,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,8-30,severe disease,severe,Singapore,≥ 80 years,80+ years,58.0,42.0,69.0,,omicron,~13 weeks,,,,,
126,Tan,Target trial emulation,13Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses of BNT162b2 (Pfizer) or mRNA-1273 (Moderna) ≥5 months prior,60+,severe disease,severe,Singapore,≥ 80 years,80+ years,57.0,46.0,66.0,,omicron,~13 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,65.0,41.0,79.0,,omicron,~18 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7-119,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,79.0,59.0,89.0,,omicron,~15 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,120+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,-124.0,-414.0,2.0,,omicron,~18 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,76.0,27.0,92.0,,omicron,~18 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7-119,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,86.0,28.0,97.0,,omicron,~15 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,120+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,-53.0,-1254.0,83.0,,omicron,~18 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,81.0,33.0,95.0,,omicron,~18 weeks,,,,,
129,Schrag,Test-negative case-control,26Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,97.0,79.0,100.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Moderna,included,complete vaccination at least 120 days prior,<60,infection,infection,Argentina,≥ 50 years,≥ 50 years,36.0,33.0,39.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Moderna,included,complete vaccination at least 120 days prior,60+,infection,infection,Argentina,≥ 50 years,≥ 50 years,8.0,-4.0,19.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Moderna,included,complete vaccination at least 120 days prior,<60,hospitalization,severe,Argentina,≥ 50 years,≥ 50 years,78.0,65.0,86.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Moderna,included,complete vaccination at least 120 days prior,60+,hospitalization,severe,Argentina,≥ 50 years,≥ 50 years,86.0,23.0,97.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Moderna,included,complete vaccination at least 120 days prior,<60,death,death,Argentina,≥ 50 years,≥ 50 years,80.0,68.0,97.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,AZD1222 (AstraZeneca),Moderna,included,complete vaccination at least 120 days prior,60+,death,death,Argentina,≥ 50 years,≥ 50 years,75.0,-17.0,95.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,BBIBP-CorV (Beijing CNBG),Moderna,included,complete vaccination at least 120 days prior,<60,infection,infection,Argentina,≥ 50 years,≥ 50 years,38.0,31.0,45.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,BBIBP-CorV (Beijing CNBG),Moderna,included,complete vaccination at least 120 days prior,60+,infection,infection,Argentina,≥ 50 years,≥ 50 years,36.0,16.0,50.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,BBIBP-CorV (Beijing CNBG),Moderna,included,complete vaccination at least 120 days prior,<60,hospitalization,severe,Argentina,≥ 50 years,≥ 50 years,78.0,49.0,91.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,BBIBP-CorV (Beijing CNBG),Moderna,included,complete vaccination at least 120 days prior,<60,death,death,Argentina,≥ 50 years,≥ 50 years,73.0,49.0,85.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,BBIBP-CorV (Beijing CNBG),Moderna,included,complete vaccination at least 120 days prior,60+,death,death,Argentina,≥ 50 years,≥ 50 years,76.0,-85.0,97.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Moderna,included,complete vaccination at least 120 days prior,<60,infection,infection,Argentina,≥ 50 years,≥ 50 years,34.0,31.0,37.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Moderna,included,complete vaccination at least 120 days prior,60+,infection,infection,Argentina,≥ 50 years,≥ 50 years,-2.0,16.0,10.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Moderna,included,complete vaccination at least 120 days prior,<60,hospitalization,severe,Argentina,≥ 50 years,≥ 50 years,76.0,68.0,83.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Moderna,included,complete vaccination at least 120 days prior,60+,hospitalization,severe,Argentina,≥ 50 years,≥ 50 years,66.0,16.0,86.0,,omicron,~18 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Moderna,included,complete vaccination at least 120 days prior,<60,death,death,Argentina,≥ 50 years,≥ 50 years,88.0,83.0,92.0,,omicron,~7 weeks,,,,,
130,Gonzalez,Test-negative case-control,27Sep2022,Sputnik V (Gamaleya),Moderna,included,complete vaccination at least 120 days prior,60+,death,death,Argentina,≥ 50 years,≥ 50 years,84.0,46.0,95.0,,omicron,~18 weeks,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,<2 months,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,83.0,82.0,84.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,8+ months,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,17.0,7.0,26.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,<2 months,hospitalization,severe,USA,≥ 18 years,general pop,89.0,88.0,90.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,8+ months,hospitalization,severe,USA,≥ 18 years,general pop,31.0,17.0,43.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,<2 months,hospitalization,severe,USA,"immunocompromised, ≥ 18 years","immunocompromised, ≥ 18 years",78.0,73.0,82.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,6+ months,hospitalization,severe,USA,"immunocompromised, ≥ 18 years","immunocompromised, ≥ 18 years",29.0,13.0,42.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,USA,"immunocompromised, ≥ 18 years","immunocompromised, ≥ 18 years",48.0,29.0,62.0,,omicron,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,<2 months,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,96.0,95.0,96.0,,delta,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,4-<6 monhts,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,88.0,62.0,96.0,,delta,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,<2 months,hospitalization,severe,USA,≥ 18 years,general pop,96.0,95.0,96.0,,delta,,,,,,
133,Ferdinands,Test-negative case-control,03Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,2+ months,hospitalization,severe,USA,≥ 18 years,general pop,92.0,90.0,93.0,,delta,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination at least 150 days prior,7-119,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,46.0,39.0,58.0,,omicron BA.4 or BA.5,,,,,,
134,Link-Gelles,Test-negative case-control,05Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination at least 150 days prior,7-119,hospitalization,severe,USA,≥ 18 years,general pop,57.0,35.0,72.0,,omicron BA.4 or BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,receipt of 3 doses at least 84 days prior,<84,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,23.0,17.0,29.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,receipt of 3 doses at least 84 days prior,168+,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,-24.0,-41.0,-9.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,receipt of 3 doses at least 84 days prior,<84,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,36.0,26.0,44.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,receipt of 3 doses at least 84 days prior,168+,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,-15.0,-49.0,11.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,receipt of 3 doses at least 84 days prior,<84,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,37.0,24.0,48.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,receipt of 3 doses at least 84 days prior,168+,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,6.0,-29.0,32.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,<84,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,49.0,44.0,54.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,168+,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,18.0,5.0,28.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,<84,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,69.0,61.0,75.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,168+,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,44.0,24.0,59.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,<84,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,82.0,77.0,86.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,168+,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,74.0,62.0,82.0,,omicron BA.1/BA.2/BA.4/BA.5,~29 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<84,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,38.0,32.0,43.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,84+,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,34.0,28.0,39.0,,omicron BA.1/BA.2/BA.4/BA.5,~42 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<84,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,59.0,48.0,68.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,84+,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,51.0,42.0,60.0,,omicron BA.1/BA.2/BA.4/BA.5,~42 weeks,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,<84,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,77.0,68.0,83.0,,omicron BA.1/BA.2/BA.4/BA.5,,,,,,
135,Grewal,Test-negative case-control,03Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,84+,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,72.0,64.0,78.0,,omicron BA.1/BA.2/BA.4/BA.5,~42 weeks,,,,,
137,McConeghy,Target trial emulation,30Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,receipt of 3 doses at least 120 days prior,0-60,infection,infection,USA,nursing home residents,nursing home residents,25.8,1.2,44.3,,delta,~6.5 weeks,,,,,
137,McConeghy,Target trial emulation,30Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,receipt of 3 doses at least 120 days prior,0-60,hospitalization,severe,USA,nursing home residents,nursing home residents,60.1,-18.8,91.5,,delta,~6.5 weeks,,,,,
137,McConeghy,Target trial emulation,30Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,receipt of 3 doses at least 120 days prior,0-60,death,death,USA,nursing home residents,nursing home residents,89.6,45.0,100.0,,delta,~6.5 weeks,,,,,
137,McConeghy,Target trial emulation,30Sep2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,receipt of 3 doses at least 120 days prior,0-60,hospitalization or death,severe,USA,nursing home residents,nursing home residents,73.9,36.1,92.2,,delta,~6.5 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) + CoronaVac (Sinovac) +  BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 20 years,general pop,74.1,54.8,85.2,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) + CoronaVac (Sinovac) +  BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,14+,death,death,Chile,≥ 20 years,general pop,87.7,76.1,93.7,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) (3 doses),Moderna,excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 20 years,general pop,86.3,83.2,88.8,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) (3 doses),Moderna,excluded,unvaccinated individuals,14+,death,death,Chile,≥ 20 years,general pop,81.0,76.8,84.0,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) + CoronaVac (Sinovac) +  AZD1222 (AstraZeneca) (3 doses),Moderna,excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 20 years,general pop,75.0,63.4,83.0,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,CoronaVac (Sinovac) + CoronaVac (Sinovac) +  AZD1222 (AstraZeneca) (3 doses),Moderna,excluded,unvaccinated individuals,14+,death,death,Chile,≥ 20 years,general pop,79.3,73.8,83.7,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,14+,ICU admission,severe,Chile,≥ 20 years,general pop,77.0,69.6,83.0,,omicron,~24 weeks,,,,,
141,Jara,Retrospective cohort,06Oct2022,BNT162b2 (Pfizer),Moderna,excluded,unvaccinated individuals,14+,death,death,Chile,≥ 20 years,general pop,90.8,89.4,92.0,,omicron,~24 weeks,,,,,
142,Mimura,Retrospective cohort,08Oct2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Moderna,excluded,unvaccinated individuals,14+,infection,infection,Japan,16-64 years,16-64 years,56.5,46.0,65.0,omicron,omicron,~15 weeks,,,,,
142,Mimura,Retrospective cohort,08Oct2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Moderna,excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,Japan,16-64 years,16-64 years,71.8,60.1,80.1,omicron,omicron,~15 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Moderna,excluded,unvaccinated individuals,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,81.0,75.0,85.0,,omicron BA.5,~9 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Moderna,excluded,complete vaccination with 2 doses,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,53.0,43.0,65.0,,omicron BA.5,~9 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Moderna,excluded,complete vaccination with 3 doses,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,47.0,35.0,57.0,,omicron BA.5,~9 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or Ad26.COV2.S or any mRNA primary series + any mRNA first booster,Moderna,excluded,unvaccinated individuals,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,82.0,77.0,85.0,,omicron BA.5,~9 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or any mRNA primary series + any mRNA first booster,Moderna,excluded,complete vaccination with 2 doses,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,56.0,47.0,63.0,,omicron BA.5,~9 weeks,,,,,
143,Kislaya,Retrospective cohort,15Sep2022,AZD1222 (AstraZeneca) or any mRNA primary series + any mRNA first booster,Moderna,excluded,complete vaccination with 3 doses,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,49.0,41.0,56.0,,omicron BA.5,~9 weeks,,,,,
144,UKHSA,Retrospective cohort,03Nov2022,BNT162b2 (Pfizer),Moderna,unknown,complete vaccination with 3 doses at least 25-39 weeks prior,14-28,hospitalization,severe,UK,≥ 75 years,≥ 75 years,58.8,54.1,63.0,,omicron,~26 weeks,A minority of individuals received AZD1222 as a booster vaccine.,,,,
144,UKHSA,Retrospective cohort,03Nov2022,BNT162b2 (Pfizer),Moderna,unknown,complete vaccination with 3 doses at least 25-39 weeks prior,140+,hospitalization,severe,UK,≥ 75 years,≥ 75 years,10.8,-6.2,25.1,,omicron,~26 weeks,A minority of individuals received AZD1222 as a booster vaccine.,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7-89,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,75.0,71.0,79.0,,omicron BA.1,,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,49.0,41.0,7.0,,omicron BA.1,~31 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,32.0,16.0,46.0,,omicron BA.2/BA.2.12.1,~44 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,32.0,15.0,45.0,,omicron BA.2/BA.2.12.1,~44 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,35.0,21.0,47.0,,omicron BA.4/BA.5,~51 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,36.0,22.0,47.0,,omicron BA.4/BA.5,~51 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,33.0,22.0,42.0,,omicron BA.2/BA.2.12.1/BA.4/BA.5,~51 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,90+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,32.0,21.0,42.0,,omicron BA.2/BA.2.12.1/BA.4/BA.5,~51 weeks,,,,,
149,Britton,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥ 18 years,immunocompromised,43.0,27.0,56.0,,omicron BA.2/BA.2.12.1/BA.4/BA.5,~22 weeks,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-120,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,79.0,74.0,84.0,,omicron BA.1/BA.2,,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,120+,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,41.0,23.0,55.0,,omicron BA.1/BA.2,~28 weeks,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,61.0,29.0,78.0,,omicron BA.1/BA.2,~11 weeks,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7-120,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,61.0,29.0,78.0,,omicron BA.1/BA.2,,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-120,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,60.0,12.0,81.0,,omicron BA.4/BA.5,,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,120+,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,29.0,3.0,48.0,,omicron BA.4/BA.5,~39 weeks,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,60.0,36.0,75.0,,omicron BA.4/BA.5,~22 weeks,,,,,
150,Surie,Test-negative case-control,21Oct2022,BNT162b2 (Pfizer),Moderna,included,unvaccinated individuals,7-120,hospitalization with COVID-like illness,severe,USA,≥ 18 years,general pop,61.0,37.0,76.0,,omicron BA.4/BA.5,,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,120-179,severe disease,severe,Canada,50-59 years,50-59 years,96.0,93.0,97.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180-239,severe disease,severe,Canada,50-59 years,50-59 years,98.0,93.0,99.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,50-59 years,50-59 years,97.0,77.0,100.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,60-119,severe disease,severe,Canada,60-69 years,60-69 years,95.0,96.0,96.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180-239,severe disease,severe,Canada,60-69 years,60-69 years,90.0,79.0,95.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,60-69 years,60-69 years,96.0,93.0,98.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,60-119,severe disease,severe,Canada,60-69 years,60-69 years,95.0,77.0,99.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,70-79 years,70-79 years,96.0,96.0,97.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180-239,severe disease,severe,Canada,70-79 years,70-79 years,91.0,85.0,95.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,70-79 years,70-79 years,96.0,94.0,97.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,60-119,severe disease,severe,Canada,70-79 years,70-79 years,93.0,87.0,96.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,80+ years,80+ years,92.0,90.0,93.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180-239,severe disease,severe,Canada,80+ years,80+ years,87.0,80.0,91.0,,omicron BA.1/BA.2,~43 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,80+ years,80+ years,94.0,92.0,95.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,120+,severe disease,severe,Canada,80+ years,80+ years,92.0,78.0,97.0,,omicron BA.1/BA.2,~24 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,120-179,severe disease,severe,Canada,50-59 years,50-59 years,77.0,50.0,89.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180-239,severe disease,severe,Canada,50-59 years,50-59 years,75.0,60.0,84.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,50-59 years,50-59 years,95.0,82.0,98.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,60-119,severe disease,severe,Canada,60-69 years,60-69 years,94.0,53.0,99.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180-239,severe disease,severe,Canada,60-69 years,60-69 years,69.0,55.0,78.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,60-69 years,60-69 years,88.0,78.0,94.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,60-119,severe disease,severe,Canada,60-69 years,60-69 years,81.0,70.0,88.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,70-79 years,70-79 years,86.0,37.0,97.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180-239,severe disease,severe,Canada,70-79 years,70-79 years,59.0,44.0,70.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,70-79 years,70-79 years,85.0,77.0,90.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,60-119,severe disease,severe,Canada,70-79 years,70-79 years,86.0,80.0,90.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,≥ 80 years,≥ 80 years,76.0,27.0,92.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,180-239,severe disease,severe,Canada,≥ 80 years,≥ 80 years,52.0,36.0,64.0,,omicron BA.4/BA.5,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,7-59,severe disease,severe,Canada,≥ 80 years,≥ 80 years,86.0,79.0,90.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,120+,severe disease,severe,Canada,≥ 80 years,≥ 80 years,80.0,72.0,85.0,,omicron BA.4/BA.5,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,50-59 years,50-59 years,79.0,72.0,84.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,60-119,severe disease,severe,Canada,50-59 years,50-59 years,57.0,35.0,72.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,50-59 years,50-59 years,89.0,69.0,96.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 2 doses,240+,severe disease,severe,Canada,50-59 years,50-59 years,77.0,-1.0,95.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,60-69 years,60-69 years,87.0,83.0,90.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,120+,severe disease,severe,Canada,60-69 years,60-69 years,62.0,45.0,75.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,60-69 years,60-69 years,83.0,74.0,89.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 2 doses,240+,severe disease,severe,Canada,60-69 years,60-69 years,69.0,47.0,82.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,70-79 years,70-79 years,83.0,79.0,86.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,120+,severe disease,severe,Canada,70-79 years,70-79 years,45.0,24.0,59.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,70-79 years,70-79 years,80.0,74.0,85.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 2 doses,240+,severe disease,severe,Canada,70-79 years,70-79 years,69.0,57.0,78.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,≥ 80 years,≥ 80 years,77.0,72.0,80.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses,240+,severe disease,severe,Canada,≥ 80 years,≥ 80 years,48.0,33.0,60.0,,omicron,~56 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 2 doses,7-59,severe disease,severe,Canada,≥ 80 years,≥ 80 years,82.0,78.0,86.0,,omicron,~37 weeks,,,,,
153,Grewal,Test-negative case-control,01Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with 2 doses,120+,severe disease,severe,Canada,≥ 80 years,≥ 80 years,75.0,68.0,81.0,,omicron,~37 weeks,,,,,
154,Chemaitelly,Retrospective cohort,01Nov2022,BNT162b2 (Pfizer) (3 doses),Moderna,previously infected only,complete vaccination with 2 doses prior to first infection,91+ (90+ days post primary Omicron infection),reinfection,reinfection,Qatar,≥18 years with prior breakthrough Omicron infection,≥18 years with prior breakthrough Omicron infection,-38.0,-65.0,-15.0,,omicron,~50 weeks,,,,,
154,Chemaitelly,Retrospective cohort,01Nov2022,BNT162b2 (Pfizer) (3 doses),Moderna,previously infected only,unvaccinated individuals,91+ (90+ days post primary Omicron infection),reinfection,reinfection,Qatar,≥18 years with prior breakthrough Omicron infection,≥18 years with prior breakthrough Omicron infection,47.0,37.0,56.0,,omicron,~50 weeks,,,,,
157,Jorgensen,Test-negative case-control,08Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,infection,infection,Canada,infants <6 months,infants <6 months,73.0,61.0,80.0,,omicron,~35 weeks,,,,,
157,Jorgensen,Test-negative case-control,08Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,hospitalization,severe,Canada,infants <6 months,infants <6 months,81.0,58.0,92.0,,omicron,~35 weeks,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses at least 4 months prior,14-28,infection,infection,Italy,≥ 80 years,≥ 80 years,28.5,24.7,32.1,,omicron,,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 3 doses at least 4 months prior,28-56,infection,infection,Italy,≥ 80 years,≥ 80 years,7.6,-14.1,18.3,,omicron,,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,BNT162b2 (Pfizer) (3 doses),Moderna,excluded,complete vaccination with 3 doses at least 4 months prior,14-28,severe disease,severe,Italy,≥ 80 years,≥ 80 years,43.2,30.6,54.9,,omicron,,,,,,
158,Fabiani,Retrospective cohort,14Nov2022,BNT162b2 (Pfizer) (3 doses),Moderna,excluded,complete vaccination with 3 doses at least 4 months prior,28-56,severe disease,severe,Italy,≥ 80 years,≥ 80 years,27.2,8.3,42.9,,omicron,,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses at least 6 months prior,7+,infection,infection,Qatar,all ages,general pop,41.1,40.0,42.1,,omicron,~54 weeks,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses at least 6 months prior,7-37,infection,infection,Qatar,all ages,general pop,57.1,55.9,58.3,,omicron,,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses at least 6 months prior,308+,infection,infection,Qatar,all ages,general pop,-20.3,-55.0,29.0,,omicron,~54 weeks,,,,,
159,Chemaitelly,Retrospective cohort,15Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses at least 6 months prior,7+,"severe, critical, or fatal disease",severe,Qatar,all ages,general pop,80.5,55.7,91.4,,omicron,~54 weeks,,,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,18-49 years,18-49 years,41.0,31.0,49.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,50.0,35.0,61.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,32.0,9.0,49.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,18-49 years,18-49 years,43.0,39.0,46.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,25.0,17.0,33.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,19.0,8.0,29.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Moderna,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,28.0,20.0,34.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
160,Link-Gelles,Test-negative case-control,22Nov2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Moderna,included,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,23.0,15.0,30.0,,omicron BA.4/BA.5,~8 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
162,UKHSA,Test-negative case-control,01Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) & AZD1222 (AstraZeneca) (2 or 3 doses),Moderna,included,complete vaccination with ≥ 2 doses at least 6 months prior,14+,hospitalization,severe,UK,≥ 50 years,≥ 50 years,57.0,48.0,65.0,,omicron BA.5/BQ.1,~10 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
166,Tenforde,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Moderna,included,unvaccinated individuals,7+,ED or UC encounters for COVID-like illness,symptomatic,USA,immuncompetent adults ≥ 18 years,general pop,56.0,49.0,62.0,,omicron BA.5,~9 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
166,Tenforde,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Moderna,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 18 years,general pop,57.0,41.0,69.0,,omicron BA.5,~9 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
167,Surie,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Moderna,included,unvaccinated individuals,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 65 years,≥ 65 years,84.0,64.0,93.0,,omicron BA.5/BQ.1/BQ.1.1,~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
167,Surie,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Moderna,included,≥2 doses of monovalent mRNA vaccine ≥2 mos. prior ,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 65 years,≥ 65 years,73.0,52.0,85.0,,omicron BA.5/BQ.1/BQ.1.1,~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
167,Surie,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Moderna,included,≥2 doses of monovalent mRNA vaccine 6-11 mos. prior ,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 65 years,≥ 65 years,78.0,57.0,89.0,,omicron BA.5/BQ.1/BQ.1.1,~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
167,Surie,Test-negative case-control,16Dec2022,BNT162b2 (Pfizer) & mRNA-1273 (Moderna) (2-4 doses),Moderna,included,≥2 doses of monovalent mRNA vaccine ≥12 mos. prior ,7+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥ 65 years,≥ 65 years,83.0,63.0,92.0,,omicron BA.5/BQ.1/BQ.1.1,~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) or AZD1222 (AstraZeneca) (3 doses),Moderna,included,unvaccinated individuals,14-89,pneumonia requiring invasive ventilation,severe,Thailand,≥ 18 years,general pop,99.0,92.6,99.8,,"omicron BA.1, BA.2",~15 weeks,,,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) or AZD1222 (AstraZeneca) (3 doses),Moderna,included,unvaccinated individuals,180+,pneumonia requiring invasive ventilation,severe,Thailand,≥ 18 years,general pop,100.0,99.6,100.3,,"omicron BA.1, BA.2",~15 weeks,,,,,
171,Nittayasoot,Test-negative case-control,12Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) or AZD1222 (AstraZeneca) (3 doses),Moderna,included,unvaccinated individuals,14+,death,death,Thailand,≥ 18 years,general pop,99.2,94.4,99.9,,"omicron BA.1, BA.2",~15 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,96.0,93.0,98.0,,omicron BA.1,unknown,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,96.0,92.0,98.0,,omicron BA.1,unknown,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,85.0,72.0,92.0,,omicron BA.1,unknown,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,84.0,81.0,87.0,,omicron BA.2,~9 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,82.0,78.0,86.0,,omicron BA.2,~9 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,91-179,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,85.0,69.0,93.0,,omicron BA.2,~9 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,61.0,52.0,68.0,,omicron BA.2,~9 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,68.0,63.0,72.0,,omicron BA.4/BA.5,~30 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,80.0,76.0,83.0,,omicron BA.4/BA.5,~30 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,unvaccinated individuals,270-359,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,75.0,-9.0,94.0,,omicron BA.4/BA.5,~30 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,47.0,39.0,53.0,,omicron BA.4/BA.5,~30 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Moderna,excluded,unvaccinated individuals,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,74.0,68.0,78.0,,omicron BA.4/BA.5,~10 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Moderna,excluded,unvaccinated individuals,7-90,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,73.0,67.0,78.0,,omicron BA.4/BA.5,~10 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Moderna,excluded,unvaccinated individuals,91-179,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,57.0,11.0,79.0,,omicron BA.4/BA.5,~10 weeks,,,,,
172,Carazo,Test-negative case-control,27Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (4 doses),Moderna,excluded,complete vaccination with 2 doses 6+ months prior,7+,hospitalization,severe,Canada,≥ 60 years,≥ 60 years,56.0,48.0,63.0,,omicron BA.4/BA.5,~10 weeks,,,,,
173,Arbel,Retrospective cohort,03Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (≥2 doses),"Omicron BA.4/BA.5 bivalent BNT162b2 (Pfizer) (3rd, 4th, or 5th dose)",included,≥2 doses of monovalent mRNA vaccine,14+,hospitalization,severe,Israel,≥ 65 years,≥ 65 years,81.0,58.0,92.0,,omicron BA.5,~10 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
173,Arbel,Retrospective cohort,03Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (≥2 doses),"Omicron BA.4/BA.5 bivalent BNT162b2 (Pfizer) (3rd, 4th, or 5th dose)",included,≥2 doses of monovalent mRNA vaccine,14+,death,death,Israel,≥ 65 years,≥ 65 years,86.0,-3.0,98.0,,omicron BA.5,~10 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
174,Lewis,Test-negative case-control,31Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination at least 150 days prior,7+,hospitalization,severe,USA,≥ 18 years,general pop,66.0,55.0,74.0,,"omicron BA.1, BA.2",~26 weeks,,,,,
174,Lewis,Test-negative case-control,31Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,≥ 18 years,general pop,81.0,75.0,86.0,,"omicron BA.1, BA.2",~26 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 1","≥ 18 years, Social Vulnerability Index Quartile 1",78.0,76.0,80.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 1","≥ 18 years, Social Vulnerability Index Quartile 1",88.0,85.0,91.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 2","≥ 18 years, Social Vulnerability Index Quartile 2",80.0,77.0,82.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 2","≥ 18 years, Social Vulnerability Index Quartile 2",89.0,87.0,92.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 3","≥ 18 years, Social Vulnerability Index Quartile 3",80.0,77.0,83.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 3","≥ 18 years, Social Vulnerability Index Quartile 3",87.0,83.0,90.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 4","≥ 18 years, Social Vulnerability Index Quartile 4",76.0,72.0,80.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 4","≥ 18 years, Social Vulnerability Index Quartile 4",82.0,76.0,86.0,,omicron BA.1,~25 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 1","≥ 18 years, Social Vulnerability Index Quartile 1",96.0,95.0,96.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 1","≥ 18 years, Social Vulnerability Index Quartile 1",97.0,95.0,98.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 2","≥ 18 years, Social Vulnerability Index Quartile 2",95.0,93.0,96.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 2","≥ 18 years, Social Vulnerability Index Quartile 2",98.0,96.0,99.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 3","≥ 18 years, Social Vulnerability Index Quartile 3",95.0,93.0,97.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 3","≥ 18 years, Social Vulnerability Index Quartile 3",94.0,90.0,97.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,ED/UC visit,symptomatic,USA,"≥ 18 years, Social Vulnerability Index Quartile 4","≥ 18 years, Social Vulnerability Index Quartile 4",93.0,89.0,95.0,,delta,~11.5 weeks,,,,,
175,Dalton,Test-negative case-control,06Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,7+,hospitalization,severe,USA,"≥ 18 years, Social Vulnerability Index Quartile 4","≥ 18 years, Social Vulnerability Index Quartile 4",94.0,88.0,97.0,,delta,~11.5 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,23.0,-72.0,65.0,,omicron,~27 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,57.0,20.0,76.0,,omicron,~27 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,97.0,60.0,100.0,,delta,~9 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,87.0,-86.0,99.0,,delta,~9 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,53.0,10.0,76.0,,omicron or delta,~27 weeks,,,,,
176,Tartof,Test-negative case-control,11Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,55.0,21.0,74.0,,omicron or delta,~27 weeks,,,,,
177,Tamandiou,Test-negative case-control,12Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with primary series plus any mRNA booster dose received 6-7 months prior,7-30,symptomatic disease,symptomatic,France,≥ 60 years,≥ 60 years,39.3,37.8,40.7,,"omicron BA.2, BA.4, BA.5",~30 weeks,,,,,
177,Tamandiou,Test-negative case-control,12Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna) (3 doses),Moderna,included,complete vaccination with primary series plus any mRNA booster dose received 6-7 months prior,180-210,symptomatic disease,symptomatic,France,≥ 60 years,≥ 60 years,-32.6,-39.1,26.4,,"omicron BA.2, BA.4, BA.5",~30 weeks,,,,,
178,Villar,Prospective cohort,17Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,0+,infection,infection,Multiple,pregnant women,pregnant women,32.0,20.0,42.0,,omicron,~46 weeks,,,,,
178,Villar,Prospective cohort,17Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,0+,moderate disease,symptomatic,Multiple,pregnant women,pregnant women,54.0,34.0,68.0,,omicron,~46 weeks,,,,,
178,Villar,Prospective cohort,17Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,unvaccinated individuals,0+,severe disease or death,severe,Multiple,pregnant women,pregnant women,81.0,47.0,93.0,,omicron,~46 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Denmark,≥ 50 years,≥ 50 years,74.1,66.3,82.0,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Denmark,≥ 50 years,≥ 50 years,87.5,79.3,95.7,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Denmark,≥ 50 years,≥ 50 years,73.0,66.1,79.9,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Denmark,≥ 50 years,≥ 50 years,79.8,70.5,89.1,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Denmark,≥ 50 years,≥ 50 years,75.5,34.2,100.0,,omicron BA.4/BA.5,~11 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Finland,≥ 50 years,≥ 50 years,91.2,79.9,100.0,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Finland,≥ 50 years,≥ 50 years,39.8,-30.7,100.0,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Finland,≥ 50 years,≥ 50 years,85.8,67.5,100.0,,omicron BA.4/BA.5,~8 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Finland,≥ 50 years,≥ 50 years,33.6,-58.7,100.0,,omicron BA.4/BA.5,~8 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Finland,≥ 50 years,≥ 50 years,53.6,35.6,71.6,,omicron BA.4/BA.5,~17 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Finland,≥ 50 years,≥ 50 years,60.9,43.3,78.5,,omicron BA.4/BA.5,~17 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Norway,≥ 50 years,≥ 50 years,76.6,61.0,92.3,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Norway,≥ 50 years,≥ 50 years,57.3,-33.5,100.0,,omicron BA.4/BA.5,~6 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Norway,≥ 50 years,≥ 50 years,67.9,54.7,81.1,,omicron BA.4/BA.5,~9 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Norway,≥ 50 years,≥ 50 years,84.7,61.9,100.0,,omicron BA.4/BA.5,~9 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Norway,≥ 50 years,≥ 50 years,69.3,61.6,77.0,,omicron BA.4/BA.5,~19 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Norway,≥ 50 years,≥ 50 years,60.9,43.3,78.5,,omicron BA.4/BA.5,~19 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Sweden,≥ 50 years,≥ 50 years,78.7,63.5,94.0,,omicron BA.4/BA.5,~4 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Sweden,≥ 50 years,≥ 50 years,80.5,55.4,100.0,,omicron BA.4/BA.5,~4 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,hospitalization,severe,Sweden,≥ 50 years,≥ 50 years,64.9,57.7,72.2,,omicron BA.4/BA.5,~13 weeks,,,,,
179,Andersson,Retrospective cohort,19Jan2023,AZD1222 or BNT162b2 or mRNA-1273 (primary) + BNT162b2 or mRNA-1273 (3rd dose),Moderna,included,complete vaccination with 3 doses (AZD1222 or BNT162b2 or mRNA-1273 primary + BNT162b2 or mRNA-1273 3rd dose),7+,death,death,Sweden,≥ 50 years,≥ 50 years,53.7,22.5,84.9,,omicron BA.4/BA.5,~13 weeks,,,,,
180,Alkadi,Test-negative case-control,26Dec2022,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,unknown,unvaccinated individuals,0+,infection,infection,Qatar,≥ 18 years on chronic hemodialysis,≥ 18 years on chronic hemodialysis,70.1,23.3,89.0,,"non-VOC, alpha & delta",~13.5 weeks,,,,,
181,Heidarzadeh,Test-negative case-control,23Dec2022,BBIBP-CorV (Beijing CNBG),BBIBP-CorV (Beijing CNBG),included,unvaccinated individuals,0+,hospitalization (severe),severe,Iran,≥ 5 years,≥ 5 years,96.0,92.0,98.0,,alpha & delta,~4.5 weeks,,,,,
181,Heidarzadeh,Test-negative case-control,23Dec2022,BBIBP-CorV (Beijing CNBG),BBIBP-CorV (Beijing CNBG),included,unvaccinated individuals,0+,death,death,Iran,≥ 5 years,≥ 5 years,58.0,-6.0,83.0,,alpha & delta,~4.5 weeks,,,,,
182,Lin,Retrospective cohort,19Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses of BNT162b2 or mRNA-1273,1 mo,infection,infection,USA,5-11 years,5-11 years,24.4,14.4,33.2,,omicron (all lineages),~31 weeks,,,,,
182,Lin,Retrospective cohort,19Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses of BNT162b2 or mRNA-1273,5 mos,infection,infection,USA,5-11 years,5-11 years,19.3,6.9,30.0,,omicron (all lineages),~31 weeks,,,,,
182,Lin,Retrospective cohort,19Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses of BNT162b2 or mRNA-1273,1 mo,infection,infection,USA,5-11 years,5-11 years,76.7,45.7,90.0,,omicron (all lineages),~10 weeks,,,,,
182,Lin,Retrospective cohort,19Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,included,complete vaccination with 2 doses of BNT162b2 or mRNA-1273,2 mos,infection,infection,USA,5-11 years,5-11 years,47.3,-17.9,76.4,,omicron (all lineages),~10 weeks,,,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Moderna,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,14+,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,52.0,48.0,56.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Moderna,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,14-59,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,51.0,43.0,58.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Moderna,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,60-119,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,52.0,48.0,56.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Moderna,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,14+,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,49.0,41.0,55.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Moderna,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,14-59,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,50.0,36.0,61.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,any mRNA (2nd (<4 months) or 3rd dose),Moderna,included,vaccination with 2 or 3 doses of monovalent mRNA vaccine,60-119,symptomatic disease,symptomatic,USA,immuncompetent adults aged 18-49 years,general pop,48.0,39.0,55.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14+,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,43.0,36.0,49.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14-59,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,54.0,43.0,63.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",60-119,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,39.0,30.0,46.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14+,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,37.0,28.0,44.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14-59,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,55.0,42.0,65.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",60-119,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,32.0,21.0,40.0,omicron BA.5,omicron BA.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14+,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,40.0,28.0,50.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14-59,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,45.0,25.0,60.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",60-119,symptomatic disease,symptomatic,USA,50-64 years,50-64 years,38.0,24.0,50.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14+,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,43.0,29.0,55.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",14-59,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,50.0,24.0,68.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
183,Link-Gelles,Test-negative case-control,25Jan2023,"any mRNA (2nd (<4 months), 3rd, or 4th dose)",Moderna,included,"vaccination with 2, 3, or 4 doses of monovalent mRNA vaccine",60-119,symptomatic disease,symptomatic,USA,≥ 65 years,≥ 65 years,42.0,26.0,54.0,omicron XBB/XBB.1.5,omicron XBB/XBB.1.5,~17 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data for bivalent vaccines.",,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2 (Pfizer), mRNA-1273 (Moderna) or Ad26.COV2.S (Janssen)",Moderna,included,complete primary vaccination,15-99,hospitalization,severe,USA,≥ 12 years,≥ 12 years,15.8,-39.5,49.1,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2 (Pfizer), mRNA-1273 (Moderna) or Ad26.COV2.S (Janssen)",Moderna,included,complete primary vaccination,15-99,hospitalization or death,severe,USA,≥ 12 years,≥ 12 years,4.2,-50.1,38.8,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose)",Moderna,included,complete primary + first booster vaccination (3 doses),15-99,hospitalization,severe,USA,≥ 12 years,≥ 12 years,28.0,-3.2,49.8,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose)",Moderna,included,complete primary + first booster vaccination (3 doses),15-99,hospitalization or death,severe,USA,≥ 12 years,≥ 12 years,32.2,4.5,51.8,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2 (Pfizer), mRNA-1273 (Moderna) or Ad26.COV2.S (Janssen)",Moderna,included,complete primary vaccination,15-99,hospitalization,severe,USA,≥ 12 years,≥ 12 years,54.0,-6.3,80.1,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data assessing monovalent vs. bivalent vaccines.",,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2 (Pfizer), mRNA-1273 (Moderna) or Ad26.COV2.S (Janssen)",Moderna,included,complete primary vaccination,15-99,hospitalization or death,severe,USA,≥ 12 years,≥ 12 years,54.0,-0.3,78.9,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,"This estimate does not meet inclusion critiera for the systematic review, however, it is included here due to limited available data assessing monovalent vs. bivalent vaccines.",,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose)",Moderna,included,complete primary + first booster vaccination (3 doses),15-99,hospitalization,severe,USA,≥ 12 years,≥ 12 years,61.9,43.6,74.3,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose)",Moderna,included,complete primary + first booster vaccination (3 doses),15-99,hospitalization or death,severe,USA,≥ 12 years,≥ 12 years,64.0,47.0,75.5,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose) + BNT162b2 or mRNA-1273 (4th dose)",Moderna,included,complete primary + first and second booster vaccination (4 doses),15-99,hospitalization,severe,USA,≥ 12 years,≥ 12 years,55.7,12.0,77.7,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
184,Lin,Retrospective cohort,25Jan2023,"BNT162b2, mRNA-1273 or Ad26.COV2.S (primary) + BNT162b2 or mRNA-1273 (3rd dose) + BNT162b2 or mRNA-1273 (4th dose)",Moderna,included,complete primary + first and second booster vaccination (4 doses),15-99,hospitalization or death,severe,USA,≥ 12 years,≥ 12 years,63.1,27.3,81.2,,"omicron (BA.4.6, BA.5, BQ.1, BQ.1.1)",~12 weeks,,,,,
185,Ellingson,Prospective cohort,26Jan2023,BNT162b2 (Pfizer) or mRNA-1273 (Moderna),Moderna,previously infected only,unvaccinated individuals,7+,infection,infection,USA,frontline workers,general pop,46.0,25.0,61.0,,omicron,~25.5 weeks,,,,,